Appendix G.2.

Causality Table: Observational Studies

Row	Study	Study years (study start date)	Country
1	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	1985	Finland
2	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	1985	Finland
3	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	1985	Finland
4	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	1985	Finland
5	CARDIA	1985	US
6	CARDIA	1985	US
7	CARDIA	1985	US
8	Cardiovascular Health Study	1989	US
9	Cardiovascular Health Study	1989	US
10	Cardiovascular Health Study	1989	US
11	Cardiovascular Health Study	1989	US
12	Cardiovascular Health Study	1989	US
13	Cardiovascular Health Study	1989	US
14	Cardiovascular Health Study	1989	US
15	Cardiovascular Health Study	1989	US
16	Cardiovascular Health Study	1989	US
17	Cardiovascular Health Study	1989	US
18	Cardiovascular Health Study	1989	US
19	Cardiovascular Health Study	1989	US
20	Cardiovascular Health Study	1989	US
21	Cardiovascular Health Study	1989	US
22	Cardiovascular Health Study	1989	US
23	Cardiovascular Health Study	1989	US
24	Cardiovascular Health Study	1989	US
25	Cardiovascular Health Study	1989	US
26	Cardiovascular Health Study	1989	US
27	Cardiovascular Health Study	1989	US
28	Cardiovascular Health Study	1989	US

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Population	Risk type
1	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	Primary Prevention, Healthy	na
2	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	Primary Prevention, Healthy	na
3	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	Primary Prevention, Healthy	na
4	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	Primary Prevention, Healthy	na
5	CARDIA	Primary Prevention, Healthy	na
6	CARDIA	Primary Prevention, Healthy	na
7	CARDIA	Primary Prevention, Healthy	na
8	Cardiovascular Health Study	Primary Prevention, Healthy	na
9	Cardiovascular Health Study	Primary Prevention, Healthy	na
10	Cardiovascular Health Study	Primary Prevention, Healthy	na
11	Cardiovascular Health Study	Primary Prevention, Healthy	na
12	Cardiovascular Health Study	Primary Prevention, Healthy	na
13	Cardiovascular Health Study	Primary Prevention, Healthy	na
14	Cardiovascular Health Study	Primary Prevention, Healthy	na
15	Cardiovascular Health Study	Primary Prevention, Healthy	na
16	Cardiovascular Health Study	Primary Prevention, Healthy	na
17	Cardiovascular Health Study	Primary Prevention, Healthy	na
18	Cardiovascular Health Study	Primary Prevention, Healthy	na
19	Cardiovascular Health Study	Primary Prevention, Healthy	na
20	Cardiovascular Health Study	Primary Prevention, Healthy	na
21	Cardiovascular Health Study	Primary Prevention, Healthy	na
22	Cardiovascular Health Study	Primary Prevention, Healthy	na
23	Cardiovascular Health Study	Primary Prevention, Healthy	na
24	Cardiovascular Health Study	Primary Prevention, Healthy	na
25	Cardiovascular Health Study	Primary Prevention, Healthy	na
26	Cardiovascular Health Study	Primary Prevention, Healthy	na
27	Cardiovascular Health Study	Primary Prevention, Healthy	na
28	Cardiovascular Health Study	Primary Prevention, Healthy	na

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Sample size (total)	Age mean (SD) [median]	Sex (% male)
1	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	21930	range 50, 69	100
2	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	21930	range 50, 69	100
3	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	21930	range 50, 69	100
4	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	21930	range 50, 69	100
5	CARDIA	4508	24.9 (3.7)	46.9
6	CARDIA	4508	24.9 (3.7)	46.9
7	CARDIA	4508	24.9 (3.7)	46.9
8	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
9	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
10	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
11	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
12	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
13	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
14	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
15	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
16	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
17	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
18	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
19	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
20	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
21	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
22	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
23	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
24	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
25	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
26	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
27	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
28	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Race	Blood pressure SBP/DBP (mmHg)
1	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	nd	nd
2	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	nd	nd
3	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	nd	nd
4	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	nd	nd
5	CARDIA	50.6 black	110 (10.2)/68.3 (8.8)
6	CARDIA	50.6 black	110 (10.2)/68.3 (8.8)
7	CARDIA	50.6 black	110 (10.2)/68.3 (8.8)
8	Cardiovascular Health Study	87.8 white, 11.7 black	nd
9	Cardiovascular Health Study	87.8 white, 11.7 black	nd
10	Cardiovascular Health Study	87.8 white, 11.7 black	nd
11	Cardiovascular Health Study	87.8 white, 11.7 black	nd
12	Cardiovascular Health Study	87.8 white, 11.7 black	nd
13	Cardiovascular Health Study	87.8 white, 11.7 black	nd
14	Cardiovascular Health Study	87.8 white, 11.7 black	nd
15	Cardiovascular Health Study	87.8 white, 11.7 black	nd
16	Cardiovascular Health Study	87.8 white, 11.7 black	nd
17	Cardiovascular Health Study	87.8 white, 11.7 black	nd
18	Cardiovascular Health Study	87.8 white, 11.7 black	nd
19	Cardiovascular Health Study	87.8 white, 11.7 black	nd
20	Cardiovascular Health Study	87.8 white, 11.7 black	nd
21	Cardiovascular Health Study	87.8 white, 11.7 black	nd
22	Cardiovascular Health Study	87.8 white, 11.7 black	nd
23	Cardiovascular Health Study	87.8 white, 11.7 black	nd
24	Cardiovascular Health Study	87.8 white, 11.7 black	nd
25	Cardiovascular Health Study	87.8 white, 11.7 black	nd
26	Cardiovascular Health Study	87.8 white, 11.7 black	nd
27	Cardiovascular Health Study	87.8 white, 11.7 black	nd
28	Cardiovascular Health Study	87.8 white, 11.7 black	nd

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
1	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	nd
2	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	nd
3	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	nd
4	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	nd
5	CARDIA	nd
6	CARDIA	nd
7	CARDIA	nd
8	Cardiovascular Health Study	nd
9	Cardiovascular Health Study	nd
10	Cardiovascular Health Study	nd
11	Cardiovascular Health Study	nd
12	Cardiovascular Health Study	nd
13	Cardiovascular Health Study	nd
14	Cardiovascular Health Study	nd
15	Cardiovascular Health Study	nd
16	Cardiovascular Health Study	nd
17	Cardiovascular Health Study	nd
18	Cardiovascular Health Study	nd
19	Cardiovascular Health Study	nd
20	Cardiovascular Health Study	nd
21	Cardiovascular Health Study	nd
22	Cardiovascular Health Study	nd
23	Cardiovascular Health Study	nd
24	Cardiovascular Health Study	nd
25	Cardiovascular Health Study	nd
26	Cardiovascular Health Study	nd
27	Cardiovascular Health Study	nd
28	Cardiovascular Health Study	nd

Appendix G.2.
Causality Table: Observational Studies

Row	Study	BMI mean (SD)/weight mean (SD) Kg
1	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	nd
2	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	nd
3	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	nd
4	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	nd
5	CARDIA	24.4 (4.9)
6	CARDIA	24.4 (4.9)
7	CARDIA	24.4 (4.9)
8	Cardiovascular Health Study	nd
9	Cardiovascular Health Study	nd
10	Cardiovascular Health Study	nd
11	Cardiovascular Health Study	nd
12	Cardiovascular Health Study	nd
13	Cardiovascular Health Study	nd
14	Cardiovascular Health Study	nd
15	Cardiovascular Health Study	nd
16	Cardiovascular Health Study	nd
17	Cardiovascular Health Study	nd
18	Cardiovascular Health Study	nd
19	Cardiovascular Health Study	nd
20	Cardiovascular Health Study	nd
21	Cardiovascular Health Study	nd
22	Cardiovascular Health Study	nd
23	Cardiovascular Health Study	nd
24	Cardiovascular Health Study	nd
25	Cardiovascular Health Study	nd
26	Cardiovascular Health Study	nd
27	Cardiovascular Health Study	nd
28	Cardiovascular Health Study	nd

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Baseline n-3 intake/level (median (IQR), unless noted)
1	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	ALA: 1.5 g/d, EPA+DHA+DPA: 0.4 g/d
2	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	ALA: 1.5 g/d, EPA+DHA+DPA: 0.4 g/d
3	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	ALA: 1.5 g/d, EPA+DHA+DPA: 0.4 g/d
4	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	ALA: 1.5 g/d, EPA+DHA+DPA: 0.4 g/d
5	CARDIA	EPA+DHA+DPA: 0.114 g/d
6	CARDIA	EPA+DHA+DPA: 0.114 g/d
7	CARDIA	EPA+DHA+DPA: 0.114 g/d
8	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
9	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
10	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
11	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
12	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
13	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
14	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
15	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
16	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
17	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
18	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
19	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
20	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
21	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
22	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
23	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
24	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
25	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
26	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
27	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
28	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA

Appendix G.2.
Causality Table: Observational Studies

Row	Study	n-3 source	n-3 measure	n-3 type(s)
1	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	intake	g/d	ALA
2	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	intake	g/d	EPA+DHA+DPA
3	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	intake	g/d	ALA
4	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	intake	g/d	EPA+DHA+DPA
5	CARDIA	intake	g/d	EPA + DHA + DPA
6	CARDIA	intake	g/d	EPA
7	CARDIA	intake	g/d	DHA
8	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	ALA
9	Cardiovascular Health Study	intake	% of total fat intake	ALA
10	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	EPA
11	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	DPA
12	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	DHA
13	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	ALA
14	Cardiovascular Health Study	intake	% of total fat intake	ALA
15	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	EPA
16	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	DPA
17	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	All n-3
18	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	ALA
19	Cardiovascular Health Study	intake	% of total fat intake	ALA
20	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	EPA
21	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	DPA
22	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	DHA
23	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	All n-3
24	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	ALA
25	Cardiovascular Health Study	intake	% of total fat intake	ALA
26	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	EPA
27	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	DPA
28	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	DHA

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Study design
1	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
2	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
3	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
4	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
5	CARDIA	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
6	CARDIA	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
7	CARDIA	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
8	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
9	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
10	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
11	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
12	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
13	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
14	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
15	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
16	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
17	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
18	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
19	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
20	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
21	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
22	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
23	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
24	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
25	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
26	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
27	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
28	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Outcome	Reported effect Size
1	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	Death, cardiac	See appendix F
2	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	Death, cardiac	See appendix F
3	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	Death, CHD	See appendix F
4	Alpha-Tocopherol, Beta-Carotene Cancer Prevention	Death, CHD	See appendix F
5	CARDIA	Hypertension	See appendix F
6	CARDIA	Hypertension	See appendix F
7	CARDIA	Hypertension	See appendix F
8	Cardiovascular Health Study	Atrial fibrillation	See appendix F
9	Cardiovascular Health Study	Atrial fibrillation	See appendix F
10	Cardiovascular Health Study	Atrial fibrillation	See appendix F
11	Cardiovascular Health Study	Atrial fibrillation	See appendix F
12	Cardiovascular Health Study	Atrial fibrillation	See appendix F
13	Cardiovascular Health Study	Congestive heart failure	See appendix F
14	Cardiovascular Health Study	Congestive heart failure	See appendix F
15	Cardiovascular Health Study	Congestive heart failure	See appendix F
16	Cardiovascular Health Study	Congestive heart failure	See appendix F
17	Cardiovascular Health Study	Congestive heart failure	See appendix F
18	Cardiovascular Health Study	Coronary heart disease	See appendix F
19	Cardiovascular Health Study	Coronary heart disease	See appendix F
20	Cardiovascular Health Study	Coronary heart disease	See appendix F
21	Cardiovascular Health Study	Coronary heart disease	See appendix F
22	Cardiovascular Health Study	Coronary heart disease	See appendix F
23	Cardiovascular Health Study	Coronary heart disease	See appendix F
24	Cardiovascular Health Study	Death, all cause	See appendix F
25	Cardiovascular Health Study	Death, all cause	See appendix F
26	Cardiovascular Health Study	Death, all cause	See appendix F
27	Cardiovascular Health Study	Death, all cause	See appendix F
28	Cardiovascular Health Study	Death, all cause	See appendix F

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Study years (study start date)	Country
29	Cardiovascular Health Study	1989	US
30	Cardiovascular Health Study	1989	US
31	Cardiovascular Health Study	1989	US
32	Cardiovascular Health Study	1989	US
33	Cardiovascular Health Study	1989	US
34	Cardiovascular Health Study	1989	US
35	Cardiovascular Health Study	1989	US
36	Cardiovascular Health Study	1989	US
37	Cardiovascular Health Study	1989	US
38	Cardiovascular Health Study	1989	US
39	Cardiovascular Health Study	1989	US
40	Cardiovascular Health Study	1989	US
41	Cardiovascular Health Study	1989	US
42	Cardiovascular Health Study	1989	US
43	Cardiovascular Health Study	1989	US
44	Cardiovascular Health Study	1989	US
45	Cardiovascular Health Study	1989	US
46	Cardiovascular Health Study	1989	US
47	Cardiovascular Health Study	1989	US
48	Cardiovascular Health Study	1989	US
49	Cardiovascular Health Study	1989	US
50	Cardiovascular Health Study	1989	US
51	Cardiovascular Health Study	1989	US
52	Cardiovascular Health Study	1989	US
53	Cardiovascular Health Study	1989	US

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Population	Risk type
29	Cardiovascular Health Study	Primary Prevention, Healthy	na
30	Cardiovascular Health Study	Primary Prevention, Healthy	na
31	Cardiovascular Health Study	Primary Prevention, Healthy	na
32	Cardiovascular Health Study	Primary Prevention, Healthy	na
33	Cardiovascular Health Study	Primary Prevention, Healthy	na
34	Cardiovascular Health Study	Primary Prevention, Healthy	na
35	Cardiovascular Health Study	Primary Prevention, Healthy	na
36	Cardiovascular Health Study	Primary Prevention, Healthy	na
37	Cardiovascular Health Study	Primary Prevention, Healthy	na
38	Cardiovascular Health Study	Primary Prevention, Healthy	na
39	Cardiovascular Health Study	Primary Prevention, Healthy	na
40	Cardiovascular Health Study	Primary Prevention, Healthy	na
41	Cardiovascular Health Study	Primary Prevention, Healthy	na
42	Cardiovascular Health Study	Primary Prevention, Healthy	na
43	Cardiovascular Health Study	Primary Prevention, Healthy	na
44	Cardiovascular Health Study	Primary Prevention, Healthy	na
45	Cardiovascular Health Study	Primary Prevention, Healthy	na
46	Cardiovascular Health Study	Primary Prevention, Healthy	na
47	Cardiovascular Health Study	Primary Prevention, Healthy	na
48	Cardiovascular Health Study	Primary Prevention, Healthy	na
49	Cardiovascular Health Study	Primary Prevention, Healthy	na
50	Cardiovascular Health Study	Primary Prevention, Healthy	na
51	Cardiovascular Health Study	Primary Prevention, Healthy	na
52	Cardiovascular Health Study	Primary Prevention, Healthy	na
53	Cardiovascular Health Study	Primary Prevention, Healthy	na

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Sample size (total)	Age mean (SD) [median]	Sex (% male)
29	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
30	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
31	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
32	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
33	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
34	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
35	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
36	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
37	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
38	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
39	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
40	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
41	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
42	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
43	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
44	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
45	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
46	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
47	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
48	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
49	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
50	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
51	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
52	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
53	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Race	Blood pressure SBP/DBP (mmHg)
29	Cardiovascular Health Study	87.8 white, 11.7 black	nd
30	Cardiovascular Health Study	87.8 white, 11.7 black	nd
31	Cardiovascular Health Study	87.8 white, 11.7 black	nd
32	Cardiovascular Health Study	87.8 white, 11.7 black	nd
33	Cardiovascular Health Study	87.8 white, 11.7 black	nd
34	Cardiovascular Health Study	87.8 white, 11.7 black	nd
35	Cardiovascular Health Study	87.8 white, 11.7 black	nd
36	Cardiovascular Health Study	87.8 white, 11.7 black	nd
37	Cardiovascular Health Study	87.8 white, 11.7 black	nd
38	Cardiovascular Health Study	87.8 white, 11.7 black	nd
39	Cardiovascular Health Study	87.8 white, 11.7 black	nd
40	Cardiovascular Health Study	87.8 white, 11.7 black	nd
41	Cardiovascular Health Study	87.8 white, 11.7 black	nd
42	Cardiovascular Health Study	87.8 white, 11.7 black	nd
43	Cardiovascular Health Study	87.8 white, 11.7 black	nd
44	Cardiovascular Health Study	87.8 white, 11.7 black	nd
45	Cardiovascular Health Study	87.8 white, 11.7 black	nd
46	Cardiovascular Health Study	87.8 white, 11.7 black	nd
47	Cardiovascular Health Study	87.8 white, 11.7 black	nd
48	Cardiovascular Health Study	87.8 white, 11.7 black	nd
49	Cardiovascular Health Study	87.8 white, 11.7 black	nd
50	Cardiovascular Health Study	87.8 white, 11.7 black	nd
51	Cardiovascular Health Study	87.8 white, 11.7 black	nd
52	Cardiovascular Health Study	87.8 white, 11.7 black	nd
53	Cardiovascular Health Study	87.8 white, 11.7 black	nd

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
29	Cardiovascular Health Study	nd
30	Cardiovascular Health Study	nd
31	Cardiovascular Health Study	nd
32	Cardiovascular Health Study	nd
33	Cardiovascular Health Study	nd
34	Cardiovascular Health Study	nd
35	Cardiovascular Health Study	nd
36	Cardiovascular Health Study	nd
37	Cardiovascular Health Study	nd
38	Cardiovascular Health Study	nd
39	Cardiovascular Health Study	nd
40	Cardiovascular Health Study	nd
41	Cardiovascular Health Study	nd
42	Cardiovascular Health Study	nd
43	Cardiovascular Health Study	nd
44	Cardiovascular Health Study	nd
45	Cardiovascular Health Study	nd
46	Cardiovascular Health Study	nd
47	Cardiovascular Health Study	nd
48	Cardiovascular Health Study	nd
49	Cardiovascular Health Study	nd
50	Cardiovascular Health Study	nd
51	Cardiovascular Health Study	nd
52	Cardiovascular Health Study	nd
53	Cardiovascular Health Study	nd

Appendix G.2.
Causality Table: Observational Studies

Row	Study	BMI mean (SD)/weight mean (SD) Kg
29	Cardiovascular Health Study	nd
30	Cardiovascular Health Study	nd
31	Cardiovascular Health Study	nd
32	Cardiovascular Health Study	nd
33	Cardiovascular Health Study	nd
34	Cardiovascular Health Study	nd
35	Cardiovascular Health Study	nd
36	Cardiovascular Health Study	nd
37	Cardiovascular Health Study	nd
38	Cardiovascular Health Study	nd
39	Cardiovascular Health Study	nd
40	Cardiovascular Health Study	nd
41	Cardiovascular Health Study	nd
42	Cardiovascular Health Study	nd
43	Cardiovascular Health Study	nd
44	Cardiovascular Health Study	nd
45	Cardiovascular Health Study	nd
46	Cardiovascular Health Study	nd
47	Cardiovascular Health Study	nd
48	Cardiovascular Health Study	nd
49	Cardiovascular Health Study	nd
50	Cardiovascular Health Study	nd
51	Cardiovascular Health Study	nd
52	Cardiovascular Health Study	nd
53	Cardiovascular Health Study	nd

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Baseline n-3 intake/level (median (IQR), unless noted)
29	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
30	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
31	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
32	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
33	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
34	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
35	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
36	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
37	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
38	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
39	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
40	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
41	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
42	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
43	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
44	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
45	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
46	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
47	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
48	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
49	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
50	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
51	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
52	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
53	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA

Appendix G.2.
Causality Table: Observational Studies

Row	Study	n-3 source	n-3 measure	n-3 type(s)
29	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	All n-3
30	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	ALA
31	Cardiovascular Health Study	intake	% of total fat intake	ALA
32	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	EPA
33	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	DPA
34	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	DHA
35	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	All n-3
36	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	ALA
37	Cardiovascular Health Study	intake	% of total fat intake	ALA
38	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	EPA
39	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	DPA
40	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	DHA
41	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	All n-3
42	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	EPA
43	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	DPA
44	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	DHA
45	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	All n-3
46	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	ALA
47	Cardiovascular Health Study	intake	% of total fat intake	ALA
48	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	EPA
49	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	DPA
50	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	DHA
51	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	All n-3
52	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	ALA
53	Cardiovascular Health Study	intake	% of total fat intake	ALA

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Study design
29	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
30	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
31	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
32	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
33	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
34	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
35	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
36	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
37	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
38	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
39	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
40	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
41	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
42	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
43	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
44	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
45	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
46	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
47	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
48	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
49	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
50	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
51	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
52	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
53	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Outcome	Reported effect Size
29	Cardiovascular Health Study	Death, all cause	See appendix F
30	Cardiovascular Health Study	Death, CHD	See appendix F
31	Cardiovascular Health Study	Death, CHD	See appendix F
32	Cardiovascular Health Study	Death, CHD	See appendix F
33	Cardiovascular Health Study	Death, CHD	See appendix F
34	Cardiovascular Health Study	Death, CHD	See appendix F
35	Cardiovascular Health Study	Death, CHD	See appendix F
36	Cardiovascular Health Study	Death, CVD	See appendix F
37	Cardiovascular Health Study	Death, CVD	See appendix F
38	Cardiovascular Health Study	Death, CVD	See appendix F
39	Cardiovascular Health Study	Death, CVD	See appendix F
40	Cardiovascular Health Study	Death, CVD	See appendix F
41	Cardiovascular Health Study	Death, CVD	See appendix F
42	Cardiovascular Health Study	Death, stroke	See appendix F
43	Cardiovascular Health Study	Death, stroke	See appendix F
44	Cardiovascular Health Study	Death, stroke	See appendix F
45	Cardiovascular Health Study	Death, stroke	See appendix F
46	Cardiovascular Health Study	Stroke, hemorrhagic	See appendix F
47	Cardiovascular Health Study	Stroke, hemorrhagic	See appendix F
48	Cardiovascular Health Study	Stroke, hemorrhagic	See appendix F
49	Cardiovascular Health Study	Stroke, hemorrhagic	See appendix F
50	Cardiovascular Health Study	Stroke, hemorrhagic	See appendix F
51	Cardiovascular Health Study	Stroke, hemorrhagic	See appendix F
52	Cardiovascular Health Study	Stroke, ischemic	See appendix F
53	Cardiovascular Health Study	Stroke, ischemic	See appendix F

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Study years (study start date)	Country
54	Cardiovascular Health Study	1989	US
55	Cardiovascular Health Study	1989	US
56	Cardiovascular Health Study	1989	US
57	Cardiovascular Health Study	1989	US
58	Cardiovascular Health Study	1989	US
59	Cardiovascular Health Study	1989	US
60	Cardiovascular Health Study	1989	US
61	Cardiovascular Health Study	1989	US
62	Cardiovascular Health Study	1989	US
63	Cardiovascular Health Study	1989	US
64	Cardiovascular Health Study	1989	US
65	Cardiovascular Health Study	1989	US
66	Cardiovascular Health Study	1989	US
67	Cardiovascular Health Study	1989	US
68	Cardiovascular Health Study	1989	US
69	Cardiovascular Health Study	1989	US
70	Cohort of Swedish Men	1997	Sweden
71	Danish National Birth Cohort	1996	Denmark
72	Diet, Cancer, Health (Danish)	34304	Denmark
73	Diet, Cancer, Health (Danish)	34304	Denmark
74	Diet, Cancer, Health (Danish)	34304	Denmark
75	Diet, Cancer, Health (Danish)	34304	Denmark
76	Diet, Cancer, Health (Danish)	34304	Denmark
77	Diet, Cancer, Health (Danish)	34304	Denmark
78	Diet, Cancer, Health (Danish)	34304	Denmark
79	Diet, Cancer, Health (Danish)	34304	Denmark

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Population	Risk type
54	Cardiovascular Health Study	Primary Prevention, Healthy	na
55	Cardiovascular Health Study	Primary Prevention, Healthy	na
56	Cardiovascular Health Study	Primary Prevention, Healthy	na
57	Cardiovascular Health Study	Primary Prevention, Healthy	na
58	Cardiovascular Health Study	Primary Prevention, Healthy	na
59	Cardiovascular Health Study	Primary Prevention, Healthy	na
60	Cardiovascular Health Study	Primary Prevention, Healthy	na
61	Cardiovascular Health Study	Primary Prevention, Healthy	na
62	Cardiovascular Health Study	Primary Prevention, Healthy	na
63	Cardiovascular Health Study	Primary Prevention, Healthy	na
64	Cardiovascular Health Study	Primary Prevention, Healthy	na
65	Cardiovascular Health Study	Primary Prevention, Healthy	na
66	Cardiovascular Health Study	Primary Prevention, Healthy	na
67	Cardiovascular Health Study	Primary Prevention, Healthy	na
68	Cardiovascular Health Study	Primary Prevention, Healthy	na
69	Cardiovascular Health Study	Primary Prevention, Healthy	na
70	Cohort of Swedish Men	Primary Prevention, Healthy	na
71	Danish National Birth Cohort	Primary Prevention, Healthy	na
72	Diet, Cancer, Health (Danish)	Primary Prevention, Healthy	na
73	Diet, Cancer, Health (Danish)	Primary Prevention, Healthy	na
74	Diet, Cancer, Health (Danish)	Primary Prevention, Healthy	na
75	Diet, Cancer, Health (Danish)	Primary Prevention, Healthy	na
76	Diet, Cancer, Health (Danish)	Primary Prevention, Healthy	na
77	Diet, Cancer, Health (Danish)	Primary Prevention, Healthy	na
78	Diet, Cancer, Health (Danish)	Primary Prevention, Healthy	na
79	Diet, Cancer, Health (Danish)	Primary Prevention, Healthy	na

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Sample size (total)	Age mean (SD) [median]	Sex (% male)
54	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
55	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
56	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
57	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
58	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
59	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
60	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
61	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
62	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
63	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
64	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
65	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
66	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
67	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
68	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
69	Cardiovascular Health Study	3941	74 (5) median 73 IQR 7198	36.1
70	Cohort of Swedish Men	44601	nd	100
71	Danish National Birth Cohort	48627	29.9 range 15.746.9	0
72	Diet, Cancer, Health (Danish)	1708	[men: 55.9, women 56.2]	47.6
73	Diet, Cancer, Health (Danish)	1708	[men: 55.9, women 56.2]	47.6
74	Diet, Cancer, Health (Danish)	1708	[men: 55.9, women 56.2]	47.6
75	Diet, Cancer, Health (Danish)	1708	[men: 55.9, women 56.2]	47.6
76	Diet, Cancer, Health (Danish)	1708	[men: 55.9, women 56.2]	47.6
77	Diet, Cancer, Health (Danish)	1708	[men: 55.9, women 56.2]	47.6
78	Diet, Cancer, Health (Danish)	1708	[men: 55.9, women 56.2]	47.6
79	Diet, Cancer, Health (Danish)	1708	[men: 55.9, women 56.2]	47.6

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Race	Blood pressure SBP/DBP (mmHg)
54	Cardiovascular Health Study	87.8 white, 11.7 black	nd
55	Cardiovascular Health Study	87.8 white, 11.7 black	nd
56	Cardiovascular Health Study	87.8 white, 11.7 black	nd
57	Cardiovascular Health Study	87.8 white, 11.7 black	nd
58	Cardiovascular Health Study	87.8 white, 11.7 black	nd
59	Cardiovascular Health Study	87.8 white, 11.7 black	nd
60	Cardiovascular Health Study	87.8 white, 11.7 black	nd
61	Cardiovascular Health Study	87.8 white, 11.7 black	nd
62	Cardiovascular Health Study	87.8 white, 11.7 black	nd
63	Cardiovascular Health Study	87.8 white, 11.7 black	nd
64	Cardiovascular Health Study	87.8 white, 11.7 black	nd
65	Cardiovascular Health Study	87.8 white, 11.7 black	nd
66	Cardiovascular Health Study	87.8 white, 11.7 black	nd
67	Cardiovascular Health Study	87.8 white, 11.7 black	nd
68	Cardiovascular Health Study	87.8 white, 11.7 black	nd
69	Cardiovascular Health Study	87.8 white, 11.7 black	nd
70	Cohort of Swedish Men	nd	nd
71	Danish National Birth Cohort	nd	nd
72	Diet, Cancer, Health (Danish)	nd	[men: 140, women 136]/
73	Diet, Cancer, Health (Danish)	nd	[men: 140, women 136]/
74	Diet, Cancer, Health (Danish)	nd	[men: 140, women 136]/
75	Diet, Cancer, Health (Danish)	nd	[men: 140, women 136]/
76	Diet, Cancer, Health (Danish)	nd	[men: 140, women 136]/
77	Diet, Cancer, Health (Danish)	nd	[men: 140, women 136]/
78	Diet, Cancer, Health (Danish)	nd	[men: 140, women 136]/
79	Diet, Cancer, Health (Danish)	nd	[men: 140, women 136]/

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
54	Cardiovascular Health Study	nd
55	Cardiovascular Health Study	nd
56	Cardiovascular Health Study	nd
57	Cardiovascular Health Study	nd
58	Cardiovascular Health Study	nd
59	Cardiovascular Health Study	nd
60	Cardiovascular Health Study	nd
61	Cardiovascular Health Study	nd
62	Cardiovascular Health Study	nd
63	Cardiovascular Health Study	nd
64	Cardiovascular Health Study	nd
65	Cardiovascular Health Study	nd
66	Cardiovascular Health Study	nd
67	Cardiovascular Health Study	nd
68	Cardiovascular Health Study	nd
69	Cardiovascular Health Study	nd
70	Cohort of Swedish Men	nd
71	Danish National Birth Cohort	nd
72	Diet, Cancer, Health (Danish)	[median men: 5.9, women: 6.2]/nd/nd/nd
73	Diet, Cancer, Health (Danish)	[median men: 5.9, women: 6.2]/nd/nd/nd
74	Diet, Cancer, Health (Danish)	[median men: 5.9, women: 6.2]/nd/nd/nd
75	Diet, Cancer, Health (Danish)	[median men: 5.9, women: 6.2]/nd/nd/nd
76	Diet, Cancer, Health (Danish)	[median men: 5.9, women: 6.2]/nd/nd/nd
77	Diet, Cancer, Health (Danish)	[median men: 5.9, women: 6.2]/nd/nd/nd
78	Diet, Cancer, Health (Danish)	[median men: 5.9, women: 6.2]/nd/nd/nd
79	Diet, Cancer, Health (Danish)	[median men: 5.9, women: 6.2]/nd/nd/nd

Appendix G.2.
Causality Table: Observational Studies

Row	Study	BMI mean (SD)/weight mean (SD) Kg
54	Cardiovascular Health Study	nd
55	Cardiovascular Health Study	nd
56	Cardiovascular Health Study	nd
57	Cardiovascular Health Study	nd
58	Cardiovascular Health Study	nd
59	Cardiovascular Health Study	nd
60	Cardiovascular Health Study	nd
61	Cardiovascular Health Study	nd
62	Cardiovascular Health Study	nd
63	Cardiovascular Health Study	nd
64	Cardiovascular Health Study	nd
65	Cardiovascular Health Study	nd
66	Cardiovascular Health Study	nd
67	Cardiovascular Health Study	nd
68	Cardiovascular Health Study	nd
69	Cardiovascular Health Study	nd
70	Cohort of Swedish Men	nd
71	Danish National Birth Cohort	nd
72	Diet, Cancer, Health (Danish)	25.9 (3.9)
73	Diet, Cancer, Health (Danish)	25.9 (3.9)
74	Diet, Cancer, Health (Danish)	25.9 (3.9)
75	Diet, Cancer, Health (Danish)	25.9 (3.9)
76	Diet, Cancer, Health (Danish)	25.9 (3.9)
77	Diet, Cancer, Health (Danish)	25.9 (3.9)
78	Diet, Cancer, Health (Danish)	25.9 (3.9)
79	Diet, Cancer, Health (Danish)	25.9 (3.9)

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Baseline n-3 intake/level (median (IQR), unless noted)
54	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
55	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
56	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
57	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
58	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
59	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
60	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
61	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
62	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
63	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
64	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
65	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
66	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
67	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
68	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
69	Cardiovascular Health Study	ALA: 0.14% FA, EPA: 0.51% FA, DHA: 2.87% FA, DPA: 0.82% FA, Total n-3 FA 4.21% FA
70	Cohort of Swedish Men	Marine oil: 0.36 g/d
71	Danish National Birth Cohort	Total n-3 FA: 0.31 g/d
72	Diet, Cancer, Health (Danish)	EPA: 0.18 g/d, DHA: 0.43 g/d, DPA: 0.08 g/d, EPA+DPA+DHA: 0.7 g/d
73	Diet, Cancer, Health (Danish)	EPA: 0.18 g/d, DHA: 0.43 g/d, DPA: 0.08 g/d, EPA+DPA+DHA: 0.7 g/d
74	Diet, Cancer, Health (Danish)	EPA: 0.18 g/d, DHA: 0.43 g/d, DPA: 0.08 g/d, EPA+DPA+DHA: 0.7 g/d
75	Diet, Cancer, Health (Danish)	EPA: 0.18 g/d, DHA: 0.43 g/d, DPA: 0.08 g/d, EPA+DPA+DHA: 0.7 g/d
76	Diet, Cancer, Health (Danish)	EPA: 0.18 g/d, DHA: 0.43 g/d, DPA: 0.08 g/d, EPA+DPA+DHA: 0.7 g/d
77	Diet, Cancer, Health (Danish)	EPA: 0.18 g/d, DHA: 0.43 g/d, DPA: 0.08 g/d, EPA+DPA+DHA: 0.7 g/d
78	Diet, Cancer, Health (Danish)	EPA: 0.18 g/d, DHA: 0.43 g/d, DPA: 0.08 g/d, EPA+DPA+DHA: 0.7 g/d
79	Diet, Cancer, Health (Danish)	EPA: 0.18 g/d, DHA: 0.43 g/d, DPA: 0.08 g/d, EPA+DPA+DHA: 0.7 g/d

Appendix G.2.
Causality Table: Observational Studies

Row	Study	n-3 source	n-3 measure	n-3 type(s)
54	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	EPA
55	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	DPA
56	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	DHA
57	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	All n-3
58	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	ALA
59	Cardiovascular Health Study	intake	% of total fat intake	ALA
60	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	EPA
61	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	DPA
62	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	DHA
63	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	All n-3
64	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	ALA
65	Cardiovascular Health Study	intake	% of total fat intake	ALA
66	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	EPA
67	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	DPA
68	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	DHA
69	Cardiovascular Health Study	plasma	% of total plasma phospholipid fatty acids	All n-3
70	Cohort of Swedish Men	intake	g/d	EPA+DHA
71	Danish National Birth Cohort	intake	g/d	Total n-3
72	Diet, Cancer, Health (Danish)	Intake	g/d	EPA+DPA+DHA
73	Diet, Cancer, Health (Danish)	Intake	g/d	EPA
74	Diet, Cancer, Health (Danish)	Intake	g/d	DPA
75	Diet, Cancer, Health (Danish)	Intake	g/d	DHA
76	Diet, Cancer, Health (Danish)	Adipose tissue	%	EPA+DPA+DHA
77	Diet, Cancer, Health (Danish)	Adipose tissue	%	EPA
78	Diet, Cancer, Health (Danish)	Adipose tissue	%	DPA
79	Diet, Cancer, Health (Danish)	Adipose tissue	%	DHA

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Study design
54	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
55	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
56	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
57	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
58	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
59	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
60	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
61	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
62	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
63	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
64	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
65	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
66	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
67	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
68	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
69	Cardiovascular Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
70	Cohort of Swedish Men	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
71	Danish National Birth Cohort	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
72	Diet, Cancer, Health (Danish)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
73	Diet, Cancer, Health (Danish)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
74	Diet, Cancer, Health (Danish)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
75	Diet, Cancer, Health (Danish)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
76	Diet, Cancer, Health (Danish)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
77	Diet, Cancer, Health (Danish)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
78	Diet, Cancer, Health (Danish)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
79	Diet, Cancer, Health (Danish)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Outcome	Reported effect Size
54	Cardiovascular Health Study	Stroke, ischemic	See appendix F
55	Cardiovascular Health Study	Stroke, ischemic	See appendix F
56	Cardiovascular Health Study	Stroke, ischemic	See appendix F
57	Cardiovascular Health Study	Stroke, ischemic	See appendix F
58	Cardiovascular Health Study	Stroke, total	See appendix F
59	Cardiovascular Health Study	Stroke, total	See appendix F
60	Cardiovascular Health Study	Stroke, total	See appendix F
61	Cardiovascular Health Study	Stroke, total	See appendix F
62	Cardiovascular Health Study	Stroke, total	See appendix F
63	Cardiovascular Health Study	Stroke, total	See appendix F
64	Cardiovascular Health Study	Sudden cardiac death	See appendix F
65	Cardiovascular Health Study	Sudden cardiac death	See appendix F
66	Cardiovascular Health Study	Sudden cardiac death	See appendix F
67	Cardiovascular Health Study	Sudden cardiac death	See appendix F
68	Cardiovascular Health Study	Sudden cardiac death	See appendix F
69	Cardiovascular Health Study	Sudden cardiac death	See appendix F
70	Cohort of Swedish Men	Congestive heart failure	See appendix F
71	Danish National Birth Cohort	CVD, total	See appendix F
72	Diet, Cancer, Health (Danish)	Acute coronary syndrome	See appendix F
73	Diet, Cancer, Health (Danish)	Acute coronary syndrome	See appendix F
74	Diet, Cancer, Health (Danish)	Acute coronary syndrome	See appendix F
75	Diet, Cancer, Health (Danish)	Acute coronary syndrome	See appendix F
76	Diet, Cancer, Health (Danish)	Acute coronary syndrome	See appendix F
77	Diet, Cancer, Health (Danish)	Acute coronary syndrome	See appendix F
78	Diet, Cancer, Health (Danish)	Acute coronary syndrome	See appendix F
79	Diet, Cancer, Health (Danish)	Acute coronary syndrome	See appendix F

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Study years (study start date)	Country
80	Diet, Cancer, Health (Danish)	34304	Denmark
81	EPIC Norfolk	1993	UK
82	EPIC Norfolk	1993	UK
83	EPIC Norfolk	1993	UK
84	EPIC Norfolk	1993	UK
85	EPIC Norfolk	1993	UK
86	EPIC Norfolk	1993	UK
87	Glostrup Population Studies	1964	Denmark
88	Glostrup Population Studies	1964	Denmark
89	Guangzhou	2008	China
90	Guangzhou	2008	China
91	Guangzhou	2008	China
92	Guangzhou	2008	China
93	Guangzhou	2008	China
94	Guangzhou	2008	China
95	Guangzhou	2008	China
96	Guangzhou	2008	China
97	Health Professional Follow-up Study	1986	US
98	Health Professional Follow-up Study	1986	US
99	Health Professional Follow-up Study	1986	US
100	Health Professional Follow-up Study	1986	US
101	Health Professional Follow-up Study	1986	US
102	Health Professional Follow-up Study	1986	US
103	Health Professional Follow-up Study	1986	US
104	Health Professional Follow-up Study	1986	US
105	Health Professional Follow-up Study	1986	US
106	Health Professional Follow-up Study	1986	US
107	Health Professional Follow-up Study	1986	US
108	Health Professional Follow-up Study	1986	US
109	Hisayama	2002	Japan
110	Hisayama	2002	Japan
111	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	1987	US
112	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	1987	US

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Population	Risk type
80	Diet, Cancer, Health (Danish)	Primary Prevention, Healthy	na
81	EPIC Norfolk	Primary Prevention, Healthy	na
82	EPIC Norfolk	Primary Prevention, Healthy	na
83	EPIC Norfolk	Primary Prevention, Healthy	na
84	EPIC Norfolk	Primary Prevention, Healthy	na
85	EPIC Norfolk	Primary Prevention, Healthy	na
86	EPIC Norfolk	Primary Prevention, Healthy	na
87	Glostrup Population Studies	Primary Prevention, Healthy	na
88	Glostrup Population Studies	Primary Prevention, Healthy	na
89	Guangzhou	Primary Prevention, Healthy	na
90	Guangzhou	Primary Prevention, Healthy	na
91	Guangzhou	Primary Prevention, Healthy	na
92	Guangzhou	Primary Prevention, Healthy	na
93	Guangzhou	Primary Prevention, Healthy	na
94	Guangzhou	Primary Prevention, Healthy	na
95	Guangzhou	Primary Prevention, Healthy	na
96	Guangzhou	Primary Prevention, Healthy	na
97	Health Professional Follow-up Study	Primary Prevention, Healthy	na
98	Health Professional Follow-up Study	Primary Prevention, Healthy	na
99	Health Professional Follow-up Study	Primary Prevention, Healthy	na
100	Health Professional Follow-up Study	Primary Prevention, Healthy	na
101	Health Professional Follow-up Study	Primary Prevention, Healthy	na
102	Health Professional Follow-up Study	Primary Prevention, Healthy	na
103	Health Professional Follow-up Study	Primary Prevention, Healthy	na
104	Health Professional Follow-up Study	Primary Prevention, Healthy	na
105	Health Professional Follow-up Study	Primary Prevention, Healthy	na
106	Health Professional Follow-up Study	Primary Prevention, Healthy	na
107	Health Professional Follow-up Study	Primary Prevention, Healthy	na
108	Health Professional Follow-up Study	Primary Prevention, Healthy	na
109	Hisayama	Primary Prevention, Healthy	na
110	Hisayama	Primary Prevention, Healthy	na
111	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Primary Prevention, Healthy	The population is a mixture of people
112	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Primary Prevention, Healthy	The population is a mixture of people

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Sample size (total)	Age mean (SD) [median]	Sex (% male)
80	Diet, Cancer, Health (Danish)	1708	[men: 55.9, women 56.2]	47.6
81	EPIC Norfolk	7364	men: 60 (8), women 59.4 (8.5)	45.6
82	EPIC Norfolk	7364	men: 60 (8), women 59.4 (8.5)	45.6
83	EPIC Norfolk	7364	men: 60 (8), women 59.4 (8.5)	45.6
84	EPIC Norfolk	7364	men: 60 (8), women 59.4 (8.5)	45.6
85	EPIC Norfolk	7364	men: 60 (8), women 59.4 (8.5)	45.6
86	EPIC Norfolk	7364	men: 60 (8), women 59.4 (8.5)	45.6
87	Glostrup Population Studies	3277	50.6 range 30.8, 60.8	49.9
88	Glostrup Population Studies	3277	50.6 range 30.8, 60.8	49.9
89	Guangzhou	1477	nd	25.3
90	Guangzhou	1477	nd	25.3
91	Guangzhou	1477	nd	25.3
92	Guangzhou	1477	nd	25.3
93	Guangzhou	1477	nd	25.3
94	Guangzhou	1477	nd	25.3
95	Guangzhou	1477	nd	25.3
96	Guangzhou	1477	nd	25.3
97	Health Professional Follow-up Study	44895	53 (9.6) range 40,75	100
98	Health Professional Follow-up Study	44895	53 (9.6) range 40,75	100
99	Health Professional Follow-up Study	44895	53 (9.6) range 40,75	100
100	Health Professional Follow-up Study	44895	53 (9.6) range 40,75	100
101	Health Professional Follow-up Study	44895	53 (9.6) range 40,75	100
102	Health Professional Follow-up Study	44895	53 (9.6) range 40,75	100
103	Health Professional Follow-up Study	44895	53 (9.6) range 40,75	100
104	Health Professional Follow-up Study	44895	53 (9.6) range 40,75	100
105	Health Professional Follow-up Study	44895	53 (9.6) range 40,75	100
106	Health Professional Follow-up Study	44895	53 (9.6) range 40,75	100
107	Health Professional Follow-up Study	44895	53 (9.6) range 40,75	100
108	Health Professional Follow-up Study	44895	53 (9.6) range 40,75	100
109	Hisayama	3103	61.3 (12.5)	42
110	Hisayama	3103	61.3 (12.5	42
111	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	3592	men: 54.2 (5.6), women 53.3 (5.5)	46.6
112	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	3592	men: 54.2 (5.6), women 53.3 (5.5)	46.6

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Race	Blood pressure SBP/DBP (mmHg)
80	Diet, Cancer, Health (Danish)	nd	[men: 140, women 136]/
81	EPIC Norfolk	nd	men: 136.1 (16.4), women: 132.6 (18.0)/men: 83.7 (10.6), women: 80 (10.7)
82	EPIC Norfolk	nd	men: 136.1 (16.4), women: 132.6 (18.0)/men: 83.7 (10.6), women: 80 (10.7)
83	EPIC Norfolk	nd	men: 136.1 (16.4), women: 132.6 (18.0)/men: 83.7 (10.6), women: 80 (10.7)
84	EPIC Norfolk	nd	men: 136.1 (16.4), women: 132.6 (18.0)/men: 83.7 (10.6), women: 80 (10.7)
85	EPIC Norfolk	nd	men: 136.1 (16.4), women: 132.6 (18.0)/men: 83.7 (10.6), women: 80 (10.7)
86	EPIC Norfolk	nd	men: 136.1 (16.4), women: 132.6 (18.0)/men: 83.7 (10.6), women: 80 (10.7)
87	Glostrup Population Studies	nd	123 range 104, 152/
88	Glostrup Population Studies	nd	123 range 104, 152/
89	Guangzhou	nd	nd
90	Guangzhou	nd	nd
91	Guangzhou	nd	nd
92	Guangzhou	nd	nd
93	Guangzhou	nd	nd
94	Guangzhou	nd	nd
95	Guangzhou	nd	nd
96	Guangzhou	nd	nd
97	Health Professional Follow-up Study	nd	nd
98	Health Professional Follow-up Study	nd	nd
99	Health Professional Follow-up Study	nd	nd
100	Health Professional Follow-up Study	nd	nd
101	Health Professional Follow-up Study	nd	nd
102	Health Professional Follow-up Study	nd	nd
103	Health Professional Follow-up Study	nd	nd
104	Health Professional Follow-up Study	nd	nd
105	Health Professional Follow-up Study	nd	nd
106	Health Professional Follow-up Study	nd	nd
107	Health Professional Follow-up Study	nd	nd
108	Health Professional Follow-up Study	nd	nd
109	Hisayama	nd	131.8 (21.1)/78.4 (11.9)
110	Hisayama	nd	131.8 (21.1)/78.4 (11.9)
111	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	100 white	men: 120.5 (14.8), women 116.9 (17.0)/men 75.5(9.2); women 72.1 (9.1)
112	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	100 white	men: 120.5 (14.8), women 116.9 (17.0)/men 75.5(9.2); women 72.1 (9.1)

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
80	Diet, Cancer, Health (Danish)	[median men: 5.9, women: 6.2]/nd/nd/nd
81	EPIC Norfolk	[men: 6.03 (1.05) 6.35 (1.20)]/[men: 3.92 (0.95), women: 4.03 (1.06)/men: 1.25 (0.33), women: 1.58 (0.42)/[men: 2.01 (1.15), women: 1.64 (1.07)]
82	EPIC Norfolk	[men: 6.03 (1.05) 6.35 (1.20)]/[men: 3.92 (0.95), women: 4.03 (1.06)/men: 1.25 (0.33), women: 1.58 (0.42)/[men: 2.01 (1.15), women: 1.64 (1.07)]
83	EPIC Norfolk	[men: 6.03 (1.05) 6.35 (1.20)]/[men: 3.92 (0.95), women: 4.03 (1.06)/men: 1.25 (0.33), women: 1.58 (0.42)/[men: 2.01 (1.15), women: 1.64 (1.07)]
84	EPIC Norfolk	[men: 6.03 (1.05) 6.35 (1.20)]/[men: 3.92 (0.95), women: 4.03 (1.06)/men: 1.25 (0.33), women: 1.58 (0.42)/[men: 2.01 (1.15), women: 1.64 (1.07)]
85	EPIC Norfolk	[men: 6.03 (1.05) 6.35 (1.20)]/[men: 3.92 (0.95), women: 4.03 (1.06)/men: 1.25 (0.33), women: 1.58 (0.42)/[men: 2.01 (1.15), women: 1.64 (1.07)]
86	EPIC Norfolk	[men: 6.03 (1.05) 6.35 (1.20)]/[men: 3.92 (0.95), women: 4.03 (1.06)/men: 1.25 (0.33), women: 1.58 (0.42)/[men: 2.01 (1.15), women: 1.64 (1.07)]
87	Glostrup Population Studies	nd
88	Glostrup Population Studies	nd
89	Guangzhou	[5.43 (0.05)/nd/nd/nd]
90	Guangzhou	[5.43 (0.05)/nd/nd/nd]
91	Guangzhou	[5.43 (0.05)/nd/nd/nd]
92	Guangzhou	[5.43 (0.05)/nd/nd/nd]
93	Guangzhou	[5.43 (0.05)/nd/nd/nd]
94	Guangzhou	[5.43 (0.05)/nd/nd/nd]
95	Guangzhou	[5.43 (0.05)/nd/nd/nd]
96	Guangzhou	[5.43 (0.05)/nd/nd/nd]
97	Health Professional Follow-up Study	203/nd/nd/nd
98	Health Professional Follow-up Study	203/nd/nd/nd
99	Health Professional Follow-up Study	203/nd/nd/nd
100	Health Professional Follow-up Study	203/nd/nd/nd
101	Health Professional Follow-up Study	203/nd/nd/nd
102	Health Professional Follow-up Study	203/nd/nd/nd
103	Health Professional Follow-up Study	203/nd/nd/nd
104	Health Professional Follow-up Study	203/nd/nd/nd
105	Health Professional Follow-up Study	203/nd/nd/nd
106	Health Professional Follow-up Study	203/nd/nd/nd
107	Health Professional Follow-up Study	203/nd/nd/nd
108	Health Professional Follow-up Study	203/nd/nd/nd
109	Hisayama	[nd/nd/1.62 (0.42)/Median 1.1 (IQR 0.78, 1.63)]
110	Hisayama	[nd/nd/1.62 (0.42)/Median 1.1 (IQR 0.78, 1.63)]
111	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 212 (39), women 216 (42)/nd/men: 44(12); women: 60(17)/men: 139 (94), women: 116 (73)
112	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 212 (39), women 216 (42)/nd/men: 44(12); women: 60(17)/men: 139 (94), women: 116 (73)

Appendix G.2.
Causality Table: Observational Studies

Row	Study	BMI mean (SD)/weight mean (SD) Kg
80	Diet, Cancer, Health (Danish)	25.9 (3.9)
81	EPIC Norfolk	men: 26.3 (3.1), women: 25.9 (3.9)
82	EPIC Norfolk	men: 26.3 (3.1), women: 25.9 (3.9)
83	EPIC Norfolk	men: 26.3 (3.1), women: 25.9 (3.9)
84	EPIC Norfolk	men: 26.3 (3.1), women: 25.9 (3.9)
85	EPIC Norfolk	men: 26.3 (3.1), women: 25.9 (3.9)
86	EPIC Norfolk	men: 26.3 (3.1), women: 25.9 (3.9)
87	Glostrup Population Studies	23.9 (range 19.7, 29.6)
88	Glostrup Population Studies	23.9 (range 19.7, 29.6)
89	Guangzhou	nd
90	Guangzhou	nd
91	Guangzhou	nd
92	Guangzhou	nd
93	Guangzhou	nd
94	Guangzhou	nd
95	Guangzhou	nd
96	Guangzhou	nd
97	Health Professional Follow-up Study	25.5 (SE 0.02)
98	Health Professional Follow-up Study	25.5 (SE 0.02)
99	Health Professional Follow-up Study	25.5 (SE 0.02)
100	Health Professional Follow-up Study	25.5 (SE 0.02)
101	Health Professional Follow-up Study	25.5 (SE 0.02)
102	Health Professional Follow-up Study	25.5 (SE 0.02)
103	Health Professional Follow-up Study	25.5 (SE 0.02)
104	Health Professional Follow-up Study	25.5 (SE 0.02)
105	Health Professional Follow-up Study	25.5 (SE 0.02)
106	Health Professional Follow-up Study	25.5 (SE 0.02)
107	Health Professional Follow-up Study	25.5 (SE 0.02)
108	Health Professional Follow-up Study	25.5 (SE 0.02)
109	Hisayama	23.1
110	Hisayama	23.1
111	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 27.7 (3.7), women: 26.2 (5)
112	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 27.7 (3.7), women: 26.2 (5)

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Baseline n-3 intake/level (median (IQR), unless noted)
80	Diet, Cancer, Health (Danish)	EPA: 0.18 g/d, DHA: 0.43 g/d, DPA: 0.08 g/d, EPA+DPA+DHA: 0.7 g/d
81	EPIC Norfolk	ALA: mean 11.4 (SD 6.4) mmol/L, EPA: mean 63.1 (SD 45.2) mmol/l, DHA: mean 237.4 (SD 106.2) mmol/l, DPA: mean 65.1 (SD 28) mmol/l, Total n-3 FA: mean 377 (SD 165.7) mmol/l
82	EPIC Norfolk	ALA: mean 11.4 (SD 6.4) mmol/L, EPA: mean 63.1 (SD 45.2) mmol/l, DHA: mean 237.4 (SD 106.2) mmol/l, DPA: mean 65.1 (SD 28) mmol/l, Total n-3 FA: mean 377 (SD 165.7) mmol/l
83	EPIC Norfolk	ALA: mean 11.4 (SD 6.4) mmol/L, EPA: mean 63.1 (SD 45.2) mmol/l, DHA: mean 237.4 (SD 106.2) mmol/l, DPA: mean 65.1 (SD 28) mmol/l, Total n-3 FA: mean 377 (SD 165.7) mmol/l
84	EPIC Norfolk	ALA: mean 11.4 (SD 6.4) mmol/L, EPA: mean 63.1 (SD 45.2) mmol/l, DHA: mean 237.4 (SD 106.2) mmol/l, DPA: mean 65.1 (SD 28) mmol/l, Total n-3 FA: mean 377 (SD 165.7) mmol/l
85	EPIC Norfolk	ALA: mean 11.4 (SD 6.4) mmol/L, EPA: mean 63.1 (SD 45.2) mmol/l, DHA: mean 237.4 (SD 106.2) mmol/l, DPA: mean 65.1 (SD 28) mmol/l, Total n-3 FA: mean 377 (SD 165.7) mmol/l
86	EPIC Norfolk	ALA: mean 11.4 (SD 6.4) mmol/L, EPA: mean 63.1 (SD 45.2) mmol/l, DHA: mean 237.4 (SD 106.2) mmol/l, DPA: mean 65.1 (SD 28) mmol/l, Total n-3 FA: mean 377 (SD 165.7) mmol/l
87	Glostrup Population Studies	ALA: men 1.61, women 1.24, All n-3: men 0.38, women 0.3 g/d
88	Glostrup Population Studies	ALA: men 1.61, women 1.24, All n-3: men 0.38, women 0.3 g/d
89	Guangzhou	nd
90	Guangzhou	nd
91	Guangzhou	nd
92	Guangzhou	nd
93	Guangzhou	nd
94	Guangzhou	nd
95	Guangzhou	nd
96	Guangzhou	nd
97	Health Professional Follow-up Study	Marine oil: 0.24 g/d
98	Health Professional Follow-up Study	Marine oil: 0.24 g/d
99	Health Professional Follow-up Study	EPA+DHA 0.25 g/d
100	Health Professional Follow-up Study	ALA 1.08 g/d
101	Health Professional Follow-up Study	Marine oil: 0.24 g/d
102	Health Professional Follow-up Study	Marine oil: 0.24 g/d
103	Health Professional Follow-up Study	Marine oil: 0.24 g/d
104	Health Professional Follow-up Study	Marine oil: 0.24 g/d
105	Health Professional Follow-up Study	Marine oil: 0.24 g/d
106	Health Professional Follow-up Study	Marine oil: 0.24 g/d
107	Health Professional Follow-up Study	EPA+DHA 0.25 g/d
108	Health Professional Follow-up Study	ALA 1.08 g/d
109	Hisayama	EPA: 0.41
110	Hisayama	DHA: 0.93
111	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	DHA: 0.38% FA, EPA+DHA+DPA: 0.94% FA
112	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	DHA: 0.38% FA, EPA+DHA+DPA: 0.94% FA

Appendix G.2.
Causality Table: Observational Studies

Row	Study	n-3 source	n-3 measure	n-3 type(s)
80	Diet, Cancer, Health (Danish)	Intake	g/d	EPA+DPA+DHA
81	EPIC Norfolk	blood	mmol/l	all n-3
82	EPIC Norfolk	blood	Mol%	all n-3
83	EPIC Norfolk	blood	mmol/l	ALA
84	EPIC Norfolk	blood	mmol/l	EPA
85	EPIC Norfolk	blood	mmol/l	DPA
86	EPIC Norfolk	blood	mmol/l	DHA
87	Glostrup Population Studies	intake	g/d	ALA
88	Glostrup Population Studies	intake	g/d	n-3 LC-PUFA
89	Guangzhou	erythrocyte	% FA	ALA
90	Guangzhou	erythrocyte	% FA	EPA
91	Guangzhou	erythrocyte	% FA	DPA
92	Guangzhou	erythrocyte	% FA	DHA
93	Guangzhou	erythrocyte	% FA	ALA
94	Guangzhou	erythrocyte	% FA	EPA
95	Guangzhou	erythrocyte	% FA	DPA
96	Guangzhou	erythrocyte	% FA	DHA
97	Health Professional Follow-up Study	intake	g/d	EPA+DHA
98	Health Professional Follow-up Study	intake	g/d	EPA+DHA
99	Health Professional Follow-up Study	intake	g/d	EPA+DHA
100	Health Professional Follow-up Study	intake	g/d	ALA
101	Health Professional Follow-up Study	intake	g/d	EPA+DHA
102	Health Professional Follow-up Study	intake	g/d	EPA+DHA
103	Health Professional Follow-up Study	intake	g/d	EPA+DHA
104	Health Professional Follow-up Study	intake	g/d	EPA+DHA
105	Health Professional Follow-up Study	intake	g/d	EPA+DHA
106	Health Professional Follow-up Study	intake	g/d	EPA+DHA
107	Health Professional Follow-up Study	intake	g/d	EPA+DHA
108	Health Professional Follow-up Study	intake	g/d	ALA
109	Hisayama	serum	EPA/AA ratio	EPA
110	Hisayama	serum	DHA/AA ratio	DHA
111	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Intake	grams/day	DHA+EPA
112	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Intake	grams/day	DHA

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Study design
80	Diet, Cancer, Health (Danish)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
81	EPIC Norfolk	Nested Case Control
82	EPIC Norfolk	Nested Case Control
83	EPIC Norfolk	Nested Case Control
84	EPIC Norfolk	Nested Case Control
85	EPIC Norfolk	Nested Case Control
86	EPIC Norfolk	Nested Case Control
87	Glostrup Population Studies	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
88	Glostrup Population Studies	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
89	Guangzhou	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
90	Guangzhou	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
91	Guangzhou	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
92	Guangzhou	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
93	Guangzhou	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
94	Guangzhou	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
95	Guangzhou	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
96	Guangzhou	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
97	Health Professional Follow-up Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
98	Health Professional Follow-up Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
99	Health Professional Follow-up Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
100	Health Professional Follow-up Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
101	Health Professional Follow-up Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
102	Health Professional Follow-up Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
103	Health Professional Follow-up Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
104	Health Professional Follow-up Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
105	Health Professional Follow-up Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
106	Health Professional Follow-up Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
107	Health Professional Follow-up Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
108	Health Professional Follow-up Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
109	Hisayama	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
110	Hisayama	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
111	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
112	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Outcome	Reported effect Size
80	Diet, Cancer, Health (Danish)	Atrial fibrillation or flutter	See appendix F
81	EPIC Norfolk	Myocardial infarction	See appendix F
82	EPIC Norfolk	Myocardial infarction	See appendix F
83	EPIC Norfolk	Myocardial infarction	See appendix F
84	EPIC Norfolk	Myocardial infarction	See appendix F
85	EPIC Norfolk	Myocardial infarction	See appendix F
86	EPIC Norfolk	Myocardial infarction	See appendix F
87	Glostrup Population Studies	Coronary heart disease	See appendix F
88	Glostrup Population Studies	Coronary heart disease	See appendix F
89	Guangzhou	SBP	See appendix F
90	Guangzhou	SBP	See appendix F
91	Guangzhou	SBP	See appendix F
92	Guangzhou	SBP	See appendix F
93	Guangzhou	DBP	See appendix F
94	Guangzhou	DBP	See appendix F
95	Guangzhou	DBP	See appendix F
96	Guangzhou	DBP	See appendix F
97	Health Professional Follow-up Study	CABG	See appendix F
98	Health Professional Follow-up Study	Coronary heart disease	See appendix F
99	Health Professional Follow-up Study	Coronary heart disease	See appendix F
100	Health Professional Follow-up Study	Coronary heart disease	See appendix F
101	Health Professional Follow-up Study	Death, CHD	See appendix F
102	Health Professional Follow-up Study	MACE	See appendix F
103	Health Professional Follow-up Study	Myocardial infarction	See appendix F
104	Health Professional Follow-up Study	Stroke, hemorrhagic	See appendix F
105	Health Professional Follow-up Study	Stroke, ischemic	See appendix F
106	Health Professional Follow-up Study	Stroke, total	See appendix F
107	Health Professional Follow-up Study	Sudden cardiac death	See appendix F
108	Health Professional Follow-up Study	Sudden cardiac death	See appendix F
109	Hisayama	CVD, total	See appendix F
110	Hisayama	CVD, total	See appendix F
111	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Atrial fibrillation	See appendix F
112	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Atrial fibrillation	See appendix F

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Study years (study start date)	Country
113	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	1987	US
114	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	1987	US
115	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	1987	US
116	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	1987	US
117	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	1987	US
118	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	1987	US
119	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	1987	US
120	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	1987	US
121	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	1987	US
122	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	1987	US
123	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	1987	US
124	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	1987	US
125	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	1988-1990	Japan
126	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	1988-1990	Japan
127	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	1988-1990	Japan
128	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	1988-1990	Japan
129	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	1988-1990	Japan
130	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	1988-1990	Japan
131	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	1988-1990	Japan

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Population	Risk type
113	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Primary Prevention, Healthy	The population is a mixture of people
114	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Primary Prevention, Healthy	The population is a mixture of people
115	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Primary Prevention, Healthy	The population is a mixture of people
116	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Primary Prevention, Healthy	The population is a mixture of people
117	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Primary Prevention, Healthy	The population is a mixture of people
118	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Primary Prevention, Healthy	The population is a mixture of people
119	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Primary Prevention, Healthy	The population is a mixture of people
120	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Primary Prevention, Healthy	The population is a mixture of people
121	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Primary Prevention, Healthy	The population is a mixture of people
122	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Primary Prevention, Healthy	The population is a mixture of people
123	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Primary Prevention, Healthy	The population is a mixture of people
124	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Primary Prevention, Healthy	The population is a mixture of people
125	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Primary Prevention, Healthy	na
126	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Primary Prevention, Healthy	na
127	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Primary Prevention, Healthy	na
128	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Primary Prevention, Healthy	na
129	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Primary Prevention, Healthy	na
130	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Primary Prevention, Healthy	na
131	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Primary Prevention, Healthy	na

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Sample size (total)	Age mean (SD) [median]	Sex (% male)
113	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	3592	men: 54.2 (5.6), women 53.3 (5.5)	46.6
114	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	3592	men: 54.2 (5.6), women 53.3 (5.5)	46.6
115	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	3592	men: 54.2 (5.6), women 53.3 (5.5)	46.6
116	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	3592	men: 54.2 (5.6), women 53.3 (5.5)	46.6
117	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	3592	men: 54.2 (5.6), women 53.3 (5.5)	46.6
118	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	3592	men: 54.2 (5.6), women 53.3 (5.5)	46.6
119	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	3592	men: 54.2 (5.6), women 53.3 (5.5)	46.6
120	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	3592	men: 54.2 (5.6), women 53.3 (5.5)	46.6
121	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	3592	men: 54.2 (5.6), women 53.3 (5.5)	46.6
122	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	3592	men: 54.2 (5.6), women 53.3 (5.5)	46.6
123	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	3592	men: 54.2 (5.6), women 53.3 (5.5)	46.6
124	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	3592	men: 54.2 (5.6), women 53.3 (5.5)	46.6
125	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	57972	55.7	39.5
126	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	57972	55.7	39.5
127	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	57972	55.7	39.5
128	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	57972	55.7	39.5
129	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	57972	55.7	39.5
130	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	57972	55.7	39.5
131	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	57972	55.7	39.5

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Race	Blood pressure SBP/DBP (mmHg)
113	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	100 white	men: 120.5 (14.8), women 116.9 (17.0)/men 75.5(9.2); women 72.1 (9.1)
114	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	100 white	men: 120.5 (14.8), women 116.9 (17.0)/men 75.5(9.2); women 72.1 (9.1)
115	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	100 white	men: 120.5 (14.8), women 116.9 (17.0)/men 75.5(9.2); women 72.1 (9.1)
116	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	100 white	men: 120.5 (14.8), women 116.9 (17.0)/men 75.5(9.2); women 72.1 (9.1)
117	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	100 white	men: 120.5 (14.8), women 116.9 (17.0)/men 75.5(9.2); women 72.1 (9.1)
118	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	100 white	men: 120.5 (14.8), women 116.9 (17.0)/men 75.5(9.2); women 72.1 (9.1)
119	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	100 white	men: 120.5 (14.8), women 116.9 (17.0)/men 75.5(9.2); women 72.1 (9.1)
120	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	100 white	men: 120.5 (14.8), women 116.9 (17.0)/men 75.5(9.2); women 72.1 (9.1)
121	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	100 white	men: 120.5 (14.8), women 116.9 (17.0)/men 75.5(9.2); women 72.1 (9.1)
122	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	100 white	men: 120.5 (14.8), women 116.9 (17.0)/men 75.5(9.2); women 72.1 (9.1)
123	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	100 white	men: 120.5 (14.8), women 116.9 (17.0)/men 75.5(9.2); women 72.1 (9.1)
124	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	100 white	men: 120.5 (14.8), women 116.9 (17.0)/men 75.5(9.2); women 72.1 (9.1)
125	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	100 Asian	nd
126	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	100 Asian	nd
127	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	100 Asian	nd
128	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	100 Asian	nd
129	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	100 Asian	nd
130	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	100 Asian	nd
131	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	100 Asian	nd

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
113	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 212 (39), women 216 (42)/nd/men: 44(12); women: 60(17)/men: 139 (94), women: 116 (73)
114	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 212 (39), women 216 (42)/nd/men: 44(12); women: 60(17)/men: 139 (94), women: 116 (73)
115	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 212 (39), women 216 (42)/nd/men: 44(12); women: 60(17)/men: 139 (94), women: 116 (73)
116	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 212 (39), women 216 (42)/nd/men: 44(12); women: 60(17)/men: 139 (94), women: 116 (73)
117	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 212 (39), women 216 (42)/nd/men: 44(12); women: 60(17)/men: 139 (94), women: 116 (73)
118	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 212 (39), women 216 (42)/nd/men: 44(12); women: 60(17)/men: 139 (94), women: 116 (73)
119	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 212 (39), women 216 (42)/nd/men: 44(12); women: 60(17)/men: 139 (94), women: 116 (73)
120	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 212 (39), women 216 (42)/nd/men: 44(12); women: 60(17)/men: 139 (94), women: 116 (73)
121	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 212 (39), women 216 (42)/nd/men: 44(12); women: 60(17)/men: 139 (94), women: 116 (73)
122	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 212 (39), women 216 (42)/nd/men: 44(12); women: 60(17)/men: 139 (94), women: 116 (73)
123	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 212 (39), women 216 (42)/nd/men: 44(12); women: 60(17)/men: 139 (94), women: 116 (73)
124	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 212 (39), women 216 (42)/nd/men: 44(12); women: 60(17)/men: 139 (94), women: 116 (73)
125	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	nd
126	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	nd
127	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	nd
128	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	nd
129	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	nd
130	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	nd
131	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	nd

Appendix G.2.
Causality Table: Observational Studies

Row	Study	BMI mean (SD)/weight mean (SD) Kg
113	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 27.7 (3.7), women: 26.2 (5)
114	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 27.7 (3.7), women: 26.2 (5)
115	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 27.7 (3.7), women: 26.2 (5)
116	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 27.7 (3.7), women: 26.2 (5)
117	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 27.7 (3.7), women: 26.2 (5)
118	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 27.7 (3.7), women: 26.2 (5)
119	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 27.7 (3.7), women: 26.2 (5)
120	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 27.7 (3.7), women: 26.2 (5)
121	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 27.7 (3.7), women: 26.2 (5)
122	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 27.7 (3.7), women: 26.2 (5)
123	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 27.7 (3.7), women: 26.2 (5)
124	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 27.7 (3.7), women: 26.2 (5)
125	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 22.7, women 22.9
126	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 22.7, women 22.9
127	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 22.7, women 22.9
128	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 22.7, women 22.9
129	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 22.7, women 22.9
130	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 22.7, women 22.9
131	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 22.7, women 22.9

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Baseline n-3 intake/level (median (IQR), unless noted)
113	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	DHA: 0.38% FA, EPA+DHA+DPA: 0.94% FA
114	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	DHA: 0.38% FA, EPA+DHA+DPA: 0.94% FA
115	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	DHA: 0.38% FA, EPA+DHA+DPA: 0.94% FA
116	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	DHA: 0.38% FA, EPA+DHA+DPA: 0.94% FA
117	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	DHA: 0.38% FA, EPA+DHA+DPA: 0.94% FA
118	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	DHA: 0.38% FA, EPA+DHA+DPA: 0.94% FA
119	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	DHA: 0.38% FA, EPA+DHA+DPA: 0.94% FA
120	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	DHA: 0.38% FA, EPA+DHA+DPA: 0.94% FA
121	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	DHA: 0.38% FA, EPA+DHA+DPA: 0.94% FA
122	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	DHA: 0.38% FA, EPA+DHA+DPA: 0.94% FA
123	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	DHA: 0.38% FA, EPA+DHA+DPA: 0.94% FA
124	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	DHA: 0.38% FA, EPA+DHA+DPA: 0.94% FA
125	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	All n-3 FA: 1.61 g/d
126	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	All n-3 FA: 1.61 g/d
127	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	All n-3 FA: 1.61 g/d
128	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	All n-3 FA: 1.61 g/d
129	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	All n-3 FA: 1.61 g/d
130	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	All n-3 FA: 1.61 g/d
131	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	All n-3 FA: 1.61 g/d

Appendix G.2.
Causality Table: Observational Studies

Row	Study	n-3 source	n-3 measure	n-3 type(s)
113	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Intake	grams/day	EPA
114	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Phospholipid	grams/day	DHA+EPA
115	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Phospholipid	grams/day	DHA
116	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Phospholipid	grams/day	EPA
117	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Cholesterol ester	% of total FA	ALA
118	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Phospholipid	% of total FA	ALA
119	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Cholesterol ester	% of total FA	EPA+DHA+DPA
120	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Phospholipid	% of total FA	EPA+DHA+DPA
121	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Cholesterol ester	% of total FA	EPA
122	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Phospholipid	% of total FA	EPA
123	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Cholesterol ester	% of total FA	DHA
124	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Phospholipid	% of total FA	DHA
125	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	intake	g/d	all n-3
126	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	intake	g/d	all n-3
127	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	intake	g/d	all n-3
128	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	intake	g/d	all n-3
129	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	intake	g/d	all n-3
130	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	intake	g/d	all n-3
131	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	intake	g/d	all n-3

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Study design
113	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
114	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
115	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
116	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
117	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
118	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
119	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
120	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
121	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
122	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
123	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
124	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
125	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
126	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
127	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
128	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
129	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
130	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
131	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Outcome	Reported effect Size
113	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Atrial fibrillation	See appendix F
114	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Atrial fibrillation	See appendix F
115	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Atrial fibrillation	See appendix F
116	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Atrial fibrillation	See appendix F
117	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Congestive heart failure	See appendix F
118	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Congestive heart failure	See appendix F
119	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Congestive heart failure	See appendix F
120	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Congestive heart failure	See appendix F
121	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Congestive heart failure	See appendix F
122	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Congestive heart failure	See appendix F
123	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Congestive heart failure	See appendix F
124	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Congestive heart failure	See appendix F
125	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Death, all cause	See appendix F
126	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Death, cardiac arrest	See appendix F
127	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Death, CHD	See appendix F
128	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Death, CVD	See appendix F
129	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Death, heart failure	See appendix F
130	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Death, MI	See appendix F
131	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Death, stroke	See appendix F

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Study years (study start date)	Country
132	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	1988-1990	Japan
133	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	1987	US
134	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	1987	US
135	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	1987	US
136	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	1987	US
137	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	1987	US
138	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	1987	US
139	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	1987	US
140	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	1987	US
141	Japan Public Health Center-Based (JPHC) Study - Cohort I	1990	Japan
142	Japan Public Health Center-Based (JPHC) Study - Cohort I	1990	Japan
143	Japan Public Health Center-Based (JPHC) Study - Cohort I	1990	Japan
144	Japan Public Health Center-Based (JPHC) Study - Cohort I	1990	Japan
145	JELIS	1996-1999	Japan
146	JELIS	1996-1999	Japan
147	Kuopio Ischemic Heart Disease Risk Factor Study	1984	Finland
148	Kuopio Ischemic Heart Disease Risk Factor Study	1984	Finland
149	Kuopio Ischemic Heart Disease Risk Factor Study	1984	Finland
150	Kuopio Ischemic Heart Disease Risk Factor Study	1984	Finland

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Population	Risk type
132	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Primary Prevention, Healthy	na
133	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Primary Prevention, Healthy	The population is a mixture of people
134	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Primary Prevention, Healthy	The population is a mixture of people
135	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Primary Prevention, Healthy	The population is a mixture of people
136	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Primary Prevention, Healthy	The population is a mixture of people
137	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Primary Prevention, Healthy	The population is a mixture of people
138	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Primary Prevention, Healthy	The population is a mixture of people
139	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Primary Prevention, Healthy	The population is a mixture of people
140	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Primary Prevention, Healthy	The population is a mixture of people
141	Japan Public Health Center-Based (JPHC) Study - Cohort I	Primary Prevention, Healthy	na
142	Japan Public Health Center-Based (JPHC) Study - Cohort I	Primary Prevention, Healthy	na
143	Japan Public Health Center-Based (JPHC) Study - Cohort I	Primary Prevention, Healthy	na
144	Japan Public Health Center-Based (JPHC) Study - Cohort I	Primary Prevention, Healthy	na
145	JELIS	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome, hypertension, dyslipidemia, or chronic kidney disease)	Dyslipidemia (>250mg/dL total cholesterol or >170mg/dL LDL)
146	JELIS	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome, hypertension, dyslipidemia, or chronic kidney disease)	Dyslipidemia (>250mg/dL total cholesterol or >170mg/dL LDL)
147	Kuopio Ischemic Heart Disease Risk Factor Study	Primary Prevention, Healthy	na
148	Kuopio Ischemic Heart Disease Risk Factor Study	Primary Prevention, Healthy	na
149	Kuopio Ischemic Heart Disease Risk Factor Study	Primary Prevention, Healthy	na
150	Kuopio Ischemic Heart Disease Risk Factor Study	Primary Prevention, Healthy	na

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Sample size (total)	Age mean (SD) [median]	Sex (% male)
132	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	57972	55.7	39.5
133	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	3592	men: 54.2 (5.6), women 53.3 (5.5)	46.6
134	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	3592	men: 54.2 (5.6), women 53.3 (5.5)	46.6
135	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	3592	men: 54.2 (5.6), women 53.3 (5.5)	46.6
136	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	3592	men: 54.2 (5.6), women 53.3 (5.5)	46.6
137	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	3592	men: 54.2 (5.6), women 53.3 (5.5)	46.6
138	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	3592	men: 54.2 (5.6), women 53.3 (5.5)	46.6
139	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	3592	men: 54.2 (5.6), women 53.3 (5.5)	46.6
140	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	3592	men: 54.2 (5.6), women 53.3 (5.5)	46.6
141	Japan Public Health Center-Based (JPHC) Study - Cohort I	41578	49	48
142	Japan Public Health Center-Based (JPHC) Study - Cohort I	41578	49	48
143	Japan Public Health Center-Based (JPHC) Study - Cohort I	41578	49	48
144	Japan Public Health Center-Based (JPHC) Study - Cohort I	41578	49	48
145	JELIS	15534	controls: 61 (9), cases: 61 (8)	30.25
146	JELIS	15534	controls: 61 (9), cases: 61 (8)	30.25
147	Kuopio Ischemic Heart Disease Risk Factor Study	1941	52.8 (5.3)	100
148	Kuopio Ischemic Heart Disease Risk Factor Study	1941	52.8 (5.3)	100
149	Kuopio Ischemic Heart Disease Risk Factor Study	1941	52.8 (5.3)	100
150	Kuopio Ischemic Heart Disease Risk Factor Study	1941	52.8 (5.3)	100

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Race	Blood pressure SBP/DBP (mmHg)
132	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	100 Asian	nd
133	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	100 white	men: 120.5 (14.8), women 116.9 (17.0)/men 75.5(9.2); women 72.1 (9.1)
134	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	100 white	men: 120.5 (14.8), women 116.9 (17.0)/men 75.5(9.2); women 72.1 (9.1)
135	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	100 white	men: 120.5 (14.8), women 116.9 (17.0)/men 75.5(9.2); women 72.1 (9.1)
136	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	100 white	men: 120.5 (14.8), women 116.9 (17.0)/men 75.5(9.2); women 72.1 (9.1)
137	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	100 white	men: 120.5 (14.8), women 116.9 (17.0)/men 75.5(9.2); women 72.1 (9.1)
138	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	100 white	men: 120.5 (14.8), women 116.9 (17.0)/men 75.5(9.2); women 72.1 (9.1)
139	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	100 white	men: 120.5 (14.8), women 116.9 (17.0)/men 75.5(9.2); women 72.1 (9.1)
140	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	100 white	men: 120.5 (14.8), women 116.9 (17.0)/men 75.5(9.2); women 72.1 (9.1)
141	Japan Public Health Center-Based (JPHC) Study - Cohort I	nd	nd
142	Japan Public Health Center-Based (JPHC) Study - Cohort I	nd	nd
143	Japan Public Health Center-Based (JPHC) Study - Cohort I	nd	nd
144	Japan Public Health Center-Based (JPHC) Study - Cohort I	nd	nd
145	JELIS	100 Asian	controls: 134.9 (20.9), cases: 134.9 (21.4)/controls 79.2 (12.6), cases: 78.9 (12.6)
146	JELIS	100 Asian	controls: 134.9 (20.9), cases: 134.9 (21.4)/controls 79.2 (12.6), cases: 78.9 (12.6)
147	Kuopio Ischemic Heart Disease Risk Factor Study	nd	nd
148	Kuopio Ischemic Heart Disease Risk Factor Study	nd	nd
149	Kuopio Ischemic Heart Disease Risk Factor Study	nd	nd
150	Kuopio Ischemic Heart Disease Risk Factor Study	nd	nd

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
132	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	nd
133	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 212 (39), women 216 (42)/nd/men: 44(12); women: 60(17)/men: 139 (94), women: 116 (73)
134	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 212 (39), women 216 (42)/nd/men: 44(12); women: 60(17)/men: 139 (94), women: 116 (73)
135	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 212 (39), women 216 (42)/nd/men: 44(12); women: 60(17)/men: 139 (94), women: 116 (73)
136	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 212 (39), women 216 (42)/nd/men: 44(12); women: 60(17)/men: 139 (94), women: 116 (73)
137	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 212 (39), women 216 (42)/nd/men: 44(12); women: 60(17)/men: 139 (94), women: 116 (73)
138	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 212 (39), women 216 (42)/nd/men: 44(12); women: 60(17)/men: 139 (94), women: 116 (73)
139	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 212 (39), women 216 (42)/nd/men: 44(12); women: 60(17)/men: 139 (94), women: 116 (73)
140	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 212 (39), women 216 (42)/nd/men: 44(12); women: 60(17)/men: 139 (94), women: 116 (73)
141	Japan Public Health Center-Based (JPHC) Study - Cohort I	nd
142	Japan Public Health Center-Based (JPHC) Study - Cohort I	nd
143	Japan Public Health Center-Based (JPHC) Study - Cohort I	nd
144	Japan Public Health Center-Based (JPHC) Study - Cohort I	nd
145	JELIS	nd
146	JELIS	nd
147	Kuopio Ischemic Heart Disease Risk Factor Study	nd
148	Kuopio Ischemic Heart Disease Risk Factor Study	nd
149	Kuopio Ischemic Heart Disease Risk Factor Study	nd
150	Kuopio Ischemic Heart Disease Risk Factor Study	nd

Appendix G.2.
Causality Table: Observational Studies

Row	Study	BMI mean (SD)/weight mean (SD) Kg
132	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 22.7, women 22.9
133	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 27.7 (3.7), women: 26.2 (5)
134	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 27.7 (3.7), women: 26.2 (5)
135	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 27.7 (3.7), women: 26.2 (5)
136	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 27.7 (3.7), women: 26.2 (5)
137	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 27.7 (3.7), women: 26.2 (5)
138	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 27.7 (3.7), women: 26.2 (5)
139	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 27.7 (3.7), women: 26.2 (5)
140	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	men: 27.7 (3.7), women: 26.2 (5)
141	Japan Public Health Center-Based (JPHC) Study - Cohort I	nd
142	Japan Public Health Center-Based (JPHC) Study - Cohort I	nd
143	Japan Public Health Center-Based (JPHC) Study - Cohort I	nd
144	Japan Public Health Center-Based (JPHC) Study - Cohort I	nd
145	JELIS	controls: 24.1 (3.3), cases 24.0 (3.2)
146	JELIS	controls: 24.1 (3.3), cases 24.0 (3.2)
147	Kuopio Ischemic Heart Disease Risk Factor Study	nd
148	Kuopio Ischemic Heart Disease Risk Factor Study	nd
149	Kuopio Ischemic Heart Disease Risk Factor Study	nd
150	Kuopio Ischemic Heart Disease Risk Factor Study	nd

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Baseline n-3 intake/level (median (IQR), unless noted)
132	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	All n-3 FA: 1.61 g/d
133	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	DHA: 0.38% FA, EPA+DHA+DPA: 0.94% FA
134	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	DHA: 0.38% FA, EPA+DHA+DPA: 0.94% FA
135	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	DHA: 0.38% FA, EPA+DHA+DPA: 0.94% FA
136	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	DHA: 0.38% FA, EPA+DHA+DPA: 0.94% FA
137	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	DHA: 0.38% FA, EPA+DHA+DPA: 0.94% FA
138	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	DHA: 0.38% FA, EPA+DHA+DPA: 0.94% FA
139	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	DHA: 0.38% FA, EPA+DHA+DPA: 0.94% FA
140	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	DHA: 0.38% FA, EPA+DHA+DPA: 0.94% FA
141	Japan Public Health Center-Based (JPHC) Study - Cohort I	EPA+DHA: mean 0.9
142	Japan Public Health Center-Based (JPHC) Study - Cohort I	EPA+DHA: mean 0.9
143	Japan Public Health Center-Based (JPHC) Study - Cohort I	EPA+DHA: mean 0.9
144	Japan Public Health Center-Based (JPHC) Study - Cohort I	EPA+DHA: mean 0.9
145	JELIS	EPA: 133 mcg/mL, DHA: 160 mcg/mL
146	JELIS	EPA: 133 mcg/mL, DHA: 160 mcg/mL
147	Kuopio Ischemic Heart Disease Risk Factor Study	EPA: 1.48% FA, DPA: 0.55% FA, DHA: 2.37% FA, EPA+DPA+DHA: 4.36% FA
148	Kuopio Ischemic Heart Disease Risk Factor Study	EPA: 1.48% FA, DPA: 0.55% FA, DHA: 2.37% FA, EPA+DPA+DHA: 4.36% FA
149	Kuopio Ischemic Heart Disease Risk Factor Study	EPA: 1.48% FA, DPA: 0.55% FA, DHA: 2.37% FA, EPA+DPA+DHA: 4.36% FA
150	Kuopio Ischemic Heart Disease Risk Factor Study	EPA: 1.48% FA, DPA: 0.55% FA, DHA: 2.37% FA, EPA+DPA+DHA: 4.36% FA

Appendix G.2.
Causality Table: Observational Studies

Row	Study	n-3 source	n-3 measure	n-3 type(s)
132	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	intake	g/d	all n-3
133	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Cholesterol ester	% plasma LC n-3 FA	EPA+DHA+DPA
134	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Phospholipid	% plasma LC n-3 FA	EPA+DHA+DPA
135	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Cholesterol ester	% plasma LC n-3 FA	ALA
136	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Phospholipid	% plasma LC n-3 FA	ALA
137	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Cholesterol ester	% plasma LC n-3 FA	EPA
138	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Phospholipid	% plasma LC n-3 FA	EPA
139	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Cholesterol ester	% plasma LC n-3 FA	DHA
140	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Phospholipid	% plasma LC n-3 FA	DHA
141	Japan Public Health Center-Based (JPHC) Study - Cohort I	intake	g/d	EPA + DHA
142	Japan Public Health Center-Based (JPHC) Study - Cohort I	intake	g/d	EPA + DHA
143	Japan Public Health Center-Based (JPHC) Study - Cohort I	intake	g/d	EPA + DHA
144	Japan Public Health Center-Based (JPHC) Study - Cohort I	intake	g/d	EPA + DHA
145	JELIS	plasma	mcg/mL	EPA
146	JELIS	plasma	mcg/mL	DHA
147	Kuopio Ischemic Heart Disease Risk Factor Study	serum	% of serum FA	EPA+DPA+DHA
148	Kuopio Ischemic Heart Disease Risk Factor Study	serum	% of serum FA	EPA
149	Kuopio Ischemic Heart Disease Risk Factor Study	serum	% of serum FA	DPA
150	Kuopio Ischemic Heart Disease Risk Factor Study	serum	% of serum FA	DHA

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Study design
132	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
133	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
134	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
135	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
136	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
137	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
138	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
139	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
140	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
141	Japan Public Health Center-Based (JPHC) Study - Cohort I	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
142	Japan Public Health Center-Based (JPHC) Study - Cohort I	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
143	Japan Public Health Center-Based (JPHC) Study - Cohort I	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
144	Japan Public Health Center-Based (JPHC) Study - Cohort I	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
145	JELIS	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
146	JELIS	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
147	Kuopio Ischemic Heart Disease Risk Factor Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
148	Kuopio Ischemic Heart Disease Risk Factor Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
149	Kuopio Ischemic Heart Disease Risk Factor Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
150	Kuopio Ischemic Heart Disease Risk Factor Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Outcome	Reported effect Size
132	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Death, stroke, ischemic	See appendix F
133	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Stroke, ischemic	See appendix F
134	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Stroke, ischemic	See appendix F
135	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Stroke, ischemic	See appendix F
136	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Stroke, ischemic	See appendix F
137	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Stroke, ischemic	See appendix F
138	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Stroke, ischemic	See appendix F
139	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Stroke, ischemic	See appendix F
140	JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk)	Stroke, ischemic	See appendix F
141	Japan Public Health Center-Based (JPHC) Study - Cohort I	Coronary heart disease	See appendix F
142	Japan Public Health Center-Based (JPHC) Study - Cohort I	Death, cardiac	See appendix F
143	Japan Public Health Center-Based (JPHC) Study - Cohort I	Myocardial infarction	See appendix F
144	Japan Public Health Center-Based (JPHC) Study - Cohort I	Sudden cardiac death	See appendix F
145	JELIS	MACE	See appendix F
146	JELIS	MACE	See appendix F
147	Kuopio Ischemic Heart Disease Risk Factor Study	Atrial fibrillation	See appendix F
148	Kuopio Ischemic Heart Disease Risk Factor Study	Atrial fibrillation	See appendix F
149	Kuopio Ischemic Heart Disease Risk Factor Study	Atrial fibrillation	See appendix F
150	Kuopio Ischemic Heart Disease Risk Factor Study	Atrial fibrillation	See appendix F

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Study years (study start date)	Country
151	MDC (Malmo Diet and Cancer)	1991	Sweden
152	MDC (Malmo Diet and Cancer)	1991	Sweden
153	MDC (Malmo Diet and Cancer)	1991	Sweden
154	MDC (Malmo Diet and Cancer)	1991	Sweden
155	MDC (Malmo Diet and Cancer)	1991	Sweden
156	MDC (Malmo Diet and Cancer)	1991	Sweden
157	MESA	2000	US
158	MESA	2000	US
159	MESA	2000	US
160	MESA	2000	US
161	MESA	2000	US
162	MESA	2000	US
163	MESA	2000	US
164	MESA	2000	US
165	MESA	2000	US
166	MESA	2000	US
167	MESA	2000	US
168	MESA	2000	US
169	MESA	2000	US
170	MESA	2000	US
171	MESA	2000	US
172	MESA	2000	US
173	MESA	2000	US

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Population	Risk type
151	MDC (Malmo Diet and Cancer)	Primary Prevention, Healthy	na
152	MDC (Malmo Diet and Cancer)	Primary Prevention, Healthy	na
153	MDC (Malmo Diet and Cancer)	Primary Prevention, Healthy	na
154	MDC (Malmo Diet and Cancer)	Primary Prevention, Healthy	na
155	MDC (Malmo Diet and Cancer)	Primary Prevention, Healthy	na
156	MDC (Malmo Diet and Cancer)	Primary Prevention, Healthy	na
157	MESA	Primary Prevention, Healthy	na
158	MESA	Primary Prevention, Healthy	na
159	MESA	Primary Prevention, Healthy	na
160	MESA	Primary Prevention, Healthy	na
161	MESA	Primary Prevention, Healthy	na
162	MESA	Primary Prevention, Healthy	na
163	MESA	Primary Prevention, Healthy	na
164	MESA	Primary Prevention, Healthy	na
165	MESA	Primary Prevention, Healthy	na
166	MESA	Primary Prevention, Healthy	na
167	MESA	Primary Prevention, Healthy	na
168	MESA	Primary Prevention, Healthy	na
169	MESA	Primary Prevention, Healthy	na
170	MESA	Primary Prevention, Healthy	na
171	MESA	Primary Prevention, Healthy	na
172	MESA	Primary Prevention, Healthy	na
173	MESA	Primary Prevention, Healthy	na

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Sample size (total)	Age mean (SD) [median]	Sex (% male)
151	MDC (Malmo Diet and Cancer)	24032	range 44, 74	37
152	MDC (Malmo Diet and Cancer)	24032	range 44, 74	37
153	MDC (Malmo Diet and Cancer)	24032	range 44, 74	37
154	MDC (Malmo Diet and Cancer)	24032	range 44, 74	37
155	MDC (Malmo Diet and Cancer)	24032	range 44, 74	37
156	MDC (Malmo Diet and Cancer)	24032	range 44, 74	37
157	MESA	2837	61.5 (10.2)	46.8
158	MESA	2837	61.5 (10.2)	46.8
159	MESA	2837	61.5 (10.2)	46.8
160	MESA	2837	61.5 (10.2)	46.8
161	MESA	2837	61.5 (10.2)	46.8
162	MESA	2837	61.5 (10.2)	46.8
163	MESA	2837	61.5 (10.2)	46.8
164	MESA	2837	61.5 (10.2)	46.8
165	MESA	2837	61.5 (10.2)	46.8
166	MESA	2837	61.5 (10.2)	46.8
167	MESA	2837	61.5 (10.2)	46.8
168	MESA	2837	61.5 (10.2)	46.8
169	MESA	2837	61.5 (10.2)	46.8
170	MESA	2837	61.5 (10.2)	46.8
171	MESA	2837	61.5 (10.2)	46.8
172	MESA	2837	61.5 (10.2)	46.8
173	MESA	2837	61.5 (10.2)	46.8

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Race	Blood pressure SBP/DBP (mmHg)
151	MDC (Malmo Diet and Cancer)	nd	nd
152	MDC (Malmo Diet and Cancer)	nd	nd
153	MDC (Malmo Diet and Cancer)	nd	nd
154	MDC (Malmo Diet and Cancer)	nd	nd
155	MDC (Malmo Diet and Cancer)	nd	nd
156	MDC (Malmo Diet and Cancer)	nd	nd
157	MESA	26 white, 25 black, 25 Asian, 25 Hispanic	nd
158	MESA	26 white, 25 black, 25 Asian, 25 Hispanic	nd
159	MESA	26 white, 25 black, 25 Asian, 25 Hispanic	nd
160	MESA	26 white, 25 black, 25 Asian, 25 Hispanic	nd
161	MESA	26 white, 25 black, 25 Asian, 25 Hispanic	nd
162	MESA	26 white, 25 black, 25 Asian, 25 Hispanic	nd
163	MESA	26 white, 25 black, 25 Asian, 25 Hispanic	nd
164	MESA	26 white, 25 black, 25 Asian, 25 Hispanic	nd
165	MESA	26 white, 25 black, 25 Asian, 25 Hispanic	nd
166	MESA	26 white, 25 black, 25 Asian, 25 Hispanic	nd
167	MESA	26 white, 25 black, 25 Asian, 25 Hispanic	nd
168	MESA	26 white, 25 black, 25 Asian, 25 Hispanic	nd
169	MESA	26 white, 25 black, 25 Asian, 25 Hispanic	nd
170	MESA	26 white, 25 black, 25 Asian, 25 Hispanic	nd
171	MESA	26 white, 25 black, 25 Asian, 25 Hispanic	nd
172	MESA	26 white, 25 black, 25 Asian, 25 Hispanic	nd
173	MESA	26 white, 25 black, 25 Asian, 25 Hispanic	nd

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
151	MDC (Malmo Diet and Cancer)	nd
152	MDC (Malmo Diet and Cancer)	nd
153	MDC (Malmo Diet and Cancer)	nd
154	MDC (Malmo Diet and Cancer)	nd
155	MDC (Malmo Diet and Cancer)	nd
156	MDC (Malmo Diet and Cancer)	nd
157	MESA	nd
158	MESA	nd
159	MESA	nd
160	MESA	nd
161	MESA	nd
162	MESA	nd
163	MESA	nd
164	MESA	nd
165	MESA	nd
166	MESA	nd
167	MESA	nd
168	MESA	nd
169	MESA	nd
170	MESA	nd
171	MESA	nd
172	MESA	nd
173	MESA	nd

Appendix G.2.
Causality Table: Observational Studies

Row	Study	BMI mean (SD)/weight mean (SD) Kg
151	MDC (Malmo Diet and Cancer)	25.6
152	MDC (Malmo Diet and Cancer)	25.6
153	MDC (Malmo Diet and Cancer)	25.6
154	MDC (Malmo Diet and Cancer)	25.6
155	MDC (Malmo Diet and Cancer)	25.6
156	MDC (Malmo Diet and Cancer)	25.6
157	MESA	27.9 (5.5)
158	MESA	27.9 (5.5)
159	MESA	27.9 (5.5)
160	MESA	27.9 (5.5)
161	MESA	27.9 (5.5)
162	MESA	27.9 (5.5)
163	MESA	27.9 (5.5)
164	MESA	27.9 (5.5)
165	MESA	27.9 (5.5)
166	MESA	27.9 (5.5)
167	MESA	27.9 (5.5)
168	MESA	27.9 (5.5)
169	MESA	27.9 (5.5)
170	MESA	27.9 (5.5)
171	MESA	27.9 (5.5)
172	MESA	27.9 (5.5)
173	MESA	27.9 (5.5)

Row	Study	Baseline n-3 intake/level (median (IQR), unless noted)
151	MDC (Malmo Diet and Cancer)	ALA 0.72% energy, EPA+DPA+DHA: 0.19% energy, Total n-3 FA: 0.96% energy
152	MDC (Malmo Diet and Cancer)	ALA 0.72% energy, EPA+DPA+DHA: 0.19% energy, Total n-3 FA: 0.96% energy
153	MDC (Malmo Diet and Cancer)	ALA 0.72% energy, EPA+DPA+DHA: 0.19% energy, Total n-3 FA: 0.96% energy
154	MDC (Malmo Diet and Cancer)	ALA 0.72% energy, EPA+DPA+DHA: 0.19% energy, Total n-3 FA: 0.96% energy
155	MDC (Malmo Diet and Cancer)	ALA 0.72% energy, EPA+DPA+DHA: 0.19% energy, Total n-3 FA: 0.96% energy
156	MDC (Malmo Diet and Cancer)	ALA 0.72% energy, EPA+DPA+DHA: 0.19% energy, Total n-3 FA: 0.96% energy
157	MESA	ALA: mean 1.0 (SD 0.6) g/d, EPA: mean 45 (SD 50) mg/d, DHA: mean 82 (SD 73) mg/d, DPA: mean 20 (SD 20) mg/d
158	MESA	ALA: mean 1.0 (SD 0.6) g/d, EPA: mean 45 (SD 50) mg/d, DHA: mean 82 (SD 73) mg/d, DPA: mean 20 (SD 20) mg/d
159	MESA	ALA: mean 1.0 (SD 0.6) g/d, EPA: mean 45 (SD 50) mg/d, DHA: mean 82 (SD 73) mg/d, DPA: mean 20 (SD 20) mg/d
160	MESA	ALA: mean 1.0 (SD 0.6) g/d, EPA: mean 45 (SD 50) mg/d, DHA: mean 82 (SD 73) mg/d, DPA: mean 20 (SD 20) mg/d
161	MESA	ALA: mean 1.0 (SD 0.6) g/d, EPA: mean 45 (SD 50) mg/d, DHA: mean 82 (SD 73) mg/d, DPA: mean 20 (SD 20) mg/d
162	MESA	ALA: mean 1.0 (SD 0.6) g/d, EPA: mean 45 (SD 50) mg/d, DHA: mean 82 (SD 73) mg/d, DPA: mean 20 (SD 20) mg/d
163	MESA	ALA: mean 1.0 (SD 0.6) g/d, EPA: mean 45 (SD 50) mg/d, DHA: mean 82 (SD 73) mg/d, DPA: mean 20 (SD 20) mg/d
164	MESA	ALA: mean 1.0 (SD 0.6) g/d, EPA: mean 45 (SD 50) mg/d, DHA: mean 82 (SD 73) mg/d, DPA: mean 20 (SD 20) mg/d
165	MESA	ALA: mean 1.0 (SD 0.6) g/d, EPA: mean 45 (SD 50) mg/d, DHA: mean 82 (SD 73) mg/d, DPA: mean 20 (SD 20) mg/d
166	MESA	ALA: mean 1.0 (SD 0.6) g/d, EPA: mean 45 (SD 50) mg/d, DHA: mean 82 (SD 73) mg/d, DPA: mean 20 (SD 20) mg/d
167	MESA	ALA: mean 1.0 (SD 0.6) g/d, EPA: mean 45 (SD 50) mg/d, DHA: mean 82 (SD 73) mg/d, DPA: mean 20 (SD 20) mg/d
168	MESA	ALA: mean 1.0 (SD 0.6) g/d, EPA: mean 45 (SD 50) mg/d, DHA: mean 82 (SD 73) mg/d, DPA: mean 20 (SD 20) mg/d
169	MESA	ALA: mean 1.0 (SD 0.6) g/d, EPA: mean 45 (SD 50) mg/d, DHA: mean 82 (SD 73) mg/d, DPA: mean 20 (SD 20) mg/d
170	MESA	ALA: mean 1.0 (SD 0.6) g/d, EPA: mean 45 (SD 50) mg/d, DHA: mean 82 (SD 73) mg/d, DPA: mean 20 (SD 20) mg/d
171	MESA	ALA: mean 1.0 (SD 0.6) g/d, EPA: mean 45 (SD 50) mg/d, DHA: mean 82 (SD 73) mg/d, DPA: mean 20 (SD 20) mg/d
172	MESA	ALA: mean 1.0 (SD 0.6) g/d, EPA: mean 45 (SD 50) mg/d, DHA: mean 82 (SD 73) mg/d, DPA: mean 20 (SD 20) mg/d
173	MESA	ALA: mean 1.0 (SD 0.6) g/d, EPA: mean 45 (SD 50) mg/d, DHA: mean 82 (SD 73) mg/d, DPA: mean 20 (SD 20) mg/d

Appendix G.2.
Causality Table: Observational Studies

Row	Study	n-3 source	n-3 measure	n-3 type(s)
151	MDC (Malmo Diet and Cancer)	intake	energy %	ALA
152	MDC (Malmo Diet and Cancer)	intake	energy %	long-chain n-3 PUFA (EPA, DPA, DHA)
153	MDC (Malmo Diet and Cancer)	intake	energy %	Total n-3 PUFA (ALA, EPA, DPA, and DHA)
154	MDC (Malmo Diet and Cancer)	intake	Per 1 E% increase of PUFA intake	ALA
155	MDC (Malmo Diet and Cancer)	intake	Per 1 E% increase of PUFA intake	long-chain n-3 PUFA (EPA, DPA, DHA)
156	MDC (Malmo Diet and Cancer)	intake	Per 1 E% increase of PUFA intake	Total n-3 PUFA (ALA, EPA, DPA, and DHA)
157	MESA	Phospholipid	% total FA	EPA
158	MESA	Phospholipid	% total FA	DPA
159	MESA	Phospholipid	% total FA	DHA
160	MESA	Phospholipid	% total FA	EPA+DPA+DHA
161	MESA	intake	mg/d	EPA
162	MESA	intake	mg/d	DPA
163	MESA	intake	mg/d	DHA
164	MESA	intake	mg/d	EPA+DPA+DHA
165	MESA	Phospholipid	% total FA	ALA
166	MESA	intake	mg/d	ALA
167	MESA	phospholipid	mg/d	EPA
168	MESA	phospholipid	mg/d	DPA
169	MESA	phospholipid	mg/d	DHA
170	MESA	phospholipid	mg/d	EPA+DPA+DHA
171	MESA	Phospholipid	% total FA	EPA
172	MESA	Phospholipid	% total FA	DPA
173	MESA	Phospholipid	% total FA	DHA

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Study design
151	MDC (Malmo Diet and Cancer)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
152	MDC (Malmo Diet and Cancer)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
153	MDC (Malmo Diet and Cancer)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
154	MDC (Malmo Diet and Cancer)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
155	MDC (Malmo Diet and Cancer)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
156	MDC (Malmo Diet and Cancer)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
157	MESA	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
158	MESA	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
159	MESA	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
160	MESA	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
161	MESA	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
162	MESA	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
163	MESA	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
164	MESA	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
165	MESA	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
166	MESA	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
167	MESA	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
168	MESA	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
169	MESA	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
170	MESA	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
171	MESA	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
172	MESA	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
173	MESA	Prospective, longitudinal study of intake (eg, FFQ, biomarker)

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Outcome	Reported effect Size
151	MDC (Malmo Diet and Cancer)	CVD, total	See appendix F
152	MDC (Malmo Diet and Cancer)	CVD, total	See appendix F
153	MDC (Malmo Diet and Cancer)	CVD, total	See appendix F
154	MDC (Malmo Diet and Cancer)	CVD, total	See appendix F
155	MDC (Malmo Diet and Cancer)	CVD, total	See appendix F
156	MDC (Malmo Diet and Cancer)	CVD, total	See appendix F
157	MESA	CVD, total	See appendix F
158	MESA	CVD, total	See appendix F
159	MESA	CVD, total	See appendix F
160	MESA	CVD, total	See appendix F
161	MESA	CVD, total	See appendix F
162	MESA	CVD, total	See appendix F
163	MESA	CVD, total	See appendix F
164	MESA	CVD, total	See appendix F
165	MESA	CVD, total	See appendix F
166	MESA	CVD, total	See appendix F
167	MESA	CVD, total	See appendix F
168	MESA	CVD, total	See appendix F
169	MESA	CVD, total	See appendix F
170	MESA	CVD, total	See appendix F
171	MESA	MACE	See appendix F
172	MESA	MACE	See appendix F
173	MESA	MACE	See appendix F

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Study years (study start date)	Country
174	MESA	2000	US
175	MESA	2000	US
176	MESA	2000	US
177	MESA	2000	US
178	MESA	2000	US
179	MESA	2000	US
180	MESA	2000	US
181	MORGEN	1993	Netherlands
182	MORGEN	1993	Netherlands
183	MORGEN	1993	Netherlands
184	MORGEN	1993	Netherlands
185	MORGEN	1993	Netherlands
186	MORGEN	1993	Netherlands
187	MORGEN	1993	Netherlands
188	MORGEN	1993	Netherlands
189	Multiple Risk Factor Intervention Trial	1973	US
190	Multiple Risk Factor Intervention Trial	1973	US
191	Multiple Risk Factor Intervention Trial	1973	US
192	Multiple Risk Factor Intervention Trial	1973	US
193	Multiple Risk Factor Intervention Trial	1973	US

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Population	Risk type
174	MESA	Primary Prevention, Healthy	na
175	MESA	Primary Prevention, Healthy	na
176	MESA	Primary Prevention, Healthy	na
177	MESA	Primary Prevention, Healthy	na
178	MESA	Primary Prevention, Healthy	na
179	MESA	Primary Prevention, Healthy	na
180	MESA	Primary Prevention, Healthy	na
181	MORGEN	Primary Prevention, Healthy	na
182	MORGEN	Primary Prevention, Healthy	na
183	MORGEN	Primary Prevention, Healthy	na
184	MORGEN	Primary Prevention, Healthy	na
185	MORGEN	Primary Prevention, Healthy	na
186	MORGEN	Primary Prevention, Healthy	na
187	MORGEN	Primary Prevention, Healthy	na
188	MORGEN	Primary Prevention, Healthy	na
189	Multiple Risk Factor Intervention Trial	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome, hypertension, dyslipidemia, or chronic kidney disease)	nd
190	Multiple Risk Factor Intervention Trial	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome, hypertension, dyslipidemia, or chronic kidney disease)	nd
191	Multiple Risk Factor Intervention Trial	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome, hypertension, dyslipidemia, or chronic kidney disease)	nd
192	Multiple Risk Factor Intervention Trial	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome, hypertension, dyslipidemia, or chronic kidney disease)	nd
193	Multiple Risk Factor Intervention Trial	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome, hypertension, dyslipidemia, or chronic kidney disease)	nd

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Sample size (total)	Age mean (SD) [median]	Sex (% male)
174	MESA	2837	61.5 (10.2)	46.8
175	MESA	2837	61.5 (10.2)	46.8
176	MESA	2837	61.5 (10.2)	46.8
177	MESA	2837	61.5 (10.2)	46.8
178	MESA	2837	61.5 (10.2)	46.8
179	MESA	2837	61.5 (10.2)	46.8
180	MESA	2837	61.5 (10.2)	46.8
181	MORGEN	21055	41.8	45
182	MORGEN	21055	41.8	45
183	MORGEN	358	Cases: 50.1 (9.5), Controls: 50.0 (9.5)	53
184	MORGEN	358	Cases: 50.1 (9.5), Controls: 50.0 (9.5)	53
185	MORGEN	358	Cases: 50.1 (9.5), Controls: 50.0 (9.5)	53
186	MORGEN	358	Cases: 50.1 (9.5), Controls: 50.0 (9.5)	53
187	MORGEN	358	Cases: 50.1 (9.5), Controls: 50.0 (9.5)	53
188	MORGEN	358	Cases: 50.1 (9.5), Controls: 50.0 (9.5)	53
189	Multiple Risk Factor Intervention Trial	6258	range 35, 57	100
190	Multiple Risk Factor Intervention Trial	6258	range 35, 57	100
191	Multiple Risk Factor Intervention Trial	6258	range 35, 57	100
192	Multiple Risk Factor Intervention Trial	6258	range 35, 57	100
193	Multiple Risk Factor Intervention Trial	6258	range 35, 57	100

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Race	Blood pressure SBP/DBP (mmHg)
174	MESA	26 white, 25 black, 25 Asian, 25 Hispanic	nd
175	MESA	26 white, 25 black, 25 Asian, 25 Hispanic	nd
176	MESA	26 white, 25 black, 25 Asian, 25 Hispanic	nd
177	MESA	26 white, 25 black, 25 Asian, 25 Hispanic	nd
178	MESA	26 white, 25 black, 25 Asian, 25 Hispanic	nd
179	MESA	26 white, 25 black, 25 Asian, 25 Hispanic	nd
180	MESA	26 white, 25 black, 25 Asian, 25 Hispanic	nd
181	MORGEN	nd	120.4 (15.9)/76.6 (10.5)
182	MORGEN	nd	120.4 (15.9)/76.6 (10.5)
183	MORGEN	nd	Cases: 132.1 (20.2), Controls: 126.1 (16.1)/Cases: 82.9 (12.0), Controls: 80.9 (11.3)
184	MORGEN	nd	Cases: 132.1 (20.2), Controls: 126.1 (16.1)/Cases: 82.9 (12.0), Controls: 80.9 (11.3)
185	MORGEN	nd	Cases: 132.1 (20.2), Controls: 126.1 (16.1)/Cases: 82.9 (12.0), Controls: 80.9 (11.3)
186	MORGEN	nd	Cases: 132.1 (20.2), Controls: 126.1 (16.1)/Cases: 82.9 (12.0), Controls: 80.9 (11.3)
187	MORGEN	nd	Cases: 132.1 (20.2), Controls: 126.1 (16.1)/Cases: 82.9 (12.0), Controls: 80.9 (11.3)
188	MORGEN	nd	Cases: 132.1 (20.2), Controls: 126.1 (16.1)/Cases: 82.9 (12.0), Controls: 80.9 (11.3)
189	Multiple Risk Factor Intervention Trial	nd	nd
190	Multiple Risk Factor Intervention Trial	nd	nd
191	Multiple Risk Factor Intervention Trial	nd	nd
192	Multiple Risk Factor Intervention Trial	nd	nd
193	Multiple Risk Factor Intervention Trial	nd	nd

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
174	MESA	nd
175	MESA	nd
176	MESA	nd
177	MESA	nd
178	MESA	nd
179	MESA	nd
180	MESA	nd
181	MORGEN	[5.2 (1.0)]/nd/[1.4 (0.4)]/nd
182	MORGEN	[5.2 (1.0)]/nd/[1.4 (0.4)]/nd
183	MORGEN	[Cases: 5.7 (1.1), Controls: 5.6 (1.1)]/nd/[Cases: 1.3 (0.4), Controls: 1.3 (0.3)/nd
184	MORGEN	[Cases: 5.7 (1.1), Controls: 5.6 (1.1)]/nd/[Cases: 1.3 (0.4), Controls: 1.3 (0.3)/nd
185	MORGEN	[Cases: 5.7 (1.1), Controls: 5.6 (1.1)]/nd/[Cases: 1.3 (0.4), Controls: 1.3 (0.3)/nd
186	MORGEN	[Cases: 5.7 (1.1), Controls: 5.6 (1.1)]/nd/[Cases: 1.3 (0.4), Controls: 1.3 (0.3)/nd
187	MORGEN	[Cases: 5.7 (1.1), Controls: 5.6 (1.1)]/nd/[Cases: 1.3 (0.4), Controls: 1.3 (0.3)/nd
188	MORGEN	[Cases: 5.7 (1.1), Controls: 5.6 (1.1)]/nd/[Cases: 1.3 (0.4), Controls: 1.3 (0.3)/nd
189	Multiple Risk Factor Intervention Trial	nd
190	Multiple Risk Factor Intervention Trial	nd
191	Multiple Risk Factor Intervention Trial	nd
192	Multiple Risk Factor Intervention Trial	nd
193	Multiple Risk Factor Intervention Trial	nd

Appendix G.2.
Causality Table: Observational Studies

Row	Study	BMI mean (SD)/weight mean (SD) Kg
174	MESA	27.9 (5.5)
175	MESA	27.9 (5.5)
176	MESA	27.9 (5.5)
177	MESA	27.9 (5.5)
178	MESA	27.9 (5.5)
179	MESA	27.9 (5.5)
180	MESA	27.9 (5.5)
181	MORGEN	25.0 (3.9)
182	MORGEN	25.0 (3.9)
183	MORGEN	Cases: 25.8 (4.1), Controls: 25.9 (4.3)
184	MORGEN	Cases: 25.8 (4.1), Controls: 25.9 (4.3)
185	MORGEN	Cases: 25.8 (4.1), Controls: 25.9 (4.3)
186	MORGEN	Cases: 25.8 (4.1), Controls: 25.9 (4.3)
187	MORGEN	Cases: 25.8 (4.1), Controls: 25.9 (4.3)
188	MORGEN	Cases: 25.8 (4.1), Controls: 25.9 (4.3)
189	Multiple Risk Factor Intervention Trial	nd
190	Multiple Risk Factor Intervention Trial	nd
191	Multiple Risk Factor Intervention Trial	nd
192	Multiple Risk Factor Intervention Trial	nd
193	Multiple Risk Factor Intervention Trial	nd

Row	Study	Baseline n-3 intake/level (median (IQR), unless noted)
174	MESA	ALA: mean 1.0 (SD 0.6) g/d, EPA: mean 45 (SD 50) mg/d, DHA: mean 82 (SD 73) mg/d, DPA: mean 20 (SD 20) mg/d
175	MESA	ALA: mean 1.0 (SD 0.6) g/d, EPA: mean 45 (SD 50) mg/d, DHA: mean 82 (SD 73) mg/d, DPA: mean 20 (SD 20) mg/d
176	MESA	ALA: mean 1.0 (SD 0.6) g/d, EPA: mean 45 (SD 50) mg/d, DHA: mean 82 (SD 73) mg/d, DPA: mean 20 (SD 20) mg/d
177	MESA	ALA: mean 1.0 (SD 0.6) g/d, EPA: mean 45 (SD 50) mg/d, DHA: mean 82 (SD 73) mg/d, DPA: mean 20 (SD 20) mg/d
178	MESA	ALA: mean 1.0 (SD 0.6) g/d, EPA: mean 45 (SD 50) mg/d, DHA: mean 82 (SD 73) mg/d, DPA: mean 20 (SD 20) mg/d
179	MESA	ALA: mean 1.0 (SD 0.6) g/d, EPA: mean 45 (SD 50) mg/d, DHA: mean 82 (SD 73) mg/d, DPA: mean 20 (SD 20) mg/d
180	MESA	ALA: mean 1.0 (SD 0.6) g/d, EPA: mean 45 (SD 50) mg/d, DHA: mean 82 (SD 73) mg/d, DPA: mean 20 (SD 20) mg/d
181	MORGEN	ALA: 1.3 g/d, EPA+DHA: 114 mg/d
182	MORGEN	ALA: 1.3 g/d, EPA+DHA: 114 mg/d
183	MORGEN	ALA: cases mean 0.53 (SD 0.14)% FA, controls mean 0.52 (SD 0.15)% FA, EPA+DHA: cases mean 1.43 (SD 1.04)% FA, controls man 1.23 (SD 0.56)% FA
184	MORGEN	ALA: cases mean 0.53 (SD 0.14)% FA, controls mean 0.52 (SD 0.15)% FA, EPA+DHA: cases mean 1.43 (SD 1.04)% FA, controls man 1.23 (SD 0.56)% FA
185	MORGEN	ALA: cases mean 0.53 (SD 0.14)% FA, controls mean 0.52 (SD 0.15)% FA, EPA+DHA: cases mean 1.43 (SD 1.04)% FA, controls man 1.23 (SD 0.56)% FA
186	MORGEN	ALA: cases mean 0.53 (SD 0.14)% FA, controls mean 0.52 (SD 0.15)% FA, EPA+DHA: cases mean 1.43 (SD 1.04)% FA, controls man 1.23 (SD 0.56)% FA
187	MORGEN	ALA: cases mean 0.53 (SD 0.14)% FA, controls mean 0.52 (SD 0.15)% FA, EPA+DHA: cases mean 1.43 (SD 1.04)% FA, controls man 1.23 (SD 0.56)% FA
188	MORGEN	ALA: cases mean 0.53 (SD 0.14)% FA, controls mean 0.52 (SD 0.15)% FA, EPA+DHA: cases mean 1.43 (SD 1.04)% FA, controls man 1.23 (SD 0.56)% FA
189	Multiple Risk Factor Intervention Trial	ALA: mean 1.577 g/d, EPA+DHA+DPA: mean 0.046 g/d
190	Multiple Risk Factor Intervention Trial	ALA: mean 1.577 g/d, EPA+DHA+DPA: mean 0.046 g/d
191	Multiple Risk Factor Intervention Trial	ALA: mean 1.577 g/d, EPA+DHA+DPA: mean 0.046 g/d
192	Multiple Risk Factor Intervention Trial	ALA: mean 1.577 g/d, EPA+DHA+DPA: mean 0.046 g/d
193	Multiple Risk Factor Intervention Trial	ALA: mean 1.577 g/d, EPA+DHA+DPA: mean 0.046 g/d

Appendix G.2.
Causality Table: Observational Studies

Row	Study	n-3 source	n-3 measure	n-3 type(s)
174	MESA	Phospholipid	% total FA	EPA+DPA+DHA
175	MESA	intake	mg/d	EPA
176	MESA	intake	mg/d	DPA
177	MESA	intake	mg/d	DHA
178	MESA	intake	mg/d	EPA+DPA+DHA
179	MESA	Phospholipid	% total FA	ALA
180	MESA	intake	mg/d	ALA
181	MORGEN	intake	mg/d	EPA+DHA
182	MORGEN	intake	mg/d	EPA+DHA
183	MORGEN	plasma	% FA	ALA
184	MORGEN	plasma	% FA	EPA+DHA
185	MORGEN	plasma	% FA	ALA
186	MORGEN	plasma	% FA	EPA-DHA
187	MORGEN	plasma	% FA	ALA
188	MORGEN	plasma	% FA	EPA-DHA
189	Multiple Risk Factor Intervention Trial	intake	g	ALA
190	Multiple Risk Factor Intervention Trial	intake	% of total kilocalories	ALA
191	Multiple Risk Factor Intervention Trial	intake	g	EPA+DHA+DPA
192	Multiple Risk Factor Intervention Trial	intake	% of total kilocalories	EPA+DHA+DPA
193	Multiple Risk Factor Intervention Trial	intake	g	ALA

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Study design
174	MESA	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
175	MESA	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
176	MESA	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
177	MESA	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
178	MESA	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
179	MESA	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
180	MESA	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
181	MORGEN	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
182	MORGEN	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
183	MORGEN	Nested Case Control
184	MORGEN	Nested Case Control
185	MORGEN	Nested Case Control
186	MORGEN	Nested Case Control
187	MORGEN	Nested Case Control
188	MORGEN	Nested Case Control
189	Multiple Risk Factor Intervention Trial	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
190	Multiple Risk Factor Intervention Trial	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
191	Multiple Risk Factor Intervention Trial	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
192	Multiple Risk Factor Intervention Trial	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
193	Multiple Risk Factor Intervention Trial	Prospective, longitudinal study of intake (eg, FFQ, biomarker)

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Outcome	Reported effect Size
174	MESA	MACE	See appendix F
175	MESA	MACE	See appendix F
176	MESA	MACE	See appendix F
177	MESA	MACE	See appendix F
178	MESA	MACE	See appendix F
179	MESA	MACE	See appendix F
180	MESA	MACE	See appendix F
181	MORGEN	Death, CVD	See appendix F
182	MORGEN	Myocardial infarction	See appendix F
183	MORGEN	Stroke, hemorrhagic	See appendix F
184	MORGEN	Stroke, hemorrhagic	See appendix F
185	MORGEN	Stroke, ischemic	See appendix F
186	MORGEN	Stroke, ischemic	See appendix F
187	MORGEN	Stroke, total	See appendix F
188	MORGEN	Stroke, total	See appendix F
189	Multiple Risk Factor Intervention Trial	Death, all cause	See appendix F
190	Multiple Risk Factor Intervention Trial	Death, all cause	See appendix F
191	Multiple Risk Factor Intervention Trial	Death, all cause	See appendix F
192	Multiple Risk Factor Intervention Trial	Death, all cause	See appendix F
193	Multiple Risk Factor Intervention Trial	Death, all cause	See appendix F

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Study years (study start date)	Country
194	Multiple Risk Factor Intervention Trial	1973	US
195	Multiple Risk Factor Intervention Trial	1973	US
196	Multiple Risk Factor Intervention Trial	1973	US
197	Multiple Risk Factor Intervention Trial	1973	US
198	Multiple Risk Factor Intervention Trial	1973	US
199	Multiple Risk Factor Intervention Trial	1973	US
200	Multiple Risk Factor Intervention Trial	1973	US
201	Multiple Risk Factor Intervention Trial	1973	US
202	Multiple Risk Factor Intervention Trial	1973	US
203	Multiple Risk Factor Intervention Trial	1973	US
204	Multiple Risk Factor Intervention Trial	1973	US
205	Multiple Risk Factor Intervention Trial	1973	US
206	Multiple Risk Factor Intervention Trial	1973	US
207	Multiple Risk Factor Intervention Trial	1973	US
208	Multiple Risk Factor Intervention Trial	1973	US
209	Multiple Risk Factor Intervention Trial	1973	US

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Population	Risk type
194	Multiple Risk Factor Intervention Trial	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome, hypertension, dyslipidemia, or chronic kidney disease)	nd
195	Multiple Risk Factor Intervention Trial	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome, hypertension, dyslipidemia, or chronic kidney disease)	nd
196	Multiple Risk Factor Intervention Trial	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome, hypertension, dyslipidemia, or chronic kidney disease)	nd
197	Multiple Risk Factor Intervention Trial	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome, hypertension, dyslipidemia, or chronic kidney disease)	nd
198	Multiple Risk Factor Intervention Trial	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome, hypertension, dyslipidemia, or chronic kidney disease)	nd
199	Multiple Risk Factor Intervention Trial	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome, hypertension, dyslipidemia, or chronic kidney disease)	nd
200	Multiple Risk Factor Intervention Trial	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome, hypertension, dyslipidemia, or chronic kidney disease)	nd
201	Multiple Risk Factor Intervention Trial	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome, hypertension, dyslipidemia, or chronic kidney disease)	nd
202	Multiple Risk Factor Intervention Trial	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome, hypertension, dyslipidemia, or chronic kidney disease)	nd
203	Multiple Risk Factor Intervention Trial	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome, hypertension, dyslipidemia, or chronic kidney disease)	nd
204	Multiple Risk Factor Intervention Trial	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome, hypertension, dyslipidemia, or chronic kidney disease)	nd
205	Multiple Risk Factor Intervention Trial	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome, hypertension, dyslipidemia, or chronic kidney disease)	nd
206	Multiple Risk Factor Intervention Trial	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome, hypertension, dyslipidemia, or chronic kidney disease)	nd
207	Multiple Risk Factor Intervention Trial	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome, hypertension, dyslipidemia, or chronic kidney disease)	nd
208	Multiple Risk Factor Intervention Trial	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome, hypertension, dyslipidemia, or chronic kidney disease)	nd
209	Multiple Risk Factor Intervention Trial	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome, hypertension, dyslipidemia, or chronic kidney disease)	nd

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Sample size (total)	Age mean (SD) [median]	Sex (% male)
194	Multiple Risk Factor Intervention Trial	6258	range 35, 57	100
195	Multiple Risk Factor Intervention Trial	6258	range 35, 57	100
196	Multiple Risk Factor Intervention Trial	6258	range 35, 57	100
197	Multiple Risk Factor Intervention Trial	6258	range 35, 57	100
198	Multiple Risk Factor Intervention Trial	6258	range 35, 57	100
199	Multiple Risk Factor Intervention Trial	6258	range 35, 57	100
200	Multiple Risk Factor Intervention Trial	6258	range 35, 57	100
201	Multiple Risk Factor Intervention Trial	6258	range 35, 57	100
202	Multiple Risk Factor Intervention Trial	6258	range 35, 57	100
203	Multiple Risk Factor Intervention Trial	6258	range 35, 57	100
204	Multiple Risk Factor Intervention Trial	6258	range 35, 57	100
205	Multiple Risk Factor Intervention Trial	6258	range 35, 57	100
206	Multiple Risk Factor Intervention Trial	6258	range 35, 57	100
207	Multiple Risk Factor Intervention Trial	6258	range 35, 57	100
208	Multiple Risk Factor Intervention Trial	6258	range 35, 57	100
209	Multiple Risk Factor Intervention Trial	6258	range 35, 57	100

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Race	Blood pressure SBP/DBP (mmHg)
194	Multiple Risk Factor Intervention Trial	nd	nd
195	Multiple Risk Factor Intervention Trial	nd	nd
196	Multiple Risk Factor Intervention Trial	nd	nd
197	Multiple Risk Factor Intervention Trial	nd	nd
198	Multiple Risk Factor Intervention Trial	nd	nd
199	Multiple Risk Factor Intervention Trial	nd	nd
200	Multiple Risk Factor Intervention Trial	nd	nd
201	Multiple Risk Factor Intervention Trial	nd	nd
202	Multiple Risk Factor Intervention Trial	nd	nd
203	Multiple Risk Factor Intervention Trial	nd	nd
204	Multiple Risk Factor Intervention Trial	nd	nd
205	Multiple Risk Factor Intervention Trial	nd	nd
206	Multiple Risk Factor Intervention Trial	nd	nd
207	Multiple Risk Factor Intervention Trial	nd	nd
208	Multiple Risk Factor Intervention Trial	nd	nd
209	Multiple Risk Factor Intervention Trial	nd	nd

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
194	Multiple Risk Factor Intervention Trial	nd
195	Multiple Risk Factor Intervention Trial	nd
196	Multiple Risk Factor Intervention Trial	nd
197	Multiple Risk Factor Intervention Trial	nd
198	Multiple Risk Factor Intervention Trial	nd
199	Multiple Risk Factor Intervention Trial	nd
200	Multiple Risk Factor Intervention Trial	nd
201	Multiple Risk Factor Intervention Trial	nd
202	Multiple Risk Factor Intervention Trial	nd
203	Multiple Risk Factor Intervention Trial	nd
204	Multiple Risk Factor Intervention Trial	nd
205	Multiple Risk Factor Intervention Trial	nd
206	Multiple Risk Factor Intervention Trial	nd
207	Multiple Risk Factor Intervention Trial	nd
208	Multiple Risk Factor Intervention Trial	nd
209	Multiple Risk Factor Intervention Trial	nd

Appendix G.2.
Causality Table: Observational Studies

Row	Study	BMI mean (SD)/weight mean (SD) Kg
194	Multiple Risk Factor Intervention Trial	nd
195	Multiple Risk Factor Intervention Trial	nd
196	Multiple Risk Factor Intervention Trial	nd
197	Multiple Risk Factor Intervention Trial	nd
198	Multiple Risk Factor Intervention Trial	nd
199	Multiple Risk Factor Intervention Trial	nd
200	Multiple Risk Factor Intervention Trial	nd
201	Multiple Risk Factor Intervention Trial	nd
202	Multiple Risk Factor Intervention Trial	nd
203	Multiple Risk Factor Intervention Trial	nd
204	Multiple Risk Factor Intervention Trial	nd
205	Multiple Risk Factor Intervention Trial	nd
206	Multiple Risk Factor Intervention Trial	nd
207	Multiple Risk Factor Intervention Trial	nd
208	Multiple Risk Factor Intervention Trial	nd
209	Multiple Risk Factor Intervention Trial	nd

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Baseline n-3 intake/level (median (IQR), unless noted)
194	Multiple Risk Factor Intervention Trial	ALA: mean 1.577 g/d, EPA+DHA+DPA: mean 0.046 g/d
195	Multiple Risk Factor Intervention Trial	ALA: mean 1.577 g/d, EPA+DHA+DPA: mean 0.046 g/d
196	Multiple Risk Factor Intervention Trial	ALA: mean 1.577 g/d, EPA+DHA+DPA: mean 0.046 g/d
197	Multiple Risk Factor Intervention Trial	ALA: mean 1.577 g/d, EPA+DHA+DPA: mean 0.046 g/d
198	Multiple Risk Factor Intervention Trial	ALA: mean 1.577 g/d, EPA+DHA+DPA: mean 0.046 g/d
199	Multiple Risk Factor Intervention Trial	ALA: mean 1.577 g/d, EPA+DHA+DPA: mean 0.046 g/d
200	Multiple Risk Factor Intervention Trial	ALA: mean 1.577 g/d, EPA+DHA+DPA: mean 0.046 g/d
201	Multiple Risk Factor Intervention Trial	ALA: mean 1.577 g/d, EPA+DHA+DPA: mean 0.046 g/d
202	Multiple Risk Factor Intervention Trial	ALA: mean 1.577 g/d, EPA+DHA+DPA: mean 0.046 g/d
203	Multiple Risk Factor Intervention Trial	ALA: mean 1.577 g/d, EPA+DHA+DPA: mean 0.046 g/d
204	Multiple Risk Factor Intervention Trial	ALA: mean 1.577 g/d, EPA+DHA+DPA: mean 0.046 g/d
205	Multiple Risk Factor Intervention Trial	ALA: mean 1.577 g/d, EPA+DHA+DPA: mean 0.046 g/d
206	Multiple Risk Factor Intervention Trial	ALA: mean 1.577 g/d, EPA+DHA+DPA: mean 0.046 g/d
207	Multiple Risk Factor Intervention Trial	ALA: mean 1.577 g/d, EPA+DHA+DPA: mean 0.046 g/d
208	Multiple Risk Factor Intervention Trial	ALA: mean 1.577 g/d, EPA+DHA+DPA: mean 0.046 g/d
209	Multiple Risk Factor Intervention Trial	ALA: mean 1.577 g/d, EPA+DHA+DPA: mean 0.046 g/d

Appendix G.2.
Causality Table: Observational Studies

Row	Study	n-3 source	n-3 measure	n-3 type(s)
194	Multiple Risk Factor Intervention Trial	intake	% of total kilocalories	ALA
195	Multiple Risk Factor Intervention Trial	intake	g	ALA
196	Multiple Risk Factor Intervention Trial	intake	% of total kilocalories	ALA
197	Multiple Risk Factor Intervention Trial	intake	g	EPA+DHA+DPA
198	Multiple Risk Factor Intervention Trial	intake	% of total kilocalories	EPA+DHA+DPA
199	Multiple Risk Factor Intervention Trial	intake	g	EPA+DHA+DPA
200	Multiple Risk Factor Intervention Trial	intake	% of total kilocalories	EPA+DHA+DPA
201	Multiple Risk Factor Intervention Trial	intake	g	ALA
202	Multiple Risk Factor Intervention Trial	intake	% of total kilocalories	ALA
203	Multiple Risk Factor Intervention Trial	intake	g	ALA
204	Multiple Risk Factor Intervention Trial	intake	% of total kilocalories	ALA
205	Multiple Risk Factor Intervention Trial	intake	g	EPA+DHA+DPA
206	Multiple Risk Factor Intervention Trial	intake	% of total kilocalories	EPA+DHA+DPA
207	Multiple Risk Factor Intervention Trial	intake	g	EPA+DHA+DPA
208	Multiple Risk Factor Intervention Trial	intake	% of total kilocalories	EPA+DHA+DPA
209	Multiple Risk Factor Intervention Trial	intake	g	EPA+DHA+DPA

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Study design
194	Multiple Risk Factor Intervention Trial	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
195	Multiple Risk Factor Intervention Trial	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
196	Multiple Risk Factor Intervention Trial	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
197	Multiple Risk Factor Intervention Trial	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
198	Multiple Risk Factor Intervention Trial	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
199	Multiple Risk Factor Intervention Trial	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
200	Multiple Risk Factor Intervention Trial	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
201	Multiple Risk Factor Intervention Trial	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
202	Multiple Risk Factor Intervention Trial	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
203	Multiple Risk Factor Intervention Trial	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
204	Multiple Risk Factor Intervention Trial	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
205	Multiple Risk Factor Intervention Trial	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
206	Multiple Risk Factor Intervention Trial	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
207	Multiple Risk Factor Intervention Trial	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
208	Multiple Risk Factor Intervention Trial	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
209	Multiple Risk Factor Intervention Trial	Prospective, longitudinal study of intake (eg, FFQ, biomarker)

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Outcome	Reported effect Size
194	Multiple Risk Factor Intervention Trial	Death, all cause	See appendix F
195	Multiple Risk Factor Intervention Trial	Death, CHD	See appendix F
196	Multiple Risk Factor Intervention Trial	Death, CHD	See appendix F
197	Multiple Risk Factor Intervention Trial	Death, CHD	See appendix F
198	Multiple Risk Factor Intervention Trial	Death, CHD	See appendix F
199	Multiple Risk Factor Intervention Trial	Death, CHD	See appendix F
200	Multiple Risk Factor Intervention Trial	Death, CHD	See appendix F
201	Multiple Risk Factor Intervention Trial	Death, CHD	See appendix F
202	Multiple Risk Factor Intervention Trial	Death, CHD	See appendix F
203	Multiple Risk Factor Intervention Trial	Death, CVD	See appendix F
204	Multiple Risk Factor Intervention Trial	Death, CVD	See appendix F
205	Multiple Risk Factor Intervention Trial	Death, CVD	See appendix F
206	Multiple Risk Factor Intervention Trial	Death, CVD	See appendix F
207	Multiple Risk Factor Intervention Trial	Death, CVD	See appendix F
208	Multiple Risk Factor Intervention Trial	Death, CVD	See appendix F
209	Multiple Risk Factor Intervention Trial	Death, CVD	See appendix F

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Study years (study start date)	Country
210	Multiple Risk Factor Intervention Trial	1973	US
211	Multiple Risk Factor Intervention Trial	1973	US
212	Multiple Risk Factor Intervention Trial	1973	US
213	NIPPON DATA80	1980	Japan
214	NIPPON DATA80	1980	Japan
215	NIPPON DATA80	1980	Japan
216	NIPPON DATA80	1980	Japan
217	NIPPON DATA80	1980	Japan
218	NIPPON DATA80	1980	Japan
219	NIPPON DATA80	1980	Japan
220	NIPPON DATA80	1980	Japan
221	NIPPON DATA80	1980	Japan
222	NIPPON DATA80	1980	Japan
223	NIPPON DATA80	1980	Japan
224	NIPPON DATA80	1980	Japan
225	Nurses' Health Study (NHS)	1980	US
226	Nurses' Health Study (NHS)	1980	US
227	Nurses' Health Study (NHS)	1980	US
228	Nurses' Health Study (NHS)	1980	US
229	Nurses' Health Study (NHS)	1980	US

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Population	Risk type
210	Multiple Risk Factor Intervention Trial	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome, hypertension, dyslipidemia, or chronic kidney disease)	nd
211	Multiple Risk Factor Intervention Trial	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome, hypertension, dyslipidemia, or chronic kidney disease)	nd
212	Multiple Risk Factor Intervention Trial	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome, hypertension, dyslipidemia, or chronic kidney disease)	nd
213	NIPPON DATA80	Primary Prevention, Healthy	na
214	NIPPON DATA80	Primary Prevention, Healthy	na
215	NIPPON DATA80	Primary Prevention, Healthy	na
216	NIPPON DATA80	Primary Prevention, Healthy	na
217	NIPPON DATA80	Primary Prevention, Healthy	na
218	NIPPON DATA80	Primary Prevention, Healthy	na
219	NIPPON DATA80	Primary Prevention, Healthy	na
220	NIPPON DATA80	Primary Prevention, Healthy	na
221	NIPPON DATA80	Primary Prevention, Healthy	na
222	NIPPON DATA80	Primary Prevention, Healthy	na
223	NIPPON DATA80	Primary Prevention, Healthy	na
224	NIPPON DATA80	Primary Prevention, Healthy	na
225	Nurses' Health Study (NHS)	Primary Prevention, Healthy	na
226	Nurses' Health Study (NHS)	Primary Prevention, Healthy	na
227	Nurses' Health Study (NHS)	Primary Prevention, Healthy	na
228	Nurses' Health Study (NHS)	Primary Prevention, Healthy	na
229	Nurses' Health Study (NHS)	Primary Prevention, Healthy	na

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Sample size (total)	Age mean (SD) [median]	Sex (% male)
210	Multiple Risk Factor Intervention Trial	6258	range 35, 57	100
211	Multiple Risk Factor Intervention Trial	6258	range 35, 57	100
212	Multiple Risk Factor Intervention Trial	6258	range 35, 57	100
213	NIPPON DATA80	9190	49.4 (13) (Q2)	43.8
214	NIPPON DATA80	9190	49.4 (13) (Q2)	43.8
215	NIPPON DATA80	9190	49.4 (13) (Q2)	43.8
216	NIPPON DATA80	9190	49.4 (13) (Q2)	43.8
217	NIPPON DATA80	9190	49.4 (13) (Q2)	43.8
218	NIPPON DATA80	9190	49.4 (13) (Q2)	43.8
219	NIPPON DATA80	9190	49.4 (13) (Q2)	43.8
220	NIPPON DATA80	9190	49.4 (13) (Q2)	43.8
221	NIPPON DATA80	9190	49.4 (13) (Q2)	43.8
222	NIPPON DATA80	9190	49.4 (13) (Q2)	43.8
223	NIPPON DATA80	9190	49.4 (13) (Q2)	43.8
224	NIPPON DATA80	9190	49.4 (13) (Q2)	43.8
225	Nurses' Health Study (NHS)	79839	range 34, 59	0
226	Nurses' Health Study (NHS)	79839	range 34, 59	0
227	Nurses' Health Study (NHS)	79839	range 34, 59	0
228	Nurses' Health Study (NHS)	79839	range 34, 59	0
229	Nurses' Health Study (NHS)	79839	range 34, 59	0

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Race	Blood pressure SBP/DBP (mmHg)
210	Multiple Risk Factor Intervention Trial	nd	nd
211	Multiple Risk Factor Intervention Trial	nd	nd
212	Multiple Risk Factor Intervention Trial	nd	nd
213	NIPPON DATA80	nd	Q2: 135.5 (21.5)/Q2: 81.1 (12.1)
214	NIPPON DATA80	nd	Q2: 135.5 (21.5)/Q2: 81.1 (12.1)
215	NIPPON DATA80	nd	Q2: 135.5 (21.5)/Q2: 81.1 (12.1)
216	NIPPON DATA80	nd	Q2: 135.5 (21.5)/Q2: 81.1 (12.1)
217	NIPPON DATA80	nd	Q2: 135.5 (21.5)/Q2: 81.1 (12.1)
218	NIPPON DATA80	nd	Q2: 135.5 (21.5)/Q2: 81.1 (12.1)
219	NIPPON DATA80	nd	Q2: 135.5 (21.5)/Q2: 81.1 (12.1)
220	NIPPON DATA80	nd	Q2: 135.5 (21.5)/Q2: 81.1 (12.1)
221	NIPPON DATA80	nd	Q2: 135.5 (21.5)/Q2: 81.1 (12.1)
222	NIPPON DATA80	nd	Q2: 135.5 (21.5)/Q2: 81.1 (12.1)
223	NIPPON DATA80	nd	Q2: 135.5 (21.5)/Q2: 81.1 (12.1)
224	NIPPON DATA80	nd	Q2: 135.5 (21.5)/Q2: 81.1 (12.1)
225	Nurses' Health Study (NHS)	98 white	nd
226	Nurses' Health Study (NHS)	98 white	nd
227	Nurses' Health Study (NHS)	98 white	nd
228	Nurses' Health Study (NHS)	98 white	nd
229	Nurses' Health Study (NHS)	98 white	nd

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
210	Multiple Risk Factor Intervention Trial	nd
211	Multiple Risk Factor Intervention Trial	nd
212	Multiple Risk Factor Intervention Trial	nd
213	NIPPON DATA80	Q2: 188.7 (33.8)/nd/nd/nd
214	NIPPON DATA80	Q2: 188.7 (33.8)/nd/nd/nd
215	NIPPON DATA80	Q2: 188.7 (33.8)/nd/nd/nd
216	NIPPON DATA80	Q2: 188.7 (33.8)/nd/nd/nd
217	NIPPON DATA80	Q2: 188.7 (33.8)/nd/nd/nd
218	NIPPON DATA80	Q2: 188.7 (33.8)/nd/nd/nd
219	NIPPON DATA80	Q2: 188.7 (33.8)/nd/nd/nd
220	NIPPON DATA80	Q2: 188.7 (33.8)/nd/nd/nd
221	NIPPON DATA80	Q2: 188.7 (33.8)/nd/nd/nd
222	NIPPON DATA80	Q2: 188.7 (33.8)/nd/nd/nd
223	NIPPON DATA80	Q2: 188.7 (33.8)/nd/nd/nd
224	NIPPON DATA80	Q2: 188.7 (33.8)/nd/nd/nd
225	Nurses' Health Study (NHS)	nd
226	Nurses' Health Study (NHS)	nd
227	Nurses' Health Study (NHS)	nd
228	Nurses' Health Study (NHS)	nd
229	Nurses' Health Study (NHS)	nd

Appendix G.2.
Causality Table: Observational Studies

Row	Study	BMI mean (SD)/weight mean (SD) Kg
210	Multiple Risk Factor Intervention Trial	nd
211	Multiple Risk Factor Intervention Trial	nd
212	Multiple Risk Factor Intervention Trial	nd
213	NIPPON DATA80	Q2: 22.7 (3.1)
214	NIPPON DATA80	Q2: 22.7 (3.1)
215	NIPPON DATA80	Q2: 22.7 (3.1)
216	NIPPON DATA80	Q2: 22.7 (3.1)
217	NIPPON DATA80	Q2: 22.7 (3.1)
218	NIPPON DATA80	Q2: 22.7 (3.1)
219	NIPPON DATA80	Q2: 22.7 (3.1)
220	NIPPON DATA80	Q2: 22.7 (3.1)
221	NIPPON DATA80	Q2: 22.7 (3.1)
222	NIPPON DATA80	Q2: 22.7 (3.1)
223	NIPPON DATA80	Q2: 22.7 (3.1)
224	NIPPON DATA80	Q2: 22.7 (3.1)
225	Nurses' Health Study (NHS)	nd
226	Nurses' Health Study (NHS)	nd
227	Nurses' Health Study (NHS)	nd
228	Nurses' Health Study (NHS)	nd
229	Nurses' Health Study (NHS)	nd

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Baseline n-3 intake/level (median (IQR), unless noted)
210	Multiple Risk Factor Intervention Trial	ALA: mean 1.577 g/d, EPA+DHA+DPA: mean 0.046 g/d
211	Multiple Risk Factor Intervention Trial	ALA: mean 1.577 g/d, EPA+DHA+DPA: mean 0.046 g/d
212	Multiple Risk Factor Intervention Trial	ALA: mean 1.577 g/d, EPA+DHA+DPA: mean 0.046 g/d
213	NIPPON DATA80	EPA: men 0.14, women 0.15% kcal, DHA: men 0.23, women 0.24% kcal, EPA+DHA: men 0.36, women 0.39% kcal, Total n-3 FA: men 1.06, women 1.16% kcal
214	NIPPON DATA80	EPA: men 0.14, women 0.15% kcal, DHA: men 0.23, women 0.24% kcal, EPA+DHA: men 0.36, women 0.39% kcal, Total n-3 FA: men 1.06, women 1.16% kcal
215	NIPPON DATA80	EPA: men 0.14, women 0.15% kcal, DHA: men 0.23, women 0.24% kcal, EPA+DHA: men 0.36, women 0.39% kcal, Total n-3 FA: men 1.06, women 1.16% kcal
216	NIPPON DATA80	EPA: men 0.14, women 0.15% kcal, DHA: men 0.23, women 0.24% kcal, EPA+DHA: men 0.36, women 0.39% kcal, Total n-3 FA: men 1.06, women 1.16% kcal
217	NIPPON DATA80	EPA: men 0.14, women 0.15% kcal, DHA: men 0.23, women 0.24% kcal, EPA+DHA: men 0.36, women 0.39% kcal, Total n-3 FA: men 1.06, women 1.16% kcal
218	NIPPON DATA80	EPA: men 0.14, women 0.15% kcal, DHA: men 0.23, women 0.24% kcal, EPA+DHA: men 0.36, women 0.39% kcal, Total n-3 FA: men 1.06, women 1.16% kcal
219	NIPPON DATA80	EPA: men 0.14, women 0.15% kcal, DHA: men 0.23, women 0.24% kcal, EPA+DHA: men 0.36, women 0.39% kcal, Total n-3 FA: men 1.06, women 1.16% kcal
220	NIPPON DATA80	EPA: men 0.14, women 0.15% kcal, DHA: men 0.23, women 0.24% kcal, EPA+DHA: men 0.36, women 0.39% kcal, Total n-3 FA: men 1.06, women 1.16% kcal
221	NIPPON DATA80	EPA: men 0.14, women 0.15% kcal, DHA: men 0.23, women 0.24% kcal, EPA+DHA: men 0.36, women 0.39% kcal, Total n-3 FA: men 1.06, women 1.16% kcal
222	NIPPON DATA80	EPA: men 0.14, women 0.15% kcal, DHA: men 0.23, women 0.24% kcal, EPA+DHA: men 0.36, women 0.39% kcal, Total n-3 FA: men 1.06, women 1.16% kcal
223	NIPPON DATA80	EPA: men 0.14, women 0.15% kcal, DHA: men 0.23, women 0.24% kcal, EPA+DHA: men 0.36, women 0.39% kcal, Total n-3 FA: men 1.06, women 1.16% kcal
224	NIPPON DATA80	EPA: men 0.14, women 0.15% kcal, DHA: men 0.23, women 0.24% kcal, EPA+DHA: men 0.36, women 0.39% kcal, Total n-3 FA: men 1.06, women 1.16% kcal
225	Nurses' Health Study (NHS)	ALA: 0.52% energy, EPA+DHA 0.08% energy
226	Nurses' Health Study (NHS)	ALA: 0.52% energy, EPA+DHA 0.08% energy
227	Nurses' Health Study (NHS)	ALA: 0.52% energy, EPA+DHA 0.08% energy
228	Nurses' Health Study (NHS)	ALA: 0.52% energy, EPA+DHA 0.08% energy
229	Nurses' Health Study (NHS)	ALA: 0.52% energy, EPA+DHA 0.08% energy

Appendix G.2.
Causality Table: Observational Studies

Row	Study	n-3 source	n-3 measure	n-3 type(s)
210	Multiple Risk Factor Intervention Trial	intake	% of total kilocalories	EPA+DHA+DPA
211	Multiple Risk Factor Intervention Trial	intake	g	ALA
212	Multiple Risk Factor Intervention Trial	intake	% of total kilocalories	ALA
213	NIPPON DATA80	intake	% kcal	EPA+DHA
214	NIPPON DATA80	intake	% kcal	Total n-3
215	NIPPON DATA80	intake	% kcal	EPA
216	NIPPON DATA80	intake	% kcal	DHA
217	NIPPON DATA80	intake	% kcal	EPA+DHA
218	NIPPON DATA80	intake	% kcal	Total n-3
219	NIPPON DATA80	intake	% kcal	EPA
220	NIPPON DATA80	intake	% kcal	DHA
221	NIPPON DATA80	intake	% kcal	EPA+DHA
222	NIPPON DATA80	intake	% kcal	Total n-3
223	NIPPON DATA80	intake	% kcal	EPA
224	NIPPON DATA80	intake	% kcal	DHA
225	Nurses' Health Study (NHS)	intake	% energy	EPA + DHA
226	Nurses' Health Study (NHS)	intake	% energy	EPA + DHA
227	Nurses' Health Study (NHS)	intake	g/d	EPA + DHA
228	Nurses' Health Study (NHS)	intake	g/d	EPA + DHA
229	Nurses' Health Study (NHS)	intake	g/d	EPA + DHA

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Study design
210	Multiple Risk Factor Intervention Trial	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
211	Multiple Risk Factor Intervention Trial	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
212	Multiple Risk Factor Intervention Trial	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
213	NIPPON DATA80	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
214	NIPPON DATA80	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
215	NIPPON DATA80	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
216	NIPPON DATA80	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
217	NIPPON DATA80	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
218	NIPPON DATA80	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
219	NIPPON DATA80	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
220	NIPPON DATA80	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
221	NIPPON DATA80	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
222	NIPPON DATA80	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
223	NIPPON DATA80	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
224	NIPPON DATA80	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
225	Nurses' Health Study (NHS)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
226	Nurses' Health Study (NHS)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
227	Nurses' Health Study (NHS)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
228	Nurses' Health Study (NHS)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
229	Nurses' Health Study (NHS)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Outcome	Reported effect Size
210	Multiple Risk Factor Intervention Trial	Death, CVD	See appendix F
211	Multiple Risk Factor Intervention Trial	Death, CVD	See appendix F
212	Multiple Risk Factor Intervention Trial	Death, CVD	See appendix F
213	NIPPON DATA80	Death, CHD	See appendix F
214	NIPPON DATA80	Death, CHD	See appendix F
215	NIPPON DATA80	Death, CHD	See appendix F
216	NIPPON DATA80	Death, CHD	See appendix F
217	NIPPON DATA80	Death, CVD	See appendix F
218	NIPPON DATA80	Death, CVD	See appendix F
219	NIPPON DATA80	Death, CVD	See appendix F
220	NIPPON DATA80	Death, CVD	See appendix F
221	NIPPON DATA80	Death, stroke	See appendix F
222	NIPPON DATA80	Death, stroke	See appendix F
223	NIPPON DATA80	Death, stroke	See appendix F
224	NIPPON DATA80	Death, stroke	See appendix F
225	Nurses' Health Study (NHS)	Coronary heart disease	See appendix F
226	Nurses' Health Study (NHS)	Death, CHD	See appendix F
227	Nurses' Health Study (NHS)	Stroke, hemorrhagic	See appendix F
228	Nurses' Health Study (NHS)	Stroke, ischemic	See appendix F
229	Nurses' Health Study (NHS)	Stroke, total	See appendix F

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Study years (study start date)	Country
230	Nurses' Health Study (NHS)	1980	US
231	Osaka Acute Coronary Insufficiency Study	2006	Japan
232	Osaka Acute Coronary Insufficiency Study	2006	Japan
233	Osaka Acute Coronary Insufficiency Study	2006	Japan
234	Osaka Acute Coronary Insufficiency Study	2006	Japan
235	Physician's Health Study	1995-2001	US
236	Physician's Health Study	1995-2001	US
237	Physician's Health Study	1995-2001	US
238	Physician's Health Study	1995-2001	US
239	Physician's Health Study	1995-2001	US
240	Physician's Health Study	1995-2001	US
241	Physician's Health Study	1982-1983	US
242	Physician's Health Study	1982-1983	US
243	Physician's Health Study	1982-1983	US
244	Physician's Health Study	1982-1983	US
245	Physician's Health Study	1982-1983	US
246	Physician's Health Study	1982-1983	US
247	Physician's Health Study	1995-2001	US
248	Physician's Health Study	1995-2001	US
249	Physician's Health Study	1995-2001	US
250	Physician's Health Study	1995-2001	US
251	Physician's Health Study	1995-2001	US
252	Physician's Health Study	1995-2001	US
253	Physician's Health Study	1982-1983	US
254	Physician's Health Study	1982-1983	US
255	Physician's Health Study	1982-1983	US
256	Physician's Health Study	1982-1983	US
257	Physician's Health Study	1982-1983	US
258	Physician's Health Study	1982-1983	US
259	Physician's Health Study	1982-1983	US
260	Physician's Health Study	1982-1983	US
261	Physician's Health Study	1982-1983	US
262	Pooling Project of Cohort Studies on Diet and Coronary Disease	various across cohorts: 1966-1992	US, Finland, Sweden
263	Pooling Project of Cohort Studies on Diet and Coronary Disease	various across cohorts: 1966-1992	US, Finland, Sweden
264	Rotterdam	1990	Netherlands
265	Rotterdam	1990	Netherlands
266	Rotterdam	1990	Netherlands

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Population	Risk type
230	Nurses' Health Study (NHS)	Primary Prevention, Healthy	na
231	Osaka Acute Coronary Insufficiency Study	Secondary Prevention (history of CVD event)	Acute MI
232	Osaka Acute Coronary Insufficiency Study	Secondary Prevention (history of CVD event)	Acute MI
233	Osaka Acute Coronary Insufficiency Study	Secondary Prevention (history of CVD event)	Acute MI
234	Osaka Acute Coronary Insufficiency Study	Secondary Prevention (history of CVD event)	Acute MI
235	Physician's Health Study	Primary Prevention, Healthy	na
236	Physician's Health Study	Primary Prevention, Healthy	na
237	Physician's Health Study	Primary Prevention, Healthy	na
238	Physician's Health Study	Primary Prevention, Healthy	na
239	Physician's Health Study	Primary Prevention, Healthy	na
240	Physician's Health Study	Primary Prevention, Healthy	na
241	Physician's Health Study	Primary Prevention, Healthy	na
242	Physician's Health Study	Primary Prevention, Healthy	na
243	Physician's Health Study	Primary Prevention, Healthy	na
244	Physician's Health Study	Primary Prevention, Healthy	na
245	Physician's Health Study	Primary Prevention, Healthy	na
246	Physician's Health Study	Primary Prevention, Healthy	na
247	Physician's Health Study	Primary Prevention, Healthy	na
248	Physician's Health Study	Primary Prevention, Healthy	na
249	Physician's Health Study	Primary Prevention, Healthy	na
250	Physician's Health Study	Primary Prevention, Healthy	na
251	Physician's Health Study	Primary Prevention, Healthy	na
252	Physician's Health Study	Primary Prevention, Healthy	na
253	Physician's Health Study	Primary Prevention, Healthy	na
254	Physician's Health Study	Primary Prevention, Healthy	na
255	Physician's Health Study	Primary Prevention, Healthy	na
256	Physician's Health Study	Primary Prevention, Healthy	na
257	Physician's Health Study	Primary Prevention, Healthy	na
258	Physician's Health Study	Primary Prevention, Healthy	na
259	Physician's Health Study	Primary Prevention, Healthy	na
260	Physician's Health Study	Primary Prevention, Healthy	na
261	Physician's Health Study	Primary Prevention, Healthy	na
262	Pooling Project of Cohort Studies on Diet and Coronary Disease	Primary Prevention, Healthy	na
263	Pooling Project of Cohort Studies on Diet and Coronary Disease	Primary Prevention, Healthy	na
264	Rotterdam	Primary Prevention, Healthy	No AF at baseline
265	Rotterdam	Primary Prevention, Healthy	No previous MI
266	Rotterdam	Primary Prevention, Healthy	No heart failure at baseline

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Sample size (total)	Age mean (SD) [median]	Sex (% male)
230	Nurses' Health Study (NHS)	79839	range 34, 59	0
231	Osaka Acute Coronary Insufficiency Study	671	65 range 57, 73	77.8
232	Osaka Acute Coronary Insufficiency Study	671	65 range 57, 73	77.8
233	Osaka Acute Coronary Insufficiency Study	671	65 range 57, 73	77.8
234	Osaka Acute Coronary Insufficiency Study	671	65 range 57, 73	77.8
235	Physician's Health Study	2000	68.7 (8.7)	100
236	Physician's Health Study	2000	68.7 (8.7)	100
237	Physician's Health Study	2000	68.7 (8.7)	100
238	Physician's Health Study	2000	68.7 (8.7)	100
239	Physician's Health Study	2000	68.7 (8.7)	100
240	Physician's Health Study	2000	68.7 (8.7)	100
241	Physician's Health Study	19097	53.2	100
242	Physician's Health Study	19097	53.2	100
243	Physician's Health Study	19097	53.2	100
244	Physician's Health Study	19097	53.2	100
245	Physician's Health Study	19097	53.2	100
246	Physician's Health Study	19097	53.2	100
247	Physician's Health Study	2000	68.7 (8.7)	100
248	Physician's Health Study	2000	68.7 (8.7)	100
249	Physician's Health Study	2000	68.7 (8.7)	100
250	Physician's Health Study	2000	68.7 (8.7)	100
251	Physician's Health Study	2000	68.7 (8.7)	100
252	Physician's Health Study	2000	68.7 (8.7)	100
253	Physician's Health Study	19097	53.2	100
254	Physician's Health Study	19097	53.2	100
255	Physician's Health Study	19097	53.2	100
256	Physician's Health Study	19097	53.2	100
257	Physician's Health Study	19097	53.2	100
258	Physician's Health Study	19097	53.2	100
259	Physician's Health Study	19097	53.2	100
260	Physician's Health Study	19097	53.2	100
261	Physician's Health Study	19097	53.2	100
262	Pooling Project of Cohort Studies on Diet and Coronary Disease	229043	range 49, 61	35.1
263	Pooling Project of Cohort Studies on Diet and Coronary Disease	229043	range 49, 61	35.1
264	Rotterdam	5184	67.3 (7.6)	41% in Q3 (secondary study)
265	Rotterdam	5184	67.3 (7.6)	41% in Q3 (secondary study)
266	Rotterdam	5184	67.3 (7.6)	41% in Q3 (secondary study)

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Race	Blood pressure SBP/DBP (mmHg)
230	Nurses' Health Study (NHS)	98 white	nd
231	Osaka Acute Coronary Insufficiency Study	nd	nd
232	Osaka Acute Coronary Insufficiency Study	nd	nd
233	Osaka Acute Coronary Insufficiency Study	nd	nd
234	Osaka Acute Coronary Insufficiency Study	nd	nd
235	Physician's Health Study	nd	nd
236	Physician's Health Study	nd	nd
237	Physician's Health Study	nd	nd
238	Physician's Health Study	nd	nd
239	Physician's Health Study	nd	nd
240	Physician's Health Study	nd	nd
241	Physician's Health Study	nd	nd
242	Physician's Health Study	nd	nd
243	Physician's Health Study	nd	nd
244	Physician's Health Study	nd	nd
245	Physician's Health Study	nd	nd
246	Physician's Health Study	nd	nd
247	Physician's Health Study	nd	nd
248	Physician's Health Study	nd	nd
249	Physician's Health Study	nd	nd
250	Physician's Health Study	nd	nd
251	Physician's Health Study	nd	nd
252	Physician's Health Study	nd	nd
253	Physician's Health Study	nd	nd
254	Physician's Health Study	nd	nd
255	Physician's Health Study	nd	nd
256	Physician's Health Study	nd	nd
257	Physician's Health Study	nd	nd
258	Physician's Health Study	nd	nd
259	Physician's Health Study	nd	nd
260	Physician's Health Study	nd	nd
261	Physician's Health Study	nd	nd
262	Pooling Project of Cohort Studies on Diet and Coronary Disease	nd	nd
263	Pooling Project of Cohort Studies on Diet and Coronary Disease	nd	nd
264	Rotterdam		138 (21)/73 (11)
265	Rotterdam		138 (21)/73 (11)
266	Rotterdam		138 (21)/73 (11)

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
230	Nurses' Health Study (NHS)	nd
231	Osaka Acute Coronary Insufficiency Study	191 (range 163, 222)/122 (range 100, 147)/44 (range 38, 52)/98 (range 60, 153)
232	Osaka Acute Coronary Insufficiency Study	191 (range 163, 222)/122 (range 100, 147)/44 (range 38, 52)/98 (range 60, 153)
233	Osaka Acute Coronary Insufficiency Study	191 (range 163, 222)/122 (range 100, 147)/44 (range 38, 52)/98 (range 60, 153)
234	Osaka Acute Coronary Insufficiency Study	191 (range 163, 222)/122 (range 100, 147)/44 (range 38, 52)/98 (range 60, 153)
235	Physician's Health Study	nd
236	Physician's Health Study	nd
237	Physician's Health Study	nd
238	Physician's Health Study	nd
239	Physician's Health Study	nd
240	Physician's Health Study	nd
241	Physician's Health Study	nd
242	Physician's Health Study	nd
243	Physician's Health Study	nd
244	Physician's Health Study	nd
245	Physician's Health Study	nd
246	Physician's Health Study	nd
247	Physician's Health Study	nd
248	Physician's Health Study	nd
249	Physician's Health Study	nd
250	Physician's Health Study	nd
251	Physician's Health Study	nd
252	Physician's Health Study	nd
253	Physician's Health Study	nd
254	Physician's Health Study	nd
255	Physician's Health Study	nd
256	Physician's Health Study	nd
257	Physician's Health Study	nd
258	Physician's Health Study	nd
259	Physician's Health Study	nd
260	Physician's Health Study	nd
261	Physician's Health Study	nd
262	Pooling Project of Cohort Studies on Diet and Coronary Disease	nd
263	Pooling Project of Cohort Studies on Diet and Coronary Disease	nd
264	Rotterdam	[6.6 (1.2)]/nd/[1.3 (0.4)]/nd
265	Rotterdam	[6.6 (1.2)]/nd/[1.3 (0.4)]/nd
266	Rotterdam	[6.6 (1.2)]/nd/[1.3 (0.4)]/nd

Appendix G.2.
Causality Table: Observational Studies

Row	Study	BMI mean (SD)/weight mean (SD) Kg
230	Nurses' Health Study (NHS)	nd
231	Osaka Acute Coronary Insufficiency Study	23.9 (range 22.1, 26.1)
232	Osaka Acute Coronary Insufficiency Study	23.9 (range 22.1, 26.1)
233	Osaka Acute Coronary Insufficiency Study	23.9 (range 22.1, 26.1)
234	Osaka Acute Coronary Insufficiency Study	23.9 (range 22.1, 26.1)
235	Physician's Health Study	25.8 (3.4)
236	Physician's Health Study	25.8 (3.4)
237	Physician's Health Study	25.8 (3.4)
238	Physician's Health Study	25.8 (3.4)
239	Physician's Health Study	25.8 (3.4)
240	Physician's Health Study	25.8 (3.4)
241	Physician's Health Study	24.9
242	Physician's Health Study	24.9
243	Physician's Health Study	24.9
244	Physician's Health Study	24.9
245	Physician's Health Study	24.9
246	Physician's Health Study	24.9
247	Physician's Health Study	25.8 (3.4)
248	Physician's Health Study	25.8 (3.4)
249	Physician's Health Study	25.8 (3.4)
250	Physician's Health Study	25.8 (3.4)
251	Physician's Health Study	25.8 (3.4)
252	Physician's Health Study	25.8 (3.4)
253	Physician's Health Study	24.9
254	Physician's Health Study	24.9
255	Physician's Health Study	24.9
256	Physician's Health Study	24.9
257	Physician's Health Study	24.9
258	Physician's Health Study	24.9
259	Physician's Health Study	24.9
260	Physician's Health Study	24.9
261	Physician's Health Study	24.9
262	Pooling Project of Cohort Studies on Diet and Coronary Disease	nd
263	Pooling Project of Cohort Studies on Diet and Coronary Disease	nd
264	Rotterdam	26.4 (3.6)
265	Rotterdam	26.4 (3.6)
266	Rotterdam	26.4 (3.6)

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Baseline n-3 intake/level (median (IQR), unless noted)
230	Nurses' Health Study (NHS)	ALA: 0.52% energy, EPA+DHA 0.08% energy
231	Osaka Acute Coronary Insufficiency Study	EPA: 31.7 µg/mL, DHA: 72.5 µg/mL
232	Osaka Acute Coronary Insufficiency Study	EPA: 31.7 µg/mL, DHA: 72.5 µg/mL
233	Osaka Acute Coronary Insufficiency Study	EPA: 31.7 µg/mL, DHA: 72.5 µg/mL
234	Osaka Acute Coronary Insufficiency Study	EPA: 31.7 µg/mL, DHA: 72.5 µg/mL
235	Physician's Health Study	nd
236	Physician's Health Study	nd
237	Physician's Health Study	nd
238	Physician's Health Study	nd
239	Physician's Health Study	nd
240	Physician's Health Study	nd
241	Physician's Health Study	ALA: 0.765 g/d, EPA+DPA+DHA: 0.152 g/d,
242	Physician's Health Study	ALA: 0.765 g/d, EPA+DPA+DHA: 0.152 g/d,
243	Physician's Health Study	ALA: 0.765 g/d, EPA+DPA+DHA: 0.152 g/d,
244	Physician's Health Study	ALA: 0.765 g/d, EPA+DPA+DHA: 0.152 g/d,
245	Physician's Health Study	ALA: 0.765 g/d, EPA+DPA+DHA: 0.152 g/d,
246	Physician's Health Study	ALA: 0.765 g/d, EPA+DPA+DHA: 0.152 g/d,
247	Physician's Health Study	nd
248	Physician's Health Study	nd
249	Physician's Health Study	nd
250	Physician's Health Study	nd
251	Physician's Health Study	nd
252	Physician's Health Study	nd
253	Physician's Health Study	ALA: 0.765 g/d, EPA+DPA+DHA: 0.152 g/d,
254	Physician's Health Study	ALA: 0.765 g/d, EPA+DPA+DHA: 0.152 g/d,
255	Physician's Health Study	ALA: 0.765 g/d, EPA+DPA+DHA: 0.152 g/d,
256	Physician's Health Study	ALA: 0.765 g/d, EPA+DPA+DHA: 0.152 g/d,
257	Physician's Health Study	ALA: 0.765 g/d, EPA+DPA+DHA: 0.152 g/d,
258	Physician's Health Study	ALA: 0.765 g/d, EPA+DPA+DHA: 0.152 g/d,
259	Physician's Health Study	ALA: 0.765 g/d, EPA+DPA+DHA: 0.152 g/d,
260	Physician's Health Study	ALA: 0.765 g/d, EPA+DPA+DHA: 0.152 g/d,
261	Physician's Health Study	ALA: 0.765 g/d, EPA+DPA+DHA: 0.152 g/d,
262	Pooling Project of Cohort Studies on Diet and Coronary Disease	ALA: 1.06 (80% central range 0.60, 1.06) g/d, EPA+DHA: 0.19 (80% central range 0.05, 0.50) g/d
263	Pooling Project of Cohort Studies on Diet and Coronary Disease	ALA: 1.06 (80% central range 0.60, 1.06) g/d, EPA+DHA: 0.19 (80% central range 0.05, 0.50) g/d
264	Rotterdam	EPA+DHA: 89 mg/d
265	Rotterdam	EPA+DHA: 89 mg/d
266	Rotterdam	EPA+DHA: 89 mg/d

Appendix G.2.

Causality Table: Observational Studies

Row	Study	n-3 source	n-3 measure	n-3 type(s)
230	Nurses' Health Study (NHS)	intake	% energy	ALA
231	Osaka Acute Coronary Insufficiency Study	blood	µg/mL	DHA
232	Osaka Acute Coronary Insufficiency Study	blood	µg/mL	EPA
233	Osaka Acute Coronary Insufficiency Study	blood	µg/mL	DHA
234	Osaka Acute Coronary Insufficiency Study	blood	µg/mL	EPA
235	Physician's Health Study	RBC	Per SD increase	SDA
236	Physician's Health Study	RBC	Per SD increase	ALA
237	Physician's Health Study	RBC	Per SD increase	EPA+DPA+DHA
238	Physician's Health Study	RBC	Per SD increase	EPA
239	Physician's Health Study	RBC	Per SD increase	DPA
240	Physician's Health Study	RBC	Per SD increase	DHA
241	Physician's Health Study	intake	g/d	Marine (EPA+DHA+DPA)
242	Physician's Health Study	intake	g/d	ALA
243	Physician's Health Study	plasma	% of total Fas	Marine (EPA+DHA+DPA)
244	Physician's Health Study	plasma	% of total Fas	ALA
245	Physician's Health Study	intake	g/week	Total n-3
246	Physician's Health Study	intake	g/month	Total n-3
247	Physician's Health Study	RBC	Per SD increase	SDA
248	Physician's Health Study	RBC	Per SD increase	ALA
249	Physician's Health Study	RBC	Per SD increase	EPA+DPA+DHA
250	Physician's Health Study	RBC	Per SD increase	EPA
251	Physician's Health Study	RBC	Per SD increase	DPA
252	Physician's Health Study	RBC	Per SD increase	DHA
253	Physician's Health Study	intake	g/week	Total n-3
254	Physician's Health Study	intake	g/week	Total n-3
255	Physician's Health Study	cholesterol esters	% U	EPA
256	Physician's Health Study	cholesterol esters	% U	DHA
257	Physician's Health Study	cholesterol esters	% U	EPA+DHA
258	Physician's Health Study	phospholipids	% U	EPA
259	Physician's Health Study	phospholipids	% U	DHA
260	Physician's Health Study	phospholipids	% U	EPA+DHA
261	Physician's Health Study	intake	g/week	Total n-3
262	Pooling Project of Cohort Studies on Diet and Coronary Disease	intake	g/d	ALA
263	Pooling Project of Cohort Studies on Diet and Coronary Disease	intake	g/d	ALA
264	Rotterdam	intake	mg/d	EPA+DHA
265	Rotterdam	intake	mg/d	EPA+DHA
266	Rotterdam	intake	mg/d	EPA+DHA

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Study design
230	Nurses' Health Study (NHS)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
231	Osaka Acute Coronary Insufficiency Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
232	Osaka Acute Coronary Insufficiency Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
233	Osaka Acute Coronary Insufficiency Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
234	Osaka Acute Coronary Insufficiency Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
235	Physician's Health Study	Nested Case Control
236	Physician's Health Study	Nested Case Control
237	Physician's Health Study	Nested Case Control
238	Physician's Health Study	Nested Case Control
239	Physician's Health Study	Nested Case Control
240	Physician's Health Study	Nested Case Control
241	Physician's Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
242	Physician's Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
243	Physician's Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
244	Physician's Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
245	Physician's Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
246	Physician's Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
247	Physician's Health Study	Nested Case Control
248	Physician's Health Study	Nested Case Control
249	Physician's Health Study	Nested Case Control
250	Physician's Health Study	Nested Case Control
251	Physician's Health Study	Nested Case Control
252	Physician's Health Study	Nested Case Control
253	Physician's Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
254	Physician's Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
255	Physician's Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
256	Physician's Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
257	Physician's Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
258	Physician's Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
259	Physician's Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
260	Physician's Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
261	Physician's Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
262	Pooling Project of Cohort Studies on Diet and Coronary Disease	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
263	Pooling Project of Cohort Studies on Diet and Coronary Disease	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
264	Rotterdam	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
265	Rotterdam	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
266	Rotterdam	Prospective, longitudinal study of intake (eg, FFQ, biomarker)

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Outcome	Reported effect Size
230	Nurses' Health Study (NHS)	Sudden cardiac death	See appendix F
231	Osaka Acute Coronary Insufficiency Study	Congestive heart failure	See appendix F
232	Osaka Acute Coronary Insufficiency Study	Congestive heart failure	See appendix F
233	Osaka Acute Coronary Insufficiency Study	Death, all cause	See appendix F
234	Osaka Acute Coronary Insufficiency Study	Death, all cause	See appendix F
235	Physician's Health Study	CHD	See appendix F
236	Physician's Health Study	CHD	See appendix F
237	Physician's Health Study	CHD	See appendix F
238	Physician's Health Study	CHD	See appendix F
239	Physician's Health Study	CHD	See appendix F
240	Physician's Health Study	CHD	See appendix F
241	Physician's Health Study	Congestive heart failure	See appendix F
242	Physician's Health Study	Congestive heart failure	See appendix F
243	Physician's Health Study	Congestive heart failure	See appendix F
244	Physician's Health Study	Congestive heart failure	See appendix F
245	Physician's Health Study	CVD, total	See appendix F
246	Physician's Health Study	Death, cardiac	See appendix F
247	Physician's Health Study	Death, CHD	See appendix F
248	Physician's Health Study	Death, CHD	See appendix F
249	Physician's Health Study	Death, CHD	See appendix F
250	Physician's Health Study	Death, CHD	See appendix F
251	Physician's Health Study	Death, CHD	See appendix F
252	Physician's Health Study	Death, CHD	See appendix F
253	Physician's Health Study	Death, CVD	See appendix F
254	Physician's Health Study	Myocardial infarction	See appendix F
255	Physician's Health Study	Myocardial infarction	See appendix F
256	Physician's Health Study	Myocardial infarction	See appendix F
257	Physician's Health Study	Myocardial infarction	See appendix F
258	Physician's Health Study	Myocardial infarction	See appendix F
259	Physician's Health Study	Myocardial infarction	See appendix F
260	Physician's Health Study	Myocardial infarction	See appendix F
261	Physician's Health Study	Stroke, total	See appendix F
262	Pooling Project of Cohort Studies on Diet and Coronary Disease	Coronary heart disease	See appendix F
263	Pooling Project of Cohort Studies on Diet and Coronary Disease	Death, cardiac	See appendix F
264	Rotterdam	Atrial fibrillation	See appendix F
265	Rotterdam	Atrial fibrillation	See appendix F
266	Rotterdam	Congestive heart failure	See appendix F

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Study years (study start date)	Country
267	Scottish Heart Health Extended Cohort Study	1984	UK
268	Scottish Heart Health Extended Cohort Study	1984	UK
269	Shanghai	1986	China
270	Shanghai	1986	China
271	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	1997	China
272	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	1997	China
273	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	1997	China
274	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	1997	China
275	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	1997	China
276	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	1997	China
277	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	1997	China
278	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	1997	China
279	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	1997	China
280	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	1997	China
281	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	1997	China
282	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	1997	China
283	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	1997	China
284	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	1997	China
285	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	1997	China
286	Spanish EPIC	1992	Spain
287	Spanish EPIC	1992	Spain
288	Spanish EPIC	1992	Spain
289	Spanish EPIC	1992	Spain
290	Spanish EPIC	1992	Spain

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Population	Risk type
267	Scottish Heart Health Extended Cohort Study	Primary Prevention, Healthy	na
268	Scottish Heart Health Extended Cohort Study	Primary Prevention, Healthy	na
269	Shanghai	Primary Prevention, Healthy	na
270	Shanghai	Primary Prevention, Healthy	na
271	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Primary Prevention, Healthy	na
272	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Primary Prevention, Healthy	na
273	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Primary Prevention, Healthy	na
274	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Primary Prevention, Healthy	na
275	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Primary Prevention, Healthy	na
276	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Primary Prevention, Healthy	na
277	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Primary Prevention, Healthy	na
278	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Primary Prevention, Healthy	na
279	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Primary Prevention, Healthy	na
280	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Primary Prevention, Healthy	na
281	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Primary Prevention, Healthy	na
282	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Primary Prevention, Healthy	na
283	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Primary Prevention, Healthy	na
284	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Primary Prevention, Healthy	na
285	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Primary Prevention, Healthy	na
286	Spanish EPIC	Primary Prevention, Healthy	na
287	Spanish EPIC	Primary Prevention, Healthy	na
288	Spanish EPIC	Primary Prevention, Healthy	na
289	Spanish EPIC	Primary Prevention, Healthy	na
290	Spanish EPIC	Primary Prevention, Healthy	na

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Sample size (total)	Age mean (SD) [median]	Sex (% male)
267	Scottish Heart Health Extended Cohort Study	3944	men: 49.0 (6.9), women: 48.9(6.6)	53
268	Scottish Heart Health Extended Cohort Study	3944	men: 49.0 (6.9), women: 48.9(6.6)	53
269	Shanghai	18244	55.8	100
270	Shanghai	18244	55.8	100
271	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	134296	men: 55.1 (9.54), women: 51.8 (8.76)	45.5
272	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	134296	men: 55.1 (9.54), women: 51.8 (8.76)	45.5
273	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	134296	men: 55.1 (9.54), women: 51.8 (8.76)	45.5
274	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	134296	men: 55.1 (9.54), women: 51.8 (8.76)	45.5
275	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	134296	men: 55.1 (9.54), women: 51.8 (8.76)	45.5
276	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	134296	men: 55.1 (9.54), women: 51.8 (8.76)	45.5
277	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	134296	men: 55.1 (9.54), women: 51.8 (8.76)	45.5
278	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	134296	men: 55.1 (9.54), women: 51.8 (8.76)	45.5
279	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	134296	men: 55.1 (9.54), women: 51.8 (8.76)	45.5
280	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	134296	men: 55.1 (9.54), women: 51.8 (8.76)	45.5
281	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	134296	men: 55.1 (9.54), women: 51.8 (8.76)	45.5
282	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	134296	men: 55.1 (9.54), women: 51.8 (8.76)	45.5
283	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	134296	men: 55.1 (9.54), women: 51.8 (8.76)	45.5
284	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	134296	men: 55.1 (9.54), women: 51.8 (8.76)	45.5
285	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	134296	men: 55.1 (9.54), women: 51.8 (8.76)	45.5
286	Spanish EPIC	41091	49.2 (8)	37.6
287	Spanish EPIC	41091	49.2 (8)	37.6
288	Spanish EPIC	41091	49.2 (8)	37.6
289	Spanish EPIC	41091	49.2 (8)	37.6
290	Spanish EPIC	41091	49.2 (8)	37.6

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Race	Blood pressure SBP/DBP (mmHg)
267	Scottish Heart Health Extended Cohort Study	nd	men: 133.2 (18.5), women: 130.0(20.0)/
268	Scottish Heart Health Extended Cohort Study	nd	men: 133.2 (18.5), women: 130.0(20.0)/
269	Shanghai	nd	nd
270	Shanghai	nd	nd
271	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd	nd
272	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd	nd
273	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd	nd
274	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd	nd
275	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd	nd
276	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd	nd
277	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd	nd
278	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd	nd
279	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd	nd
280	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd	nd
281	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd	nd
282	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd	nd
283	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd	nd
284	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd	nd
285	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd	nd
286	Spanish EPIC	nd	nd
287	Spanish EPIC	nd	nd
288	Spanish EPIC	nd	nd
289	Spanish EPIC	nd	nd
290	Spanish EPIC	nd	nd

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
267	Scottish Heart Health Extended Cohort Study	[men: 6.29(1.13), women: 6.49(1.31)/nd/[men: 1.38(0.37), women: 1.68(0.42)]/nd
268	Scottish Heart Health Extended Cohort Study	[men: 6.29(1.13), women: 6.49(1.31)/nd/[men: 1.38(0.37), women: 1.68(0.42)]/nd
269	Shanghai	nd
270	Shanghai	nd
271	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd
272	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd
273	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd
274	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd
275	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd
276	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd
277	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd
278	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd
279	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd
280	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd
281	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd
282	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd
283	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd
284	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd
285	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd
286	Spanish EPIC	nd
287	Spanish EPIC	nd
288	Spanish EPIC	nd
289	Spanish EPIC	nd
290	Spanish EPIC	nd

Appendix G.2.
Causality Table: Observational Studies

Row	Study	BMI mean (SD)/weight mean (SD) Kg
267	Scottish Heart Health Extended Cohort Study	nd
268	Scottish Heart Health Extended Cohort Study	nd
269	Shanghai	22.2
270	Shanghai	22.2
271	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd
272	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd
273	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd
274	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd
275	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd
276	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd
277	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd
278	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd
279	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd
280	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd
281	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd
282	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd
283	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd
284	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd
285	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	nd
286	Spanish EPIC	73.7 (12.6)
287	Spanish EPIC	73.7 (12.6)
288	Spanish EPIC	73.7 (12.6)
289	Spanish EPIC	73.7 (12.6)
290	Spanish EPIC	73.7 (12.6)

Row	Study	Baseline n-3 intake/level (median (IQR), unless noted)
267	Scottish Heart Health Extended Cohort Study	DPA: men 0.25 (0.20, 0.30)% FA, women 0.26 (0.21, 0.32)% FA, DHA: men 0.17 (0.13, 0.22)% FA, women 0.19 (0.15, 0.26)% FA, DPA+DHA: men 0.42 (0.33, 0.52)% FA, women 0.46 (0.36, 0.58)% FA
268	Scottish Heart Health Extended Cohort Study	DPA: men 0.25 (0.20, 0.30)% FA, women 0.26 (0.21, 0.32)% FA, DHA: men 0.17 (0.13, 0.22)% FA, women 0.19 (0.15, 0.26)% FA, DPA+DHA: men 0.42 (0.33, 0.52)% FA, women 0.46 (0.36, 0.58)% FA
269	Shanghai	All n-3 FA: 0.65 g/week
270	Shanghai	All n-3 FA: 0.65 g/week
271	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	EPA: men and women 0.02 g/d, DHA: men 0.05 g/d, women 0.04 g/d
272	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	EPA: men and women 0.02 g/d, DHA: men 0.05 g/d, women 0.04 g/d
273	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	EPA: men and women 0.02 g/d, DHA: men 0.05 g/d, women 0.04 g/d
274	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	EPA: men and women 0.02 g/d, DHA: men 0.05 g/d, women 0.04 g/d
275	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	EPA: men and women 0.02 g/d, DHA: men 0.05 g/d, women 0.04 g/d
276	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	EPA: men and women 0.02 g/d, DHA: men 0.05 g/d, women 0.04 g/d
277	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	EPA: men and women 0.02 g/d, DHA: men 0.05 g/d, women 0.04 g/d
278	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	EPA: men and women 0.02 g/d, DHA: men 0.05 g/d, women 0.04 g/d
279	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	EPA: men and women 0.02 g/d, DHA: men 0.05 g/d, women 0.04 g/d
280	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	EPA: men and women 0.02 g/d, DHA: men 0.05 g/d, women 0.04 g/d
281	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	EPA: men and women 0.02 g/d, DHA: men 0.05 g/d, women 0.04 g/d
282	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	EPA: men and women 0.02 g/d, DHA: men 0.05 g/d, women 0.04 g/d
283	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	EPA: men and women 0.02 g/d, DHA: men 0.05 g/d, women 0.04 g/d
284	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	EPA: men and women 0.02 g/d, DHA: men 0.05 g/d, women 0.04 g/d
285	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	EPA: men and women 0.02 g/d, DHA: men 0.05 g/d, women 0.04 g/d
286	Spanish EPIC	EPA: mean 0.2 (SD 0.2) g/d, DHA: mean 0.4 (SD 0.3) g/d, Total n-3 FA: mean 1.4 (SD 0.7) g/d
287	Spanish EPIC	EPA: mean 0.2 (SD 0.2) g/d, DHA: mean 0.4 (SD 0.3) g/d, Total n-3 FA: mean 1.4 (SD 0.7) g/d
288	Spanish EPIC	EPA: mean 0.2 (SD 0.2) g/d, DHA: mean 0.4 (SD 0.3) g/d, Total n-3 FA: mean 1.4 (SD 0.7) g/d
289	Spanish EPIC	EPA: mean 0.2 (SD 0.2) g/d, DHA: mean 0.4 (SD 0.3) g/d, Total n-3 FA: mean 1.4 (SD 0.7) g/d
290	Spanish EPIC	EPA: mean 0.2 (SD 0.2) g/d, DHA: mean 0.4 (SD 0.3) g/d, Total n-3 FA: mean 1.4 (SD 0.7) g/d

Appendix G.2.
Causality Table: Observational Studies

Row	Study	n-3 source	n-3 measure	n-3 type(s)
267	Scottish Heart Health Extended Cohort Study	adipose tissue	mmol/L	DPA
268	Scottish Heart Health Extended Cohort Study	adipose tissue	mmol/L	DHA
269	Shanghai	intake	g/week	all_n3
270	Shanghai	intake	g/week	all_n3
271	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	intake	g/d	EPA
272	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	intake	g/d	DHA
273	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	intake	g/d	EPA + DHA
274	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	intake	g/d	EPA
275	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	intake	g/d	DHA
276	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	intake	g/d	EPA + DHA
277	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	intake	g/d	EPA
278	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	intake	g/d	DHA
279	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	intake	g/d	EPA + DHA
280	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	intake	g/d	EPA
281	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	intake	g/d	DHA
282	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	intake	g/d	EPA + DHA
283	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	intake	g/d	EPA
284	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	intake	g/d	DHA
285	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	intake	g/d	EPA + DHA
286	Spanish EPIC	intake	g/d	EPA + DHA
287	Spanish EPIC	intake	g/d	EPA + DHA
288	Spanish EPIC	intake	g/d	EPA
289	Spanish EPIC	intake	g/d	EPA
290	Spanish EPIC	intake	g/d	DHA

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Study design
267	Scottish Heart Health Extended Cohort Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
268	Scottish Heart Health Extended Cohort Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
269	Shanghai	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
270	Shanghai	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
271	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
272	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
273	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
274	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
275	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
276	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
277	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
278	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
279	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
280	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
281	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
282	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
283	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
284	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
285	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
286	Spanish EPIC	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
287	Spanish EPIC	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
288	Spanish EPIC	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
289	Spanish EPIC	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
290	Spanish EPIC	Prospective, longitudinal study of intake (eg, FFQ, biomarker)

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Outcome	Reported effect Size
267	Scottish Heart Health Extended Cohort Study	CVD, total	See appendix F
268	Scottish Heart Health Extended Cohort Study	CVD, total	See appendix F
269	Shanghai	Death, CHD	See appendix F
270	Shanghai	Death, stroke	See appendix F
271	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Death, all cause	See appendix F
272	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Death, all cause	See appendix F
273	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Death, all cause	See appendix F
274	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Death, CHD	See appendix F
275	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Death, CHD	See appendix F
276	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Death, CHD	See appendix F
277	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Death, CVD	See appendix F
278	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Death, CVD	See appendix F
279	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Death, CVD	See appendix F
280	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Death, stroke, hemorrhagic	See appendix F
281	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Death, stroke, hemorrhagic	See appendix F
282	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Death, stroke, hemorrhagic	See appendix F
283	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Death, stroke, ischemic	See appendix F
284	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Death, stroke, ischemic	See appendix F
285	Shanghai Women's Health Study (SWHS) Shanghai Men's Health Study (SMHS)	Death, stroke, ischemic	See appendix F
286	Spanish EPIC	Myocardial infarction	See appendix F
287	Spanish EPIC	Myocardial infarction	See appendix F
288	Spanish EPIC	Myocardial infarction	See appendix F
289	Spanish EPIC	Myocardial infarction	See appendix F
290	Spanish EPIC	Myocardial infarction	See appendix F

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Study years (study start date)	Country
291	Spanish EPIC	1992	Spain
292	Swedish Mammography Study	1997	Sweden
293	Swedish Mammography Study	1997	Sweden
294	Swedish Mammography Study	1997	Sweden
295	Swedish Mammography Study	1997	Sweden
296	Swedish Mammography Study	1997	Sweden
297	Swedish Mammography Study	1997	Sweden
298	Swedish Mammography Study	1997	Sweden
299	Takayama	1992	Japan
300	Takayama	1992	Japan
301	The Singapore Chinese Health Study	1993	China
302	The Singapore Chinese Health Study	1993	China
303	The Singapore Chinese Health Study	1993	China
304	The Singapore Chinese Health Study	1993	China
305	The Singapore Chinese Health Study	1993	China
306	The Singapore Chinese Health Study	1993	China
307	The Singapore Chinese Health Study	1993	China
308	The Singapore Chinese Health Study	1993	China
309	The Singapore Chinese Health Study	1993	China
310	The Singapore Chinese Health Study	1993	China
311	The Singapore Chinese Health Study	1993	China
312	The Singapore Chinese Health Study	1993	China
313	ULSAM	1970	Sweden
314	ULSAM	1970	Sweden
315	ULSAM	1970	Sweden
316	ULSAM	1970	Sweden
317	ULSAM	1970	Sweden
318	ULSAM	1970	Sweden
319	VITAL	2000	US
320	VITAL	2000	US
321	VITAL	2000	US
322	Women's Health Initiative	nd	US

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Population	Risk type
291	Spanish EPIC	Primary Prevention, Healthy	na
292	Swedish Mammography Study	Primary Prevention, Healthy	na
293	Swedish Mammography Study	Primary Prevention, Healthy	na
294	Swedish Mammography Study	Primary Prevention, Healthy	na
295	Swedish Mammography Study	Primary Prevention, Healthy	na
296	Swedish Mammography Study	Primary Prevention, Healthy	na
297	Swedish Mammography Study	Primary Prevention, Healthy	na
298	Swedish Mammography Study	Primary Prevention, Healthy	na
299	Takayama	Primary Prevention, Healthy	na
300	Takayama	Primary Prevention, Healthy	na
301	The Singapore Chinese Health Study	Primary Prevention, Healthy	na
302	The Singapore Chinese Health Study	Primary Prevention, Healthy	na
303	The Singapore Chinese Health Study	Primary Prevention, Healthy	na
304	The Singapore Chinese Health Study	Primary Prevention, Healthy	na
305	The Singapore Chinese Health Study	Primary Prevention, Healthy	na
306	The Singapore Chinese Health Study	Primary Prevention, Healthy	na
307	The Singapore Chinese Health Study	CVD	history of CHD or stroke
308	The Singapore Chinese Health Study	CVD	history of CHD or stroke
309	The Singapore Chinese Health Study	CVD	history of CHD or stroke
310	The Singapore Chinese Health Study	Primary Prevention, Healthy	na
311	The Singapore Chinese Health Study	Primary Prevention, Healthy	na
312	The Singapore Chinese Health Study	Primary Prevention, Healthy	na
313	ULSAM	Primary Prevention, Healthy	na
314	ULSAM	Primary Prevention, Healthy	na
315	ULSAM	Primary Prevention, Healthy	na
316	ULSAM	Primary Prevention, Healthy	na
317	ULSAM	Primary Prevention, Healthy	na
318	ULSAM	Primary Prevention, Healthy	na
319	VITAL	Primary Prevention, Healthy	na
320	VITAL	Primary Prevention, Healthy	na
321	VITAL	Primary Prevention, Healthy	na
322	Women's Health Initiative	Primary Prevention, Healthy	na

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Sample size (total)	Age mean (SD) [median]	Sex (% male)
291	Spanish EPIC	41091	49.2 (8)	37.6
292	Swedish Mammography Study	34670	62	0
293	Swedish Mammography Study	34670	62	0
294	Swedish Mammography Study	34670	62	0
295	Swedish Mammography Study	34670	62	0
296	Swedish Mammography Study	34670	62	0
297	Swedish Mammography Study	34670	62	0
298	Swedish Mammography Study	34670	62	0
299	Takayama	30480	men: 54.0 (12.1), women: 55.1 (13.0)	nd
300	Takayama	30480	men: 54.0 (12.1), women: 55.1 (13.0)	nd
301	The Singapore Chinese Health Study	60298	56 (8)	44.2
302	The Singapore Chinese Health Study	60298	56 (8)	44.2
303	The Singapore Chinese Health Study	60298	56 (8)	44.2
304	The Singapore Chinese Health Study	60298	56 (8)	44.2
305	The Singapore Chinese Health Study	60298	56 (8)	44.2
306	The Singapore Chinese Health Study	60298	56 (8)	44.2
307	The Singapore Chinese Health Study	nd	nd	nd
308	The Singapore Chinese Health Study	nd	nd	nd
309	The Singapore Chinese Health Study	nd	nd	nd
310	The Singapore Chinese Health Study	60298	56 (8)	44.2
311	The Singapore Chinese Health Study	60298	56 (8)	44.2
312	The Singapore Chinese Health Study	60298	56 (8)	44.2
313	ULSAM	1012	nd	100
314	ULSAM	1012	nd	100
315	ULSAM	1012	nd	100
316	ULSAM	1012	nd	100
317	ULSAM	1012	nd	100
318	ULSAM	1012	nd	100
319	VITAL	70.287	range 50, 76	49
320	VITAL	70.287	range 50, 76	49
321	VITAL	70.287	range 50, 76	49
322	Women's Health Initiative	84493	range 50, 79	0

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Race	Blood pressure SBP/DBP (mmHg)
291	Spanish EPIC	nd	nd
292	Swedish Mammography Study	nd	nd
293	Swedish Mammography Study	nd	nd
294	Swedish Mammography Study	nd	nd
295	Swedish Mammography Study	nd	nd
296	Swedish Mammography Study	nd	nd
297	Swedish Mammography Study	nd	nd
298	Swedish Mammography Study	nd	nd
299	Takayama	nd	nd
300	Takayama	nd	nd
301	The Singapore Chinese Health Study	100 Asian	nd
302	The Singapore Chinese Health Study	100 Asian	nd
303	The Singapore Chinese Health Study	100 Asian	nd
304	The Singapore Chinese Health Study	100 Asian	nd
305	The Singapore Chinese Health Study	100 Asian	nd
306	The Singapore Chinese Health Study	100 Asian	nd
307	The Singapore Chinese Health Study	100 Asian	nd
308	The Singapore Chinese Health Study	100 Asian	nd
309	The Singapore Chinese Health Study	100 Asian	nd
310	The Singapore Chinese Health Study	100 Asian	nd
311	The Singapore Chinese Health Study	100 Asian	nd
312	The Singapore Chinese Health Study	100 Asian	nd
313	ULSAM	nd	nd
314	ULSAM	nd	nd
315	ULSAM	nd	nd
316	ULSAM	nd	nd
317	ULSAM	nd	nd
318	ULSAM	nd	nd
319	VITAL	93% white, 1% black, 2% Asian, 1% Hispanic, 1.5% Inuit.Eskimo, 1.5% other/missing	nd
320	VITAL	93% white, 1% black, 2% Asian, 1% Hispanic, 1.5% Inuit.Eskimo, 1.5% other/missing	nd
321	VITAL	93% white, 1% black, 2% Asian, 1% Hispanic, 1.5% Inuit.Eskimo, 1.5% other/missing	nd
322	Women's Health Initiative	~84 white, ~7% black, ~3% Asian, ~5% Hispanic, ~0.4% American Indian/Alaskan Native, ~1% unknown	127 (18)/nd

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
291	Spanish EPIC	nd
292	Swedish Mammography Study	nd
293	Swedish Mammography Study	nd
294	Swedish Mammography Study	nd
295	Swedish Mammography Study	nd
296	Swedish Mammography Study	nd
297	Swedish Mammography Study	nd
298	Swedish Mammography Study	nd
299	Takayama	nd
300	Takayama	nd
301	The Singapore Chinese Health Study	nd
302	The Singapore Chinese Health Study	nd
303	The Singapore Chinese Health Study	nd
304	The Singapore Chinese Health Study	nd
305	The Singapore Chinese Health Study	nd
306	The Singapore Chinese Health Study	nd
307	The Singapore Chinese Health Study	nd
308	The Singapore Chinese Health Study	nd
309	The Singapore Chinese Health Study	nd
310	The Singapore Chinese Health Study	nd
311	The Singapore Chinese Health Study	nd
312	The Singapore Chinese Health Study	nd
313	ULSAM	6.9 (1.3)/nd/nd/nd
314	ULSAM	6.9 (1.3)/nd/nd/nd
315	ULSAM	6.9 (1.3)/nd/nd/nd
316	ULSAM	6.9 (1.3)/nd/nd/nd
317	ULSAM	6.9 (1.3)/nd/nd/nd
318	ULSAM	6.9 (1.3)/nd/nd/nd
319	VITAL	nd
320	VITAL	nd
321	VITAL	nd
322	Women's Health Initiative	nd/nd/64 (17)/nd

Appendix G.2.
Causality Table: Observational Studies

Row	Study	BMI mean (SD)/weight mean (SD) Kg
291	Spanish EPIC	73.7 (12.6)
292	Swedish Mammography Study	25
293	Swedish Mammography Study	25
294	Swedish Mammography Study	25
295	Swedish Mammography Study	25
296	Swedish Mammography Study	25
297	Swedish Mammography Study	25
298	Swedish Mammography Study	25
299	Takayama	men: 22.5 (2.8), women: 22.0 (2.9)
300	Takayama	men: 22.5 (2.8), women: 22.0 (2.9)
301	The Singapore Chinese Health Study	23.2 (3.3)
302	The Singapore Chinese Health Study	23.2 (3.3)
303	The Singapore Chinese Health Study	23.2 (3.3)
304	The Singapore Chinese Health Study	23.2 (3.3)
305	The Singapore Chinese Health Study	23.2 (3.3)
306	The Singapore Chinese Health Study	23.2 (3.3)
307	The Singapore Chinese Health Study	nd
308	The Singapore Chinese Health Study	nd
309	The Singapore Chinese Health Study	nd
310	The Singapore Chinese Health Study	23.2 (3.3)
311	The Singapore Chinese Health Study	23.2 (3.3)
312	The Singapore Chinese Health Study	23.2 (3.3)
313	ULSAM	25.0 (3.2)
314	ULSAM	25.0 (3.2)
315	ULSAM	25.0 (3.2)
316	ULSAM	25.0 (3.2)
317	ULSAM	25.0 (3.2)
318	ULSAM	25.0 (3.2)
319	VITAL	nd
320	VITAL	nd
321	VITAL	nd
322	Women's Health Initiative	28 (6)

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Baseline n-3 intake/level (median (IQR), unless noted)
291	Spanish EPIC	EPA: mean 0.2 (SD 0.2) g/d, DHA: mean 0.4 (SD 0.3) g/d, Total n-3 FA: mean 1.4 (SD 0.7) g/d
292	Swedish Mammography Study	ALA: 1.1 g/d, EPA+DHA 289 mg/d
293	Swedish Mammography Study	ALA: 1.1 g/d, EPA+DHA 289 mg/d
294	Swedish Mammography Study	ALA: 1.1 g/d, EPA+DHA 289 mg/d
295	Swedish Mammography Study	ALA: 1.1 g/d, EPA+DHA 289 mg/d
296	Swedish Mammography Study	ALA: 1.1 g/d, EPA+DHA 289 mg/d
297	Swedish Mammography Study	ALA: 1.1 g/d, EPA+DHA 289 mg/d
298	Swedish Mammography Study	ALA: 1.1 g/d, EPA+DHA 289 mg/d
299	Takayama	Fish oil: men 788 mg/d, women 635 mg/d
300	Takayama	Fish oil: men 788 mg/d, women 635 mg/d
301	The Singapore Chinese Health Study	nd
302	The Singapore Chinese Health Study	nd
303	The Singapore Chinese Health Study	nd
304	The Singapore Chinese Health Study	nd
305	The Singapore Chinese Health Study	nd
306	The Singapore Chinese Health Study	nd
307	The Singapore Chinese Health Study	nd
308	The Singapore Chinese Health Study	nd
309	The Singapore Chinese Health Study	nd
310	The Singapore Chinese Health Study	nd
311	The Singapore Chinese Health Study	nd
312	The Singapore Chinese Health Study	nd
313	ULSAM	ALA: 0.66% FA, EPA: 1.3% FA, DHA 0.68% FA
314	ULSAM	ALA: 0.66% FA, EPA: 1.3% FA, DHA 0.68% FA
315	ULSAM	ALA: 0.66% FA, EPA: 1.3% FA, DHA 0.68% FA
316	ULSAM	ALA: 0.66% FA, EPA: 1.3% FA, DHA 0.68% FA
317	ULSAM	ALA: 0.66% FA, EPA: 1.3% FA, DHA 0.68% FA
318	ULSAM	ALA: 0.66% FA, EPA: 1.3% FA, DHA 0.68% FA
319	VITAL	EPA+DHA: 0.174 g/d; EPA 0.058 g/d; DHA 0.113 g/d
320	VITAL	EPA+DHA: 0.174 g/d; EPA 0.058 g/d; DHA 0.113 g/d
321	VITAL	EPA+DHA: 0.174 g/d; EPA 0.058 g/d; DHA 0.113 g/d
322	Women's Health Initiative	ALA: 1.02 g/d, DHA+EPA: 0.093

Appendix G.2.

Causality Table: Observational Studies

Row	Study	n-3 source	n-3 measure	n-3 type(s)
291	Spanish EPIC	intake	g/d	DHA
292	Swedish Mammography Study	intake	g/d	ALA
293	Swedish Mammography Study	intake	g/d	EPA + DHA
294	Swedish Mammography Study	intake	g/d	EPA + DHA
295	Swedish Mammography Study	intake	g/d	ALA
296	Swedish Mammography Study	intake	mg/d	EPA + DHA
297	Swedish Mammography Study	intake	g/d	ALA
298	Swedish Mammography Study	intake	mg/d	EPA + DHA
299	Takayama	intake	mg/d	FO
300	Takayama	intake	mg/d	FO
301	The Singapore Chinese Health Study	intake	nd	Total n-3
302	The Singapore Chinese Health Study	intake	nd	EPA+DHA
303	The Singapore Chinese Health Study	intake	nd	ALA
304	The Singapore Chinese Health Study	intake	nd	Total n-3
305	The Singapore Chinese Health Study	intake	nd	EPA+DHA
306	The Singapore Chinese Health Study	intake	nd	ALA
307	The Singapore Chinese Health Study	intake	nd	Total n-3
308	The Singapore Chinese Health Study	intake	nd	EPA+DHA
309	The Singapore Chinese Health Study	intake	nd	ALA
310	The Singapore Chinese Health Study	intake	nd	Total n-3
311	The Singapore Chinese Health Study	intake	nd	EPA+DHA
312	The Singapore Chinese Health Study	intake	nd	ALA
313	ULSAM	serum	% FA	ALA
314	ULSAM	serum	% FA	EPA
315	ULSAM	serum	% FA	DHA
316	ULSAM	serum	% FA	ALA
317	ULSAM	serum	% FA	EPA
318	ULSAM	serum	% FA	DHA
319	VITAL	intake	g/d	EPA+DHA
320	VITAL	intake	g/d	EPA+DHA
321	VITAL	intake	g/d	EPA+DHA
322	Women's Health Initiative	intake	g/d	Fish Intake

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Study design
291	Spanish EPIC	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
292	Swedish Mammography Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
293	Swedish Mammography Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
294	Swedish Mammography Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
295	Swedish Mammography Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
296	Swedish Mammography Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
297	Swedish Mammography Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
298	Swedish Mammography Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
299	Takayama	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
300	Takayama	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
301	The Singapore Chinese Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
302	The Singapore Chinese Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
303	The Singapore Chinese Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
304	The Singapore Chinese Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
305	The Singapore Chinese Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
306	The Singapore Chinese Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
307	The Singapore Chinese Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
308	The Singapore Chinese Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
309	The Singapore Chinese Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
310	The Singapore Chinese Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
311	The Singapore Chinese Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
312	The Singapore Chinese Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
313	ULSAM	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
314	ULSAM	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
315	ULSAM	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
316	ULSAM	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
317	ULSAM	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
318	ULSAM	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
319	VITAL	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
320	VITAL	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
321	VITAL	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
322	Women's Health Initiative	Prospective, longitudinal study of intake (eg, FFQ, biomarker)

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Outcome	Reported effect Size
291	Spanish EPIC	Myocardial infarction	See appendix F
292	Swedish Mammography Study	Myocardial infarction	See appendix F
293	Swedish Mammography Study	Myocardial infarction	See appendix F
294	Swedish Mammography Study	Myocardial infarction	See appendix F
295	Swedish Mammography Study	Stroke, hemorrhagic	See appendix F
296	Swedish Mammography Study	Stroke, hemorrhagic	See appendix F
297	Swedish Mammography Study	Stroke, total	See appendix F
298	Swedish Mammography Study	Stroke, total	See appendix F
299	Takayama	Coronary heart disease	See appendix F
300	Takayama	Death, all cause	See appendix F
301	The Singapore Chinese Health Study	Death, CHD	See appendix F
302	The Singapore Chinese Health Study	Death, CHD	See appendix F
303	The Singapore Chinese Health Study	Death, CHD	See appendix F
304	The Singapore Chinese Health Study	Death, CVD	See appendix F
305	The Singapore Chinese Health Study	Death, CVD	See appendix F
306	The Singapore Chinese Health Study	Death, CVD	See appendix F
307	The Singapore Chinese Health Study	Death, CVD	See appendix F
308	The Singapore Chinese Health Study	Death, CVD	See appendix F
309	The Singapore Chinese Health Study	Death, CVD	See appendix F
310	The Singapore Chinese Health Study	Death, stroke	See appendix F
311	The Singapore Chinese Health Study	Death, stroke	See appendix F
312	The Singapore Chinese Health Study	Death, stroke	See appendix F
313	ULSAM	Death, all cause	See appendix F
314	ULSAM	Death, all cause	See appendix F
315	ULSAM	Death, all cause	See appendix F
316	ULSAM	Death, cardiac	See appendix F
317	ULSAM	Death, cardiac	See appendix F
318	ULSAM	Death, cardiac	See appendix F
319	VITAL	Death, all cause	See appendix F
320	VITAL	Death, CHD	See appendix F
321	VITAL	Death, CVD	See appendix F
322	Women's Health Initiative	Atrial fibrillation	See appendix F

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Study years (study start date)	Country
323	Women's Health Initiative	nd	US
324	Women's Health Initiative	nd	US
325	Women's Health Study	1992	US
326	Women's Health Study	1992	US
327	Women's Health Study	1992	US
328	Women's Health Study	1992	US
329	Women's Health Study	1992	US

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Population	Risk type
323	Women's Health Initiative	Primary Prevention, Healthy	na
324	Women's Health Initiative	Primary Prevention, Healthy	na
325	Women's Health Study	Primary Prevention, Healthy	na
326	Women's Health Study	Primary Prevention, Healthy	na
327	Women's Health Study	Primary Prevention, Healthy	na
328	Women's Health Study	Primary Prevention, Healthy	na
329	Women's Health Study	Primary Prevention, Healthy	na

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Sample size (total)	Age mean (SD) [median]	Sex (% male)
323	Women's Health Initiative	84493	range 50, 79	0
324	Women's Health Initiative	84493	range 50, 79	0
325	Women's Health Study	28100	54	0
326	Women's Health Study	28100	54	0
327	Women's Health Study	28100	54	0
328	Women's Health Study	28100	54	0
329	Women's Health Study	1032	54 (6.3)	0

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Race	Blood pressure SBP/DBP (mmHg)
323	Women's Health Initiative	~84 white, ~7% black, ~3% Asian, ~5% Hispanic, ~0.4% American Indian/Alaskan Native, ~1% unknown	127 (18)/nd
324	Women's Health Initiative	~84 white, ~7% black, ~3% Asian, ~5% Hispanic, ~0.4% American Indian/Alaskan Native, ~1% unknown	127 (18)/nd
325	Women's Health Study	95 white	nd
326	Women's Health Study	95 white	nd
327	Women's Health Study	95 white	nd
328	Women's Health Study	95 white	nd
329	Women's Health Study	71.6 white, 14.1 black, 13.25 Asian	nd

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
323	Women's Health Initiative	nd/nd/64 (17)/nd
324	Women's Health Initiative	nd/nd/64 (17)/nd
325	Women's Health Study	nd
326	Women's Health Study	nd
327	Women's Health Study	nd
328	Women's Health Study	nd
329	Women's Health Study	208.45/122/54.1/nd

Appendix G.2.

Causality Table: Observational Studies

Row	Study	BMI mean (SD)/weight mean (SD) Kg
323	Women's Health Initiative	28 (6)
324	Women's Health Initiative	28 (6)
325	Women's Health Study	25
326	Women's Health Study	25
327	Women's Health Study	25
328	Women's Health Study	25
329	Women's Health Study	25.5

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Baseline n-3 intake/level (median (IQR), unless noted)
323	Women's Health Initiative	ALA: 1.02 g/d, DHA+EPA: 0.093
324	Women's Health Initiative	ALA: 1.02 g/d, DHA+EPA: 0.093
325	Women's Health Study	All n-3 FA: 10.4 g/d
326	Women's Health Study	All n-3 FA: 10.4 g/d
327	Women's Health Study	All n-3 FA: 10.4 g/d
328	Women's Health Study	All n-3 FA: 10.4 g/d
329	Women's Health Study	All n-3 FA: 6.05% FA

Appendix G.2.
Causality Table: Observational Studies

Row	Study	n-3 source	n-3 measure	n-3 type(s)
323	Women's Health Initiative	intake	g/d	DHA + EPA
324	Women's Health Initiative	intake	g/d	ALA
325	Women's Health Study	intake	g/d	all n-3
326	Women's Health Study	intake	g/d	ALA
327	Women's Health Study	intake	g/d	EPA
328	Women's Health Study	intake	g/d	DHA
329	Women's Health Study	erythrocyte	% of total FA	cis n-3 PUFA

Appendix G.2.

Causality Table: Observational Studies

Row	Study	Study design
323	Women's Health Initiative	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
324	Women's Health Initiative	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
325	Women's Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
326	Women's Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
327	Women's Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
328	Women's Health Study	Prospective, longitudinal study of intake (eg, FFQ, biomarker)
329	Women's Health Study	Nested Case Control

Appendix G.2.
Causality Table: Observational Studies

Row	Study	Outcome	Reported effect Size
323	Women's Health Initiative	Congestive heart failure	See appendix F
324	Women's Health Initiative	Congestive heart failure	See appendix F
325	Women's Health Study	Hypertension	See appendix F
326	Women's Health Study	Hypertension	See appendix F
327	Women's Health Study	Hypertension	See appendix F
328	Women's Health Study	Hypertension	See appendix F
329	Women's Health Study	Hypertension	See appendix F